News

kdm communications is a full service business-to-business marketing agency with international reach, specialising in life science, technical and medical marketing.

Lab Innovations – back for 2017!

author2017-06-19authorposted by Becca,

Lab Innovations – the UK’s only dedicated showcase for laboratory technology, analytical and biotech equipment – returns for its sixth consecutive year on 1 & 2 November 2017 at the NEC, Birmingham. With the largest gathering of laboratory suppliers in the UK, this free-to-attend show has lots on offer for professionals across a wide range of sectors, from pharmaceuticals to food and drink.

 

Lab Innovations continues its strong links with the scientific community, with partners including GAMBICA, the Science Council, the Royal Society of Chemistry, Innovation DB and UKSPA for 2017. The packed schedule will cover the latest trends in laboratory science across three live theatres, including the all new Insights and Innovations theatre, which will feature debates about the latest advances in food and drink technology, life sciences and pharma. The Royal Society of Chemistry theatre will focus on the analysis of illicit substances – including cannabis and so-called ‘legal highs’ and counterfeit pharmaceuticals – as well as laboratory automation, in-process analysis and, new for this year, sessions from the Royal Society of Chemistry’s careers service.

 

Speaking about last year’s show, Leo Daly, Laboratory Supervisor at Lagan Cement, said: “It’s great to see so many exhibitors that are experts in the field, and to have them all in one place.” Tim Daniels, Marketing Manager at Autoscribe Informatics, agreed: “It’s a must attend event in the UK calendar.”

 

New exhibitors for 2017 will include Microlit, Thermo Fisher Scientific, VWR International, GS Biotech, Alphatech and LabVantage Solutions, and there will be over 150 exhibitors in total – such as Eppendorf, Shimadzu and Scientific Laboratory Supplies (SLS) – meaning the show is not to be missed. Come and hear inspiring speakers, find out about the latest products launches, network with fellow innovators, and get involved in interactive seminars and hands-on demonstrations.

 

For more information, visit www.easyfairs.com/lab-innovations-2017

Syrris

One footprint, multiple set-ups with Syrris’ Orb Pilot

author2017-06-13authorposted by Hannah,

Syrris’ Orb Pilot jacketed reactor system is proving a big hit for chemical process scale-up, offering multiple set-ups in a single footprint, designed around your needs. Launched in 2016, this unique, flexible and cost-effective system truly bridges the gap between lab scale and production scale chemistry. The Orb Pilot is a user-friendly, floor standing scale-up reactor providing an exceptional combination of performance, versatility and value for money. It offers a choice of vessel sizes from 10 to 50 liters on a single system, and is precision engineered to withstand temperatures from -40 to +235 oC.

 

Available with a selection of single and vacuum jacketed vessels, plus a wide range of accessories – condensers, removable baffles, powder or pressure equalizing liquid funnels, port adapters, stoppers, etc. – the Orb Pilot can be easily configured to match your exact requirements. It features a unique clamp, easy motor lift and rapid oil drain mechanism, enabling vessel changes in under an hour, while a spring-loaded base avoids the need for frame adjustments to accommodate different vessels or thermal expansion. Combined with an incredibly robust and durable design, this will ensure that the Orb Pilot provides years of continuous, cost-effective service, offering all your scale-up chemistry needs in one easily customized product.

 

To find out more, please visit designedforyou.syrris.com/orb-pilot or email info@syrris.com.

 

 

 Syrris Limited

Syrris develops laboratory automation products for research and development chemists, and is renowned for its batch chemistry reactors and world-leading flow chemistry systems. It offers advanced lab-scale reactor systems – including the Atlas batch reactor, the fully automated Atlas HD system and the manually operated Orb jacketed reactor platform – as well as the Asia flow chemistry systems. The company’s latest innovations include the Orb Pilot large-scale batch reactor and the Titan continuous flow chemical processing systems.

 

In recognition of its technological achievements, Syrris received the eastern region’s UKTI Best Established Exporter award, as well as the award for the Most Outstanding Export Achievement at the Global Opportunity Conference on International Trade. In 2012, its Asia Flow Chemistry system was the recipient of a prestigious R&D award.

 

Established in 2001, Syrris is a brand of Blacktrace Holdings Ltd (www.blacktrace.com), a world leader in Productizing Science®. The company is based in Royston, near Cambridge, UK, where it employs 125 staff – including 40 chemists and engineers – with offices in the US, Japan, India and Brazil, as well as more than 45 distributors worldwide.

 

To find out more about Syrris, please visit www.syrris.com

Veolia

Webinar: Veolia Water Technologies UK launches the Plug & Play Package Exelys™ sludge treatment technology

author2017-06-13authorposted by Hannah,

Webinar: Veolia Water Technologies UK launches the Plug & Play Package Exelys™ sludge treatment technology

 

 Veolia Water Technologies UK (Veolia) is running a webinar on 29th June at 2pm to explain the benefits of its Package Exelys™ sludge treatment technology. 

Following the success of its full-size Exelys™ solution which combines thermal hydrolysis and anaerobic digestion, the new packaged version creates potential opportunities for a new set of customers - companies with smaller plants and less available space who can reap the benefits of the tried and tested Exelys™  process.  Package Exelys™ is a Plug & Play solution that can produce between 30-50% more biogas while reducing dry solids by up to 35% on a much smaller footprint.

 

All the benefits of Exelys remain in the packaged version, combined with an additional set of well-thought-out features including the Plug and Play element as well as being fully tested off-site – which minimises commissioning and installation time.

 Leading the webinar will be Andrew Gilbert, a Senior Process Engineer at Veolia. Andrew has over 30 years’ experience in the water industry, and is now particularly involved in the thermal hydrolysis process (THP) and its application in improving the reuse and recycling routes for sludge and biosolid residuals.

 The webinar will give a detailed and technical overview of how the technology works, as well as highlighting the key benefits of the THP and the packaged solution.

 

 

Veolia group is the global leader in optimized resource management. With over 163 000 employees worldwide, the Group designs and provides water, waste and energy management solutions that contribute to the sustainable development of communities and industries. Through its three complementary business activities, Veolia helps to develop access to resources, preserve available resources, and to replenish them.

In 2016, the Veolia group supplied 100 million people with drinking water and 61 million people with wastewater service, produced 54 million megawatt hours of energy and converted 31 million metric tons of waste into new materials and energy. Veolia Environnement (listed on Paris Euronext: VIE) recorded consolidated revenue of €24.39 billion in 2016. www.veolia.com

Sonosite logo

Point-of-care ultrasound helps streamline management of cardiac arrest

author2017-06-13authorposted by Caroline Lenoury,

Point-of-care ultrasound plays an important role in the management of cardiac arrest, as Dr Matthew Reed, an Emergency Medicine consultant at the Royal Infirmary of Edinburgh, explained: “We know that the prognosis for a patient with a beating heart is far better than for someone in cardiac standstill. Using ultrasound, we can see whether or not a patient remains in cardiac standstill following a period of intensive resuscitation, and may also be able to identify a previously undetected pathology – such as cardiac tamponade or ventricular fibrillation – that was not visible on the ECG. Ultrasound can also help to guide the most appropriate course of action, for example, unblocking a coronary artery in the cath lab, aggressive treatment of alternative causes of cardiac arrest, or possibly ECMO.”

 

“We set up an emergency ultrasound training programme almost 10 years ago, purchasing a FUJIFILM SonoSite point-of-care ultrasound system to complement those used in radiology and critical care in our hospital. Its robustness is ideal for the emergency department (ED), and radiologists and critical care physicians needing to scan patients in the ED are familiar with the system, which is another advantage. We now have around 60 clinicians fully trained in level 1 ultrasound, and the number of scans performed in a typical month has risen from 10 to in the region of 80 to 100. There is also considerable interest in using pre-hospital ultrasound assessment to complement care in the ED, which will help to streamline the management of cardiac arrest patients even further.”

 

 

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

www.sonosite.co.uk

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

Pnano

Precision NanoSystems @ the BIO International Convention 2017

author2017-06-13authorposted by Becca,

A key session opens up the challenges of delivering personalized genetic medicines

Visitors to the upcoming BIO International Convention in San Diego will have the opportunity to explore how key players in the industry are tackling the challenges of personalized genetic medicines. The hour-long session, hosted by Precision NanoSystems and moderated by the company’s COO and co-founder Euan Ramsay, will be held on June 22nd, from 9am, at the San Diego Convention Center, RM 6C. Speakers have been chosen for their specific focus in different stages of the clinical development process, and will talk about the challenges and possible solutions for genetic medicine development.

 

Arthur Tzianabos from Homology Medicines will begin the session by looking at genome editing from a viral vector perspective. Intellia’s Thomas Barnes will then discuss the company’s CRISPR/Cas9 genome editing technology, outlining how different drug delivery technologies may be suitable for different diseases. This will be followed by an explanation of how Gritstone Oncology is combining technologies to deliver personalized cancer vaccines from the company’s Karin Jooss. And finally, the audience will hear from Melinda Griffith from the Parker Institute, who will be describing the first CRISPR/Cas9 trial in the United States, and the regulatory and ethical challenges it has raised. The floor will then be opened up for a Q&A session with the panel.

 

Moderator Euan Ramsay said: “Precision NanoSystems is delighted to be organizing this exciting session, providing an exclusive opportunity to bring leading lights from across this fast-growing sector together to discuss the latest developments. We are very grateful to all of our speakers for agreeing to participate, and look forward to their presentations.” 

 

To register for the session, entitled Will the challenges of delivering the personalized genetic medicines of tomorrow outweigh the promise of today, visit info.precisionnanosystems.com/bio2017registration

 

To learn more about the event and Precision NanoSystems, visit info.precisionnanosystems.com/biointernational

BBI Solutions logo

Hands-on lateral flow test development workshop

author2017-06-08authorposted by Hannah,

BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar designed to provide a practical insight into lateral flow test development. Taking place from the 6th to the 8th of June at the Fota Island Resort in Cork, Ireland, this event is aimed at industry professionals, and will cover various aspects of assay development and commercialisation, as well as offering a hands-on experience in test design.

 

This comprehensive course will take delegates through the complete development and manufacture of a lateral flow test, covering everything from materials selection and test development to manufacturing, equipment considerations and troubleshooting. A practical session will give attendees the opportunity to put theory into practice, using BBI’s world class gold nanoparticles to develop a basic test under expert guidance.

 

The event will also provide the opportunity to explore the latest innovations in lateral flow – including BBI’s Morffi technology – and learn about future technologies and market trends from industry leaders, as well as offering a relaxed environment for networking.

 

For more information or to register for this event, go to https://www.bbisolutions.com/about-us/events/lateral-flow-test-development-workshop-a-hands-on-experience.html

 

   

Speedx logo

SpeeDx and Cepheid Announce Partnership on European Distribution

author2017-06-08authorposted by Hannah,

Strategic commercial partnership in key European markets  

 

SYDNEY, AUSTRALIA -- 05/06/17 -- SpeeDx Pty, Ltd. today announced an agreement with Cepheid for distribution of its PlexPCRTM and ResistancePlusTM molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus MG test, the first CE-IVD test for Mycoplasma genitalium to combine detection with testing for azithromycin resistance.

 

The timing of the agreement coincides with recent guideline changes across Europe recommending M. genitalium resistance screening in the management of non-gonococcal urethritis.1 The inclusion of a macrolide resistance test when detecting M. genitalium provides clinicians with much needed information to guide antibiotic treatment. Resistance to frontline antibiotic treatment is increasing and has been observed in up to 50 % of M. genitalium positive patients in recent studies.2

 

“This partnership is a true win-win,” said Colin Denver, CEO of SpeeDx. “We gain better access to these important European markets and Cepheid can bring its customers a comprehensive test for M. genitalium and azithromycin resistance.”

“SpeeDx offers a unique approach to simultaneous detection of pathogens and drug resistance directly from clinical specimens, consistent with Cepheid's approach to detecting tuberculosis,” said David H. Persing, MD, Ph.D., Cepheid’s Chief Medical and Technology Officer. "This technology could potentially be applied in multiple settings in which actionable treatment information is needed quickly."

Sonosite logo

Point-of-care ultrasound transforms sports and exercise medicine in Jersey

author2017-05-31authorposted by Caroline L,

Sportsmen and women on the Channel Island of Jersey are benefitting from the introduction of point-of-care ultrasound. Dr Adam Garnett, a sports and exercise medicine consultant at the Jersey Sports Medicine Clinic, explained: “My interest in sports and exercise medicine started 20 years ago when, as a GP in Bath, I got involved with the rugby club. I now look after a lot of Jersey’s sports teams, splitting my time between professional rugby players with cases of acute trauma – mainly due to impact injuries – and athletes and runners, where overuse injuries are common.”

 

“Two years ago, I bought a FUJIFILM SonoSite Edge®, which is invaluable for diagnosis, as well as monitoring progress and healing, allowing me to establish the true extent of injuries and tailor my advice accordingly. I can also provide reassurance where injuries are not as bad as first thought. This is good for the medical and physiotherapy teams, as well as the players and coaches, as there is often a lot of pressure on returning to sport. The system’s robustness and portability make it ideal for use in the sporting arena, and it has become part and parcel of injury management, giving me immediate, on-site access to good quality ultrasound imaging. It has revolutionised my practice.”

 

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

ukresponse@sonosite.com  www.sonosite.com/uk

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

Energise logo

Comply, control, analyse and save with Energise

author2017-05-25authorposted by Becca,

Energise is launching its new services portfolio focusing on the four critical stages of energy management – compliance, control, analysis and costs – to create a joined-up approach for its customers.

 

Energise’s accredited and award-winning team can help its customers to comply with current and future legislative requirements. Using its expertise and in-depth understanding of government-led schemes in areas such as carbon reduction, carbon reporting, climate change agreements, heat network regulations and EPCs/DECs/TM44 inspections, the company is committed to maintaining a 100 % compliance record for its clients.

 

Controlling utility use and building management is crucial to achieving better energy management. The company can assist in gathering information from multiple sources – including CO2 and water – providing flexible, innovative and accessible solutions to ensure full visibility. Reliable data and accurate analysis are key to making the right decisions, which is why Energise prides itself on creating engaging and easily digestible reporting systems for remote energy audits, GHG reporting, data visualisation, gap analysis and invoice validation, renewables feasibility and building services engineering.

 

All this is designed to help clients save on utility bills and identify where additional savings can be achieved. From tailored engagement and awareness programmes to a fully managed service, Energise’s expert team can develop a package to suit your business requirements and deliver the results you need.

Sonosite logo

FUJIFILM Sonosite keeps the wheels in motion

author2017-05-18authorposted by Raquel,

The medical team, Cardiosos, attending the Gaes Titan Desert by Garmin endurance mountain bike race this year had point-of-care ultrasound close at hand to help them deal with injuries and medical emergencies. The race saw over 463 top-level mountain bikers cover 612 kilometres of sand dunes in Morocco over the course of six days.

 

Dr Marc Bausili, an anaesthetist at the Sant Pau Hospital in Barcelona and a member of the Titan Desert medical team, knew what to expect: “The most frequent injuries were things like ulcerations due to friction and abrasion – dermal and cutaneous injuries from cycling in high temperatures. Then there was a lot of dehydration, fluctuating blood sugar levels, blackouts, fainting fits – the kinds of things that you’d normally expect from this type of race. We knew from our experience of similar events that, with so many participants and the technical requirements of the race, we also had to be prepared for more serious injuries and decided to take an ultrasound device with us.”

 

Marc uses ultrasound every day in his professional life, as he explained: “Ultrasound devices are really important for guiding analgesia and anaesthesia in operating theatres, as well as for applications such as echocardiography and pulmonary echography in intensive care. For the Titan Desert, we knew we were dealing with professional cyclists from all over the world, and wanted to provide them with the best possible medical service. FUJIFILM SonoSite gave us an Edge® II system to take with us for the race, which allowed us to make quick and accurate diagnoses, and even gave us access to anaesthetic guidance on the course.”

 

He concluded: “I work regularly with this type of device and the company, and so I am familiar with its features, its portability and robustness, and the qualities of the brand. The company representatives have been a tremendous support and helped to make this a successful project. SonoSite instruments are great when it comes to portability, and I believe that this quality is paramount to this type of race; the portability and robustness alongside such high imaging performance make it a brand that’s hard to compete with.”

Sonosite logo

Ultrasound guidance improves the accuracy of epidurals

author2017-05-17authorposted by Caroline ,

Anaesthetists at Liverpool Women’s Hospital are taking advantage of ultrasound guidance to administer epidurals, as consultant anaesthetist Dr Abraham Ssenoga explained: “Liverpool Women’s is a specialist obstetrics and gynaecology hospital that deals with around 8,000 deliveries a year. Of these, about 25 % of patients will require an epidural, either during labour or for an elective C-section.”

 

“We purchased an X-Porte® point-of-care system last year to use for ultrasound-guided epidurals. Its large screen appealed to us and, with no buttons to trap dust, the system is easy to keep clean. The touchscreen operation is especially popular with younger staff, who are used to smartphone and tablet technology, and the image quality is excellent. A particular advantage is the capability to change the mode according to the size of the patient, making it easier to obtain a clear image and measure depth accurately, enabling the correct needle length to be selected first time; the improved accuracy of needle placement means that it does not require several attempts to administer the anaesthetic. Administering an epidural to a patient with anatomical problems, where the landmarks are not clear, is also challenging, and this is another situation where ultrasound guidance is extremely beneficial. There is no doubt that ultrasound-guided needle placement is better for the patient and, now that the technique has gathered momentum, some patients are actually asking ‘Will you be using ultrasound to place my epidural?’”

 

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

eraf-sales@fujifilm.com  www.sonosite.com/uk

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

Dolomite micro

Dolomite Microfluidics’ Mitos P-Pumps enable reliable production of highly monodisperse droplets

author2017-05-17authorposted by Raquel,

Dolomite Microfluidics’ Mitos P-Pumps are proving popular with customers around the globe. Designed specifically for microfluidic systems, this key enabling technology is ideally suited for the production of highly monodisperse droplets in a diverse array of scientific sectors, such as food, cosmetics, agrochemicals, pharma, diagnostics, drug delivery and biomedicine. Typical applications include the generation of emulsions, capture of single or multiple cells in monodisperse droplets, and the production of polymer beads and hydrogel particles.

 

Mitos P-Pumps offer the ultimate flexibility for single chips and process scale-up, accommodating a wide range of standard and non-standard vessels, from milliliters to many liters. They can also be easily integrated with Telos high throughput droplet manufacture systems, enabling production of up to a tonne of highly monodisperse droplets, particles or emulsions per month. Easy to use and quick to set up, they offer precise pressure control from 0 to 10 bar, and deliver extremely stable, pulseless liquid flow, seamlessly integrating with Mitos Flow Sensors to allow accurate control of a wide range of flow rates, from nanoliters to milliliters per minute. A choice of modules is available, which can be controlled either directly from the pump or via PC software.

 

For more information, visit www.dolomite-microfluidics.com.

TECAN logo

New entry level reader configurations to simplify basic research

author2017-05-16authorposted by Becca,

Tecan’s popular Infinite® 200 PRO series of multimode microplate readers has been updated to even better serve the life sciences market, with a number of new options and configurations designed to provide flexible and user-friendly solutions for entry level research applications. The proven and trusted Infinite 200 PRO microplate reader has been engineered for excellence, and has so far featured in more than 1,800 peer reviewed articles around the world. Based on further customer feedback, it is now available in six application-focused configurations, allowing researchers to choose the perfect solution for their specific needs and budget today, with the option to upgrade as requirements change.

 

The new, budget-friendly configurations include two single- and four multi-mode configurations for absorbance, luminescence and fluorescence detection. Together with a range of optional modules, these instruments ensure high quality results for ELISAs, nucleic acid quantification, reporter assay technologies and drug discovery applications, including HTRF® and fluorescence polarization. This upgradable platform can help to simplify target applications and laboratory workflows, delivering performance and value to every lab, every day, for every assay.

 

For more information, visit www.tecan.com/infinite200pro

Visualsonics LOGO

Reserve your spot to see the next generation of in vivo multi-modal imaging

author2017-05-11authorposted by Caroline,

FUJIFILM VisualSonics Inc. is launching the Vevo LAZR-X system, the world’s only customizable imaging platform that combines ultra high frequency ultrasound and photoacoustics, at an exclusive event held at its Amsterdam headquarters. The event, on May 30th/31st, will give attendees the chance to learn more about this ground-breaking in vivo multi-modal imaging system, and hear from key researchers who have first-hand experience of the system’s capabilities.

 

Offering a fusion of anatomical, functional and molecular data, the Vevo LAZR-X has been designed to allow non-invasive, real-time, longitudinal studies for a variety of translational research applications, including full-body imaging, oncology, molecular biology, cardiology and neurobiology, biomarkers and nanoparticle analysis.

 

This all-in-one imaging platform features superior image resolution – down to 30 microns – and puts more data at the users’ fingertips, with an array of software applications that allow researchers to conduct in-depth analysis and rapid quantification. The new Vevo LAZR-X combines the latest ultrasound capabilities and the advanced laser technology with streamlined data management, an intuitive touchscreen interface, and a unique open imaging environment that allows the researcher to access and manipulate the subject animal during the scanning process.

 

To reserve your spot at this exclusive event, please visit:

https://www.visualsonics.com/event/special-events/special-vevo-lazr-x-launch-event-amsterdam.

PI database

Physik Instrumente enjoys success at the 2017 Motion Control Industry Awards

author2017-05-10authorposted by Becca,

Physik Instrumente (PI) is celebrating being shortlisted in the Manufacturer of the Year and Contribution to Skills and Training categories at the 2017 Motion Control Industry Awards, held at the National Conference Centre, Birmingham, on the 9th of May. The awards acknowledge the achievements of motion control companies and individuals, and have become a leading event in the industry.

 

Building on last year’s success, when the company was named Manufacturer of the Year, PI is delighted to have received further recognition in this category. This success is due to the company’s partnership approach, working closely with its customers to build long-term, trusted relationships, and helping them to realise the true potential of precision motion and control. Additionally, the company’s Lunch & Learn educational sessions, held free of charge at venues around the country, were acknowledged for their contribution to professional training and skills development. Professor Steve Dixon from the Centre for Industrial Ultrasonics, Department of Physics and School of Engineering at the University of Warwick, commenting on a Lunch & Learn session, said: “…the talk was pitched in such a way that it was accessible to everyone… If only all high tech companies were so forward thinking and supportive of the field in which they work.”

 

For more information, visit https://www.physikinstrumente.co.uk/en

ROMIL

Quantum dots to shine bright with ROMIL solvents

author2017-05-10authorposted by Becca,

ROMIL solvents are helping researchers at the Cavendish Laboratory, the University of Cambridge’s Department of Physics, to develop novel quantum dots which could be used in the next generation of solar panels. James Xiao, a PhD student in the laboratory, explained: “We’re currently working on quantum dots which emit light in the infrared range, with the aim of significantly increasing the efficiency of photovoltaic cells.”

 

“We synthesise the quantum dots entirely in-house, which is a fairly labour-intensive process and involves several dissolution/precipitation steps, so requires large quantities of various solvents. We have struggled in the past to get some of the solvents we require, particularly anhydrous solvents; they have either very long lead times or very high prices. We only recently discovered that ROMIL offers many of these solvents at the same or better purity, and at a much better price. It’s also nice to use a local company, as delivery times are faster, and they can just pop in and talk through any issues we have, which we obviously don’t get with other suppliers.”

 

Discover the world of ROMIL for yourself at www.romil.com  

 

When it works well, it's pure chemistry. And when it's pure chemistry, it's ROMIL.

Sonosite logo

FUJIFILM SonoSite donates ultrasound systems to refugee rescue services

author2017-05-10authorposted by Caroline,

FUJIFILM SonoSite has given two M-Turbo® point-of-care ultrasound systems to the non-governmental sea rescue organisation Proactiva Open Arms, based in Badalona, near Barcelona, to support its efforts in rescuing refugees.

 

Emergency doctor Guillermo Cañardo shares his time between working on ambulances and emergency helicopters, and on the three boats operated by Proactiva Open Arms in the Central Mediterranean. He explained: “We pick up around 400 people fleeing from war, prosecution or poverty, in each rescue. They are usually more than two days from land, a hospital or any possible evacuation, and so we always have a doctor and a nurse on board, plus many of our volunteers have emergency medical training.”

 

FUJIFILM SonoSite heard about the charity’s efforts and donated two M-Turbo systems for use on the rescue missions. Guillermo said: “It is fantastic to have an ultrasound machine; it is the only diagnostic imaging we have at sea, and works very well for us. We use it for abdominal scanning – particularly pregnancies – diagnosing and monitoring pneumonia, and to look at trauma injuries, such as knife and bullet wounds. Obviously we are on a boat where there’s a lot of movement – very similar to working in an ambulance – and the SonoSite systems are well suited to this. They are very robust devices, they don’t take up much space, and they are intuitive and easy to use. Our ultrasound machines are essential, as without them we would be working blind. We are grateful to FUJIFILM SonoSite for donating them, and the support they have given us encourages us to keep going with our work.”

Syrris

Syrris to launch Titan continuous processing scale-up system at InformEX

author2017-05-09authorposted by Raquel,

Syrris, a world leader in chemistry process innovation, is launching its revolutionary Titan system at InformEX in Philadelphia, USA, from the 16th to the 18th of October. This modular continuous chemical processing system is designed to enable straightforward scale-up, from kilo lab through pilot plant to manufacturing.

 

Titan is an easy to use, high performance turnkey system designed for long-term use in demanding manufacturing environments. It comprises a wide range of seamlessly integrated, rapidly reconfigurable modules, enabling simple or sophisticated continuous flow processes to be performed on a lab scale, or at rates of up to a tonne per day. Titan offers flexibility and scalable functionality – extra modules can easily be added – allowing the type and complexity of processes to be easily modified, or multiple processes to be combined into a single system. Reactors are available in 64 and 250 ml volumes, and may be connected together when larger scale systems are required. Reliable and robust, Titan offers extremely high chemical resistance. It can accommodate reaction temperatures from -40 to +250 °C and pressures up to 20 bar, at flow rates between 1 and 250 ml/min per channel. Process parameters can be controlled manually from the modules, or automated via Titan or pre-existing PLC or plant software.

 

For more information, visit www.syrris.com

Veolia

Veolia’s innovative, scalable laboratory water purification range now available

author2017-05-08authorposted by Raquel,

Veolia Water Technologies’ innovative PURELAB® Chorus range of laboratory water purifiers provides a scaleable and versatile solution to all your laboratory water requirements. Stylish, compact and, above all, high performing; the Chorus can be configured with state-of-the-art technologies to deliver the water quality that you need - where you need it.

 

The latest addition to the Chorus range of product includes PURELAB® Chorus 1 Complete and PURELAB® Chorus 2.

 

Tap-to-Type I

The new PURELAB® Chorus 1 Complete provides 18.2MW.cm ultrapure water (Type I), at up to 20 litres an hour direct from a potable water supply. With its simple and ergonomic design and ease-of-use, water can be dispensed directly from the system or from a choice of Halo Dispensers, this means you can add multiple dispense points without having to pay for additional systems. 

 

Guaranteed quality of Type II

For analytical and life science applications, it’s the new PURELAB® Chorus 2 for 15MΩ.cm water (Type II) with RO, plus, either DI or EDI. Four variants now exist; 10 and 20 litre an hour, with and without boost pumps – to help increase the pressure, if required. PURELAB Chorus includes a patented, fully recirculating, EDI technology, which is the only system on the market that is able to fully recirculate to maintain >15 MΩ.cm to ensure that there is no deterioration in purified water quality over time.

 

The PURELAB® Chorus is a single complete solution for the laboratory. Highly flexible, it allows you to customise your purification system to suit your specific research, space and budget needs. The modular PURELAB® Chorus units can be configured in stackable, bench top, wall mounted or under bench versions to fit any laboratory. And the Halo dispense unit can be located at up to four metres from the purification unit even if it’s in another lab. If your needs change; now, or in the future, the PURELAB® Chorus is so adaptable that it can grow as your laboratory expands, so you are no longer restricted to one solution!

Pnano

Precision NanoSystems @ CLINAM 2017

author2017-05-03authorposted by Becca,

Precision NanoSystems will be showcasing the benefits of its NanoAssemblr™ System and microfluidics technologies on booth #6 at this year’s European Foundation of Clinical Nanomedicine (CLINAM) conference and exhibition. Taking place in Basel, Switzerland, from the 7th to the 10th of May, this summit focuses on recent advances and current hurdles in the translation of nanomedicines from the research setting to the clinic.

 

The Precision NanoSystems team will be on hand throughout the conference to discuss the practical challenges of nanomedicine development, as well as participating in a number of other activities. In addition, company CEO and co-founder Dr James Taylor will be giving a presentation entitled Meeting the challenge with microfluidics: Enabling nanomedicine development from basic research to the clinic at 14:45 on Monday the 8th in Hall Sidney. Looking at the use of a microfluidic approach for the continuous manufacture of nanomedicines, he will be focusing on some of the new opportunities this technology offers in terms of reproducibility, scalability and the assembly of challenging particle types.

 

James commented: “Our company’s focus is on helping to accelerate this important area of medicine by developing technology that makes it easier for biopharmaceutical companies and academics to optimize and manufacture nanomedicines as drug products. We are happy to once again be supporting this important fixture in the calendar through the exhibition and our contributions to the scientific program, and look forward to discussing the latest breakthroughs and challenges with old friends and new faces alike.”

 

To learn more about Precision NanoSystems, visit www.precisionnanosystems.com

BBI Solutions logo

BBI Solutions wins Dx Creative Award for Morffi™ launch

author2017-05-02authorposted by Raquel,

BBI Solutions is pleased to announce that it has triumphed at the DxMA’s 2017 Dx Creative Awards, winning the New IVD Product Launch (less than $100m) category for the market release of its Morffi™ signal enhancement technology. The awards ceremony (held in New Orleans, USA, on the 30th of April) was an opportunity to celebrate the latest innovations in the diagnostics field ahead of the DxMA Global Marketing Summit on the 1st of May, where BBI’s Dr Neil Polwart was also presenting the company’s Novarum Dx mobile assay reader.

  

Officially unveiled at Medica 2016, the patent-pending Morffi signal enhancement technology (offered exclusively through BBI’s development service) can enhance the sensitivity of lateral flow immunoassays (LFIs), opening up new opportunities and allowing LFIs to compete with traditional lab-based testing platforms. The Medica launch included a ‘first to see’ breakfast seminar and white paper presentation, supported by an integrated marketing campaign and eye-catching exhibition stand, and garnered interest from across the diagnostics sector. “We are thrilled at this recognition of the hard work and dedication of our team,” commented Liam Taylor, Managing Director of BBI Solutions. “In this highly regulated industry, a sceptical audience is always a major challenge, but we’ve worked hard to support this innovative technology with robust and reliable data, offering a simple, swap-in technology which we hope will transform the future of diagnostics.”

 

Morffi is available as part of BBI’s research and development services through a licensing model. If you’re interested in developing a lateral flow device or redeveloping an assay, visit www.bbisolutions.com.                

dolomite_bio_logo

Dolomite Bio’s μEncapsulator System simplifies T-cell profiling

author2017-04-25authorposted by Raquel,

The μEncapsulator System from Dolomite Bio is a complete solution for high throughput encapsulation of individual cells into picoliter droplets. Ideal for profiling natively-paired T-cell receptors (TCRs), this compact, flexible and modular system can process up to 300,000 cells in 15 minutes.

 

T-cells play a vital role in the destruction and subsequent removal of pathogens in the adaptive immune response. Profiling T-cell clonotypes and functional classes from lymphocyte preparations enables researchers to investigate these individual responses to better understand the underlying biology and gain in-depth insight into the configuration of the adaptive immune system. This allows scientists to investigate a broad range of therapeutic and related research areas, including vaccine design and development, cancer and infection management, immunotherapy development and the study of autoimmunity.

 

Dolomite Bio’s µEncapsulator System uses microfluidic technology to rapidly and reliably encapsulate single T-cells, enabling downstream PCR and high throughput sequencing. The reliable and fast encapsulation of thousands of TCRs in microfluidic droplets enables a range of exciting new research capabilities and offers the possibility to observe and analyze many crucial biological events.

 

For more information, visit www.dolomite-bio.com/applications/profiling-t-cell-receptors

Speedx logo

SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of molecular diagnostic test

author2017-04-24authorposted by Raquel,

ResistancePlus™ MG Test would bring disease and antibiotic resistance testing for potential “superbug”

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement with Thermo Fisher Scientific, the world leader in serving science. The announcement was made at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna to submit its ResistancePlus MG Test for the detection of Mycoplasma genitalium to the US Food & Drug Administration (FDA).

Following ongoing validity, SpeeDx will submit the test for use with the Applied Biosystems 7500 Fast Dx Real-Time PCR System. The ResistancePlus MG Test is designed to identify both M. genitalium and mutations in the 23S rRNA gene of the bacteria that have been shown to confer resistance to azithromycin, a commonly prescribed macrolide-based antibiotic. The test has previously received a CE mark, accreditation by the Australian Therapeutic Goods Administration (TGA), and is already marketed across Europe, Australia and New Zealand.

“We developed this diagnostic test to address an immediate need for detection and resistance screening for this difficult to manage STI,” said Colin Denver, CEO of SpeeDx. “With its reputation for scientific excellence, we are very pleased to partner with Thermo Fisher to bring this test to the US market. Applied Biosystems qPCR instrumentation has a long-standing reputation for quality, and a wide install base across the region.”

”We are proud to be partnering with SpeeDx to enable them to bring their diagnostic test to the U.S. market,” said Kim Kelderman, vice president and general manager, Genetic Analysis, at Thermo Fisher Scientific. “We are committed to working with diagnostic partners around the world who share our vision of driving better health outcomes by using precision medicine.”

 

For more information on this announcement, please visit the SpeeDx (#97) and Thermo Fisher (#83) booths at ECCMID April 22-27

MT logo

Rainin TerraRack™ benefits cell differentiation studies

author2017-04-21authorposted by Becca,

METTLER TOLEDO’s Rainin TerraRack™ pipette tip racks are proving advantageous for the University of Glasgow’s Centre for Cell Engineering, where scientists are investigating cell differentiation and behavior on a variety of materials. Dr Monica Tsimbouri, a research fellow at the university, explained: “Our research involves growing bone marrow cells onto different materials – for example, plastics, titanium, nanopillars or nanoPEGs – and investigating how the cells differentiate. We use a wide range of techniques – such as GPCRs, In-Cell Westerns™ – metabolomics and next generation sequencing, to study biomarkers related to the tissue lineage at various time points, monitoring how the cells behave on different nanopatterns.”

 

“The new TerraRack tip racks from METTLER TOLEDO were recently recommended to us. We find the Rainin BioClean™ Filter Pipette Tips, which contain hydrophobic filters, ideal for our purposes. As no liquid is retained in the tip, there is no loss of pipetting volume, even when transferring as little as a microliter. The TerraRack’s hinged lids ensure that the tips remain clean and free from contaminants and, as they are smaller than our other tip boxes and use less material, the amount of waste is reduced. I would recommend them to anybody.”

Sonosite logo

Creating a new standard for ultrasound in emergency care

author2017-04-21authorposted by Caroline,

Point-of-care (POC) ultrasound is now a common sight in emergency departments throughout the UK. Professor Bob Jarman, Consultant in Emergency Medicine at the Great North Trauma and Emergency Centre, explained the potential benefits of more widespread ultrasound use: “There is a lot of interest in POC ultrasound within our department, above and beyond the FAST scans, basic echo, aortic aneurysm screening and venous access commonly performed in an emergency setting. We try to ensure that it is a routine part of our approach, helping us to assess a wide range of patients coming into the department.”

 

“Thanks to the generous support of FUJIFILM SonoSite, we currently have eight POC ultrasound machines, and we have put a lot of thought into how we planned to use the systems, as well as where to locate them to maximise use. Increasing system availability has also been key to opening up ultrasound use to allied healthcare professionals, and many of our nurses are now trained in basic practices, such as vascular access. Although straightforward, these procedures have made a real difference to our productivity, as they are performed in huge numbers. For example, difficult venous access might previously have taken up to 45 minutes, which was upsetting for patients and extremely frustrating for already busy doctors. Now, we can cannulate in five to ten minutes for even the most complex cases. Patients love it because it improves the thoroughness of their care and avoids multiple needle-sticks, and staff love it because it makes their lives easier and helps to make the department more efficient. Ultrasound is really revolutionising the patient experience and the time it takes to deliver appropriate care, and it’s only by having rapid, widespread access to systems that we can provide this level of service.”

 

Ingenza_Final brand logo

Ingenza enjoys success at the Made in Scotland awards

author2017-04-20authorposted by Raquel,

Edinburgh-based Ingenza is celebrating after being named the Innovator of the Year at the 2017 Made in Scotland awards, held at the Glasgow Science Centre on the 19th of April.  Now in its second year, the awards highlight the achievements of Scottish companies in sectors such as life sciences, food and drink, engineering, manufacturing and recycling.

 

The Innovator of the Year award acknowledges the launch or creation of a product or process with substantial commercial potential. Ingenza was recognised for its proprietary combinatorial genetic platform, inABLE®, which helps to improve the speed and predictability of bioengineering processes. This technology has opened up new commercial opportunities for Ingenza, expanding its customer base to incorporate a wide range of sectors, including bio-based chemicals, agrochemicals and biopharma.

 

Ingenza enjoyed further success as a finalist in the Life Sciences Company of the Year category, and the company’s recognition by the Made in Scotland awards is a testament to its integrated approach – combining molecular biology, fermentation and process chemistry capabilities to help realise new commercial opportunities in bio-based manufacturing. This unique blend of expertise enables the company to accelerate bioprocess development, driving the delivery of greener processes for application across the chemical, polymer, energy and pharma sectors.

Ingenza_Final brand logo

Ingenza welcomes Japanese trade delegation to Scotland

author2017-04-18authorposted by Raquel,

Ingenza is pleased to announce that it will be hosting representatives of the Japanese government, academic and technology sectors later this month. The Japanese Ministry of Economy, Trade and Industry (METI) delegation will visit the company’s Roslin BioCentre site as part of a mission to learn more about the UK’s rapidly expanding biotechnology industry.

 

The delegation includes members of METI and the New Energy and Industrial Technology Development Organisation (NEDO) – as well as representatives of leading industrial and academic organisations – and aims to understand how the UK’s bioeconomy strategy is translating research advances into commercially successful enterprises. Synthetic biology is playing a key role in this success, and the group has asked to visit Ingenza to learn more about the company’s technologies and activities.

 

Dr Ian Fotheringham, Managing Director of Ingenza, commented: “We are delighted to have been asked to host a visit from this delegation. The UK bioeconomy is one of the strongest in the world, and growing rapidly, and it is a real honour to have been singled out for our contribution to this growing sector.” 

Sonosite logo

FUJIFILM SonoSite gives clinicians the edge for rural diagnostics

author2017-03-30authorposted by Raquel,

A FUJIFILM SonoSite Edge® point-of-care ultrasound system recently helped clinicians participating in the Ukraine Christian Partnership’s (UCP’s) Summer Mission to diagnose a wide range of pathologies. Dr Fiona Witham, a consultant radiologist travelling with the group, explained: “This year’s UCP Summer Mission was to an area of subsistence farming in Zakarpattia Oblast. Medical professionals made up about a third of the group, and we provided diagnoses and limited treatment to villagers from across the area. Because our aid and advice is independent, the villagers know that we only have their best interests at heart, helping them to judge the next steps they need to take with their treatment.”

 

“Point-of-care ultrasound is an invaluable tool in these circumstances, allowing me to provide abdomino-pelvic, small part and musculoskeletal imaging – as well as echocardiographic scanning – to confirm or refute a wide range of diagnoses. When I looked into obtaining a system for the first mission 13 years ago, everyone I spoke to recommended SonoSite. The company has been kind enough to support every trip I’ve been on, providing a small, lightweight and robust system that I could easily carry in my hand luggage. This sort of application really does play to the unique strengths of SonoSite’s instruments, and the image quality improves with every new system. I am very grateful for the company’s ongoing support.”

Pnano

Precision NanoSystems NanoAssemblr™ chosen for Horizon 2020 project to develop novel RNA therapeutics

author2017-03-29authorposted by Raquel,

Precision NanoSystems NanoAssemblr™ platform has been selected for the controlled manufacture of nanomedicines as part of the multinational B-SMART (Brain-Specific, Modular and Active RNA Therapeutics) translational research project. This €6 million initiative, funded by the EU Horizon 2020 program, aims to use RNA-based therapeutics to silence the production of disease-causing proteins for a range of neurodegenerative disorders, such as Parkinson’s, Alzheimer’s and Huntington’s. Professor Raymond Schiffelers from UMC Utrecht is leading the project, and explained its goals: “RNA medicines are interesting because you can use what is essentially the same polynucleotide molecule to treat multiple diseases, just by changing the nucleotide sequence. Our goal is therefore to design modular nanoparticles capable of delivering a payload of therapeutic RNAs to the brain, allowing them to prevent the biosynthesis of harmful proteins at source.”

 

“One of the key aims for Horizon 2020 projects is to demonstrate that these technologies are transferrable from a research to a clinical setting. This means that the manufacturing processes must be reproducible and scalable. Precision NanoSystem’s NanoAssemblr platform is ideal from this perspective, allowing us to make many different types of particles in a reliable and reproducible manner. This technology also allows you to accurately predict the particle size based on the mixing speed, PEG concentration and mixing ratios, which is a significant step forward. Equally importantly, it can be easily scaled to manufacture batch volumes sufficient for clinical trials. Having a NanoAssemblr Benchtop instrument in each laboratory involved in the project – eight in total across the Netherlands, Belgium, Norway, the UK, Spain and Italy – will allow us to manufacture the same particles at each site, helping to accelerate our research.”

 

To learn more about Precision NanoSystems’ NanoAssemblr platform or arrange a demo, visit www.precisionnanosystems.com/nanoassemblr-platform                                                                                                                           

dolomite_bio_logo

Single cell technology company Dolomite Bio celebrates a successful first year

author2017-03-28authorposted by Raquel,

Dolomite Bio, a brand of Blacktrace Holdings Limited, celebrated the first anniversary of its launch on March 1st, marking the end of a fruitful year in business. This biology-focused brand, a spin out from sister company Dolomite Microfluidics, is dedicated to the development of innovative products for high throughput single cell encapsulation. A prosperous initial year of trading has seen Dolomite Bio grow significantly with clients in 32 countries, including major academic institutions and pharma companies and exceed its sales targets by 63 %.

 

Dolomite Bio’s core technology is open and fully scalable, enabling microdroplet encapsulation of individual cells and molecules – from a few to millions in just a few minutes. It is ideal for a wide variety of high throughput, single cell research applications, including:

  • - Single cell RNA-Seq
  • - Direct isolation of functional antibody coding sequence libraries
  • - Profiling natively-paired T-cell receptors
  • - Directed evolution by FACS sorting
  • - Functional antibody screening in droplets
  • - Cell encapsulation in hydrogels

 

Mike Hawes, CEO of Dolomite Bio, said: “Our first year’s sales clearly demonstrate the potential of Dolomite Bio and its single cell technology. With a team of single cell experts and numerous exciting developments underway, Dolomite Bio is in an excellent position to continue this growth and we look forward to further success in the coming year.”

 

Mark Gilligan, CEO of Blacktrace Holdings Ltd, said: “Dolomite Bio was launched to focus on developing novel products for high throughput single cell research, taking advantage of Dolomite Microfluidics’ underlying technology and the Blacktrace group’s understanding of the market to serve customers in this rapidly growing field. One year on, we are delighted with the brand’s progress, and look forward to further success as we move into the future.”

 

For more information, visit www.dolomite-bio.com.

TECAN logo

Enhance your workflow efficiency with rapid tube identification

author2017-03-28authorposted by Raquel,

Tecan is helping to reduce waiting times for bulk sample identification with an innovative high speed barcode scanner for its Fluent® Laboratory Automation Solution. The new Fluent ID* module eliminates the need to watch and wait while your liquid handling platform scans and identifies each individual sample tube, allowing 32 barcoded samples to be loaded and identified in just three seconds.

 

The Fluent ID scanner is fitted with a status indicator light offering a clear pass/fail notification as soon as the tube rack is loaded onto the worktable. If one or more barcodes is unreadable, the system’s graphical interface provides step-by-step instructions to quickly and easily resolve any issues, either by rescanning the barcodes or manually inputting the tube IDs. The user can then simply press ‘Start’ and walk away, confident that there will be no tube identification errors. For larger sample batches, the system can even start pipetting the first rack of samples while additional tubes are being loaded onto the system.

 

This easy-to-use solution supports all major 1D barcode formats, and is compatible with 10-16 mm diameter tubes, as well as microcentrifuge tubes, as standard. By combining rapid and extremely reliable scanning with instant feedback and error handling, Fluent ID can save several days of technician time annually compared to traditional automated approaches, helping to streamline busy laboratory workflows.  

 

To learn more, visit www.tecan.com/fluentid

 

*  For research use only. Not for use in clinical diagnostics. Fluent is a Class 2 Laser Product when equipped with Fluent ID option.                                                                                                                          

MT logo

Discover the Rainin SmartStand™, the world's first intelligent pipette stand

author2017-03-27authorposted by Becca,

METTLER TOLEDO’s recently launched Rainin SmartStand™ is set to transform pipette management. This intelligent, customizable and highly scalable pipette asset management system is easily adapted to any laboratory’s standard operating procedures, helping to drive compliance in regulated environments, such as pharma, GLP and QC laboratories. Non-regulated laboratories can also take advantage of SmartStand to conveniently and efficiently monitor large numbers of pipettes. Each SmartStand can accommodate four manual or electronic Rainin XLS™ and XLS+™ pipettes, reading the embedded RFID chip to determine the current calibration status, which is instantly and clearly displayed on the color LCD screen. A detailed view of the pipette’s service history and calibration status is revealed whenever it is removed from the stand, enhancing compliance by minimizing the risk of accidentally using out-of-specification equipment.

 

SmartStand is supplied with EasyDirect Pipette Asset Managementä software, a flexible, infinitely scalable Windows®-based tool that simplifies and streamlines data management. It can connect to multiple SmartStands simultaneously via Bluetooth®, monitoring anything from tens to hundreds of pipettes, identifying their location and capturing usage data to help laboratory managers reduce asset costs and eliminate obsolete equipment. Customizable fields allow information such as the user and lab, application and ID/inventory number to be entered for each pipette, and transferred to its RFID chip. An interim quick check can be scheduled – enabling deviation from specifications to be identified at an early stage – and service due dates indicated graphically, with the relevant documentation automatically completed and printed. After servicing and calibration, the updated record is conveniently exported to EasyDirect by replacing the pipette on any SmartStand. Data can also be transferred from EasyDirect to Microsoft Excel® and most LIMS applications, eliminating manual record keeping.

rdt

UK MOD awards £14 million medical monitor contract to RDT

author2017-03-22authorposted by Becca,

The Ministry of Defence has awarded a £14 million tri-service contract for medical monitors to Hampshire-based company RDT, a world-leader and fast-growing specialist in pre-hospital care solutions. The new agreement will see the delivery of around 900 compact, easy-to-use and reliable vital signs Tempus Pro monitors, which will enable the UK military to manage medical incidents in the remote and challenging locations in which they regularly operate. Tempus Pro uniquely consolidates several functions onto one system, ensuring that Armed Forces medical personnel can provide the best quality of care possible to critically injured service men and women in very challenging environments. Tempus Pro monitors will be deployed on medical evacuation vehicles and aircraft, battalion aid stations, hospital ships, field hospitals and in far forward locations by special operations teams.

 

This award is the latest in a long line of successes for RDT, which has achieved 60 % growth in the last 12 months. RDT is a significant exporter, generating more than 60 % of its revenue from international sales. Maria Miller, MP for Basingstoke, said: “RDT is a ground-breaking company and its success in securing this contract demonstrates the strong entrepreneurial, engineering and technological talent available in Basingstoke. This talent pool supports a thriving hub of high growth, high tech businesses in the town. The contract will sustain over 60 jobs at RDT’s local facility and has helped in the creation of 20 new roles. I congratulate Graham and his team on this tremendous achievement.”

 

The MOD selected RDT’s Tempus Pro monitoring system after an extensive evaluation programme that highlighted how this very small and robust monitoring platform delivers significantly more capability for British troops than existing solutions. Over the next five years, the MOD will replace all existing monitors with the Tempus Pro system. RDT has already delivered 444 monitors to the Armed Forces.

 

Minister for Defence Procurement Harriett Baldwin said: “Our Armed Forces serve with incredible commitment and bravery, and the new Tempus Pro monitor will ensure that they will receive the best possible care and treatment should they be wounded or taken ill on operations. Backed by our rising defence budget and our £178 billion equipment plan, our investment in these cutting-edge medical monitors demonstrates how we are working with our NATO allies to provide lifesaving equipment to our frontline personnel.”

 

Before awarding the contract, the Defence Equipment and Support organisation (DE&S) conducted an intensive year-long, multi-discipline monitor evaluation process that saw the system deployed and rigorously tested in extremely harsh and challenging locations. Traditionally, several various monitor types have had to be used at different levels of care in the patient pathway. Thanks to the modular and flexible nature of RDT’s Tempus Pro system, the UK MOD is now able to standardise on one monitor to provide streamlined medical support and critical patient care information from the battlefield onwards. This means the Record of Care of all sick and injured patients can easily move with them as they progress through different levels of care, and ultimately be saved into their permanent patient record. A single monitoring solution has been an objective of the UK military for some time. It is only possible because of the forward-thinking and innovative way in which RDT has approached the development of its medical monitoring technology.

 

Chief Executive Officer of the DE&S, Tony Douglas, said: “This state-of-the-art piece of equipment shows how we are delivering proven, world-leading equipment to our Armed Forces. The Tempus Pro monitor is a step forward in innovation and safety, demonstrating how we are committed to improving the medical care received by those keeping our country safe. This deal also highlights DE&S’ strong, collaborative partnership with industry, benefitting both our Armed Forces and the wider UK economy by sustaining around 60 UK jobs.”

 

Graham Murphy, RDT CEO, added: “We are incredibly proud to be providing the Tempus Pro to our Armed Forces, who do such important work to keep us all safe. One of the reasons the Tempus Pro is being adopted by the UK and many other NATO militaries is because of its unique ability to be enhanced in the field as new technologies emerge or needs evolve. The world is an ever-changing place and this flexibility is important to all our customers. To that end, RDT has an exciting set of new features in development to which the MOD will have full access as they become available.”

syrris

Syrris Orb batch reactors – designed for you

author2017-03-16authorposted by Violeta,

Syrris’ state-of-the-art Orb batch reactors are designed by chemists for chemists, ensuring they perfectly meet the demands of your work. Whether you are engaged in lab scale reactions or looking to move to pilot scale processes, there is an Orb system designed for you.

The benchtop Orb jacketed reactor combines exceptional value and high quality construction with unique user-friendly features and reliable performance, and is ideal for process development and kilo labs. It accommodates a broad selection of jacketed and vacuum jacketed vessels from 100 ml up to 10 liters, and can be operated at temperatures between -90 and +250 °C, and pressures from 50 mbara to 0.25 barg. An intuitive, patent-pending clamp mechanism enables vessels to be quickly and easily changed, complemented by a clever stirrer motor lift that can be easily raised and rotated out of the way during vessel changes. Vessel height adjustment is also rapid and straightforward, with no tools required. With a comprehensive choice of accessories and optional upgrades to allow automation of reaction parameters and rapid oil drain, Orb can be used in virtually any application.

Orb is complemented by Orb Pilot, an easy to use, floor standing scale-up jacketed reactor offering an excellent combination of performance, versatility and value for money, delivering flexible and cost-effective pilot scale batch chemistry. It offers a choice of vessel sizes from 10 to 50 liters, and is precision engineered to withstand temperatures from -40 to +235 oC. Available with a selection of single and vacuum jacketed vessels, plus a wide range of accessories and stirring options, the Orb Pilot can be easily configured to match your exact requirements.

For more information, visit http://designedforyou.syrris.com/orb

Pnano

Precision NanoSystems unveils innovative system for scale-up manufacture of nanomedicines

author2017-03-08authorposted by Becca,

Precision NanoSystems has launched the NanoAssemblr™ Scale-Up system to support the clinical development of nanomedicines. This latest addition to the NanoAssemblr range is designed for the manufacture of clinical trial material in GMP environments, and will support the production of novel medicines, including siRNA, mRNA and CRISPR/Cas9 therapeutics.

 

The NanoAssemblr Scale-Up system features the same proprietary microfluidic mixing technology as the company’s preclinical instruments – the NanoAssemblr Benchtop™ and Blaze™ – providing seamless scale-up following formulation development. Its compact, modular design uses a fully disposable fluid path with multiple microfluidic mixers connected in parallel to produce a single large volume batch in less time, and is ideally suited to manufacturing batch volumes sufficient for clinical trials.

 

“The NanoAssemblr Scale-Up system is designed to provide customers with a customizable, modular platform for the cGMP manufacture of high quality nanomedicines,” commented Ray Lockard, Vice President of Pharmaceutical Operations at Precision NanoSystems. “By using the same underlying technology as the rest of the NanoAssemblr instrument portfolio, this will allow researchers to accelerate product development from discovery to the clinic and, ultimately, help to realize the potential for novel therapeutic modalities, such as genome editing and mRNA-mediated protein expression.”

 

The NanoAssemblr Scale-Up system can be viewed at Precision NanoSystems’ facilities in Vancouver, BC, and South San Francisco, CA. For more information, visit www.precisionnanosystems.com/scale-up

PI database

Physik Instrumente acquires ACS Motion Control

author2017-03-08authorposted by Becca,

Physik Instrumente (PI), a long-established provider of specialist motion control and nanopositioning systems, has announced the recent acquisition of ACS Motion Control, an Israeli developer and manufacturer of high-end controllers and drives for multi-axis systems. ACS is known worldwide for its advanced modular systems that can manage up to 64 fully synchronized axes, perfectly complementing PI’s standalone controllers to provide extended flexibility for more complex applications.

 

PI is a market leader in precision nanopositioning technology, with an accompanying portfolio of micropositioning products. In recent years, the company’s technology-led approach has seen it extend its product range to include linear motors and air bearing technology, opening up new opportunities for growth. With the acquisition of ACS Motion Control, PI is ideally positioned to build on these advances, offering sophisticated controller technology to perfectly synchronize the motion between individual axes – a critical action that must be coordinated with other processes in real time for optimal efficiency and productivity.

 

The combination of PI’s expertise in the manufacture of precision mechanical systems, and high performance EtherCAT®-based controllers and multi-axis drivers from ACS, will enable the delivery of complete customized solutions that can be conveniently integrated into a wide variety of automation applications. Customers will also benefit from convenient, in-depth discussion of their project and provision of all their needs – including hardware, cabling, integrated motion control and metrology – via a single point of contact, backed by excellent support from experts in the field.

 

Kevin Grimley, Managing Director of PI UK, said: “The acquisition of ACS builds on PI’s expertise, complementing its product portfolio to enable the company to provide complete, often complex, customized systems, and eliminating many of the difficulties associated with using components from multiple suppliers.”

MT logo

Taking the strain out of cancer diagnostics

author2017-03-07authorposted by Becca,

Rainin electronic pipettes are helping California-based Clarient Diagnostic Services, Inc. to provide cancer diagnostic testing. Flow cytometry supervisor Brian Ngo explained: “Our laboratory uses flow cytometry to detect specific biomarkers that help to diagnose leukaemia, and this involves pipetting microliter volumes of antibodies and samples. When you are doing a lot of pipetting, user comfort is very important and so we decided to invest in electronic – rather than manual – pipettes.”

 

“We looked at the various options available, and chose Rainin E4 XLS single channel pipettes because they are ergonomically designed and very easy to hold. They are also quite intuitive to use – changing the volume is very straightforward – with the benefit of a large LCD screen. There are advantages from a GLP perspective too, as the programmed volume ranges can be password protected – preventing them from being inadvertently altered – and particular features locked down or hidden. The pipettes are very dependable and, as they can operate accurately over a range of volumes – unlike the manual pipettes we were using before – we have been able to reduce the number of pipettes in the lab from over 100 to about 10, significantly decreasing our calibration costs.”

TECAN logo

Tecan expands its OEM portfolio with Pulssar Technologies precision pumps

author2017-03-01authorposted by Becca,

Tecan has extended its OEM product portfolio through the acquisition of the PBC, PSR and PBR piston pumps from Pulssar Technologies. These long life, high precision products are ideal for the automation of dispensing and pipetting tasks in life sciences instrumentation, and perfectly complement the Tecan Cavro® range of syringe pumps and pipetting solutions. This gives instrument designers an even broader choice of liquid handling technologies – as well as an array of robotic and valve options – backed by Tecan’s application expertise and global support infrastructure.

 

Joe Rotter, Vice President of Global Marketing for Components, said: “Pulssar’s high throughput precision pumps enhance our existing product portfolio, meeting the application-specific needs of different customer segments. Pulssar’s reputation for low volume accuracy and precision is a perfect fit for the high quality liquid handling and robotic platforms and components we offer our OEM partners.”

 

Khaled Abousaleh, founder of Pulssar Technologies, added: “We are very excited that Pulssar has become part of Tecan Partnering through this acquisition. The configurability and unique features of our piston pumps, combined with Tecan’s advanced pump technologies and robotic solutions, offer real synergistic value for new and existing customers.”

 

For more information, visit partnering.tecan.com

Pnano

Precision NanoSystems offers ground-breaking transfection technology for primary cells

author2017-02-24authorposted by Raquel,

Precision NanoSystems is helping scientists to push the boundaries of neuroscience research with a range of efficient and easy-to-use primary cell transfection kits. Combining user-friendly NanoAssemblr™ microfluidics systems with advanced nanoparticle technology, the company has developed the Neuro9™, Astro9™ and iNeuro9™ non-viral gene transfection kits to allow rapid and easy knockdown or expression of genes in primary cells, both in vitro and in vivo.

 

Precision NanoSystems’ innovative transfection kits are optimized for non-viral delivery of short interfering RNA (siRNA), messenger RNA (mRNA) or plasmid DNA (pDNA) into various neural cell types, such as neurons, astrocytes and iPS-derived neurons. This technology offers transfection efficiencies of up to 95 percent with no observed toxicity by taking advantage of an endogenous pathway to deliver the nucleic acid payload. Combined with the company’s NanoAssemblr microfluidic technology, the kits make it fast and easy to reap the benefits of ground-breaking transfection technology.

 

Each kit includes all the reagents required to generate nanoparticles using the NanoAssemblr systems, and is available for either in vitro or in vivo applications. This proven technology ensures rapid, high quality and reproducible results with minimal user training, and has already become widely established in the drug formulation field.

 

To learn more about Precision NanoSystems’ transfection kits or arrange a demo, visit www.precisionnanosystems.com/transfectionreagents.

Sonosite logo

Point-of-care ultrasound improving care for chest patients

author2017-02-23authorposted by Raquel,

Ultrasound guidance is now routinely used for pleural procedures, with current British Thoracic Society guidelines stating that all pleural drain insertions and aspirations should be performed using the technique. Dr Angshu Bhowmik, a consultant chest physician specialising in lung cancer and COPD at Homerton University Hospital, discussed the benefits of point-of-care (POC) ultrasound for clinicians and patients alike: “I first started using ultrasound in my practice in 2008, following the publication of several papers highlighting the potential safety improvements for chest drains and biopsies. Although most of my generation of registrars and consultants had been successfully performing these procedures ‘blind’ for many years, ultrasound allows you to visualise any unusual anatomical features – such as an enlarged heart or pleural thickening – reducing risks and improving success rates. We put together a business case based on this safety benefit, and chose a highly portable FUJIFILM SonoSite point-of-care system to meet our needs.”


“Since this time, we have routinely used POC systems for pleural drains and aspirations. As we have developed our interest in ultrasound further, we have started using it for a number of other applications – such as performing pleural biopsies in patients who are not suitable for thoracoscopic biopsies, or dynamic assessment of the diaphragm for some COPD patients – which is often safer and more convenient for patients, avoiding the need for radiology referrals. Our latest SonoSite Edge™ system offers excellent image quality, as well as a colour Doppler function, providing the best possible balance between resolution, portability and usability.”

pw logo

Particle Works creates range of high performance quantum dots

author2017-02-21authorposted by Louise ,

Particle Works – the nano- and microparticle materials specialist – has developed a range of high quality quantum dots for use in diagnostic, biomedical and optoelectronic applications. Available with a range of functional coatings, these high performance quantum dots offer unmatched color purity and unbeatable value.  

 

The optical properties of quantum dots are determined by their size, shape and structure, making precise control of manufacturing processes crucial for the creation of high performance materials. Particle Works combines its expertise in microfluidics and flow chemistry with state-of-the-art production systems to fabricate highly monodisperse quantum dots with narrow size distributions – typical CV values of ≤2.5 % – and excellent batch-to-batch consistency. Automated, scalable production ensures that Particle Works quantum dots offer much better value than other commercially available products, backed by full characterization data and product quality guarantees. The company can supply products with a range of functional coatings to suit imaging, fluorescent labeling and lighting applications, with dedicated service support for life sciences and optoelectronic applications.

 

For more information, visit: www.particle-works.com 

TECAN logo

Tecan offers cost-effective, walkaway automation of live cell assays

author2017-02-21authorposted by Raquel,

Tecan’s updated Spark® reader combines the benefits of a multimode microplate reader and a bright field imaging system in a compact package. Unlike other multimode readers, Spark lets you actually see what’s happening to your cells, offering automated cell imaging, confluence measurements, cell counting and viability assessments to simplify cell biology protocols and enable long-term, walkaway experiments.

 

Spark has been developed specifically to address the needs of cell-based workflows, and incorporates a host of features – including precise regulation of temperature, gas partial pressures and humidity – to provide an incubator-like environment and maintain optimal assay conditions. The system’s Live Viewer function turns your microplate reader into an automated microscope at the touch of a button, allowing you to instantly image and photograph defined positions in a microplate well. It offers bright field microscope-like functionality with 4x magnification and a user-definable focus, giving you another way to perform fast and easy quality control of your cells before starting your assay. In addition, Spark’s cell imaging module offers high throughput, label-free cell counting and one-click, trypan blue-based cell viability analysis using disposable Cell Chips™.

 

Spark also helps you to generate more reproducible cell-based assay data by allowing you to continuously monitor cell confluence within your microplate, and automatically inject a reagent once a user-defined confluence level is achieved. Together with the system’s advanced Fusion Optics – which combine the flexibility of monochromators with the sensitivity of filters – this ensures there is a Spark configuration to perfectly match your budget and workflow.

 

To learn more about Tecan’s Spark multimode reader, visit www.tecan.com/spark

header-logo

When it works well, it's pure chemistry. And when it's pure chemistry, it's ROMIL

author2017-02-16authorposted by Becca,

Visit ROMIL at Stand #353 at ARABLAB 2017 between the 20th and 23rd of March to discover superior purity solvents and impressive performance at a surprisingly good price. For more than three decades, ROMIL has been dedicated to achieving the highest standards of chemical purity, using a unique blend of experienced staff and leading-edge production facilities to create a wide range of high purity solvents, acids, reagents and certified reference materials meeting ISO Guide 34 requirements. Today, the company supplies analytical and life scientists around the world with exceptional quality products, including the PrimAg® range of single and multi-element calibration solutions and pure stoichiometric substances, high purity acids with trace metal ions down to low ppt levels, and ultra-pure solvents that meet the needs of even the most sensitive techniques.

 

ROMIL’s recently redesigned website allows straightforward browsing of the product catalogue from PCs, tablets and smartphones via the interactive user interface, with individual pods enabling rapid access to different product ranges directly from the home page.

Customers also have the option to create a myROMIL account, allowing safety data sheets and certificates of analysis to be downloaded – and the download history viewed – and favourite products to be stored for quick and easy access at a later date, putting all the information you need at your fingertips.

 

Discover the world of ROMIL for yourself at Stand #353 at ARABLAB, Dubai, from the 20th to the 23rd of March.

Sonosite logo

Point-of-care ultrasound systems prove ideal for the Children’s Acute Transport Service

author2017-02-16authorposted by Caroline,

The Children’s Acute Transport Service (CATS) depends on point-of-care ultrasound systems to get quick and accurate vascular access in critically ill children being transferred to specialist treatment centres. Advanced Nurse Practitioner Cathy Roberts explained: “In the UK, paediatric intensive care is provided at centralised units, and children needing this care must be safely transferred there by people with appropriate knowledge and skills. CATS provides a retrieval service for the North Thames area, transferring around 1,200 critically ill children a year from regional hospitals to those offering paediatric intensive care, such as Great Ormond Street, St Mary’s, the Royal Brompton, the Royal London and Addenbrooke’s.”

 

“Successful vascular access is vital for patient retrievals, and we frequently need to insert central or arterial lines as we stabilise children prior to transfer. I learned how to obtain vascular access under ultrasound guidance through a combination of supervised practice and a SonoSite training course. The training course was excellent, giving me the opportunity to practice different ways of holding the probe in the safety of a non-clinical environment, and discover various tips to help me get the most benefit from using ultrasound at the point of patient care. CATS has two SonoSite Edge® systems that we take with us wherever we go, and these are now used on around 70 to 80 % of our retrievals. Ultrasound has become so much a part of our routine that we would be lost without them.”

MT logo

Rainin TerraRacks™ benefit researchers at the University of Barcelona

author2017-02-15authorposted by Becca,

METTLER TOLEDO’s Rainin pipettes and TerraRack™ pipette tip racks are helping PhD students in the Department of Biochemistry and Molecular Biomedicine at the University of Barcelona, Spain, to study metabolic syndrome. Laia Oliva Lorenzo explained: “Our research involves the study of metabolic syndrome at cellular, tissue and organism levels, looking at the cellular metabolism – particularly adipocytes – of rats, and the effects of different diets and obesity. We analyze plasma and tissue samples, and carry out primary adipocyte culture and stromal cell tests.” Cecilia Ho Palma added: “We use a range of Rainin pipettes and tips for our work; single and multichannel, large and small volumes. The pipettes are very light, with a smooth action, and we have a choice of filtered and non-filtered tips, which is especially useful when working in a sterile, RNase-free environment.”

 

Floriana Rotondo continued: “In the past, we have reused non-recyclable tip boxes, refilling them with non-sterile tips. However, when TerraRacks were launched, we realised they were perfect for us. They are compact, easy to use and sterile, and can be stacked for storage, saving space. Another big advantage is that they can be recycled and so, from an environmental perspective, it was a natural progression to switch over to TerraRacks. We would definitely recommend them to other laboratories, they are so practical.”

 

Bulgin_logo_

Bulgin launches M-Series automation interconnects

author2017-02-09authorposted by Raquel,

Bulgin has launched a new range of industrial automation components which have been designed to offer flexible connectivity solutions for a variety of rugged automation applications. The M-Series interconnects includes a range of sizes and pin configurations – from 3 to 19 pins – and is designed for use in industries requiring exceptionally reliable and robust connections, from automotive production and machine building to food and beverage processing. A variety of connector types and keying options are available, including A-, B- and D-coded configurations. In addition to straight and right-angled field installable versions, Bulgin’s M5, M8 and M12 variants also offer PVC/PUR overmolded cable options to provide end-to-end automation connectivity for almost any situation.

 

To find out more about the M-Series interconnects, go to www.bulgin.com.

PLA-logos

The Paperless Lab Academy introduces the 2017 edition in Barcelona and announces new management

author2017-02-07authorposted by Violeta,

The fifth Paperless Lab Academy (PLA), Europe’s leading laboratory automation event, will be held on 4 to 5 April 2017 in Barcelona, Spain, on the theme of 2020 Roadmap for digital convergence.

The two-day event, organized by Industrial Lab Automation and NL42 Consulting, brings partners and attendees together in an environment designed to promote mutual interaction and exchange of views during plenary sessions and topic-focused workshops.

The founder of the event, Peter Boogaard, CEO of Industrial Lab Automation, explained: 'Over the past four years, the PLA has been raising awareness of "what works and what doesn't". At PLA2017, we'll be investigating a roadmap for the next decade, and how the convergence of paper and digital is bringing a new dimension to laboratory informatics. The extensive use of data analytics and applying lessons learnt from other industries, such as adopting an Industry 4.0 mind-set, will accelerate and make easer the badly needed integration of scientific equipment with enterprise software, to ensure a cost effective and high quality contribution from the laboratory to the enterprise as a whole.’

Roberto Castelnovo and Isabel Muñoz-Willery, founders of NL42 Consulting, are to take over as new owners of the event, and have emphasized that they will maintain the unique concept of this annual conference. Isabel said: ‘Under the new management, Peter will continue to play an important role as a member of the scientific committee.’ Roberto added: ‘We believe in the successful formula of the PLA which is based on three pillars: content-rich, non-commercial sessions; a showcase of informatics tools and methodologies available today, through interactive workshops hosted by leading suppliers; and free access to all industry delegates.’

About the Paperless Lab Academy

The PLA takes place annually and is aimed at directors and managers of research and development, IT and quality departments in pharmaceutical, cosmetic, biotechnological, petro-chemical and chemical markets. The event is focused on building the ideal learning platform for all organizations involved in running laboratories, and in consolidating, integrating or simplifying the data they generate.

Registration and programme are available at www.paperlesslabacademy.com

About NL42 Consulting

NL42 Consulting is a dynamic, free-thinking, independent management consultancy. Combining the flexibility and enthusiasm of a newly created company with the many decades of experience of its owners, NL42 provides services to support moving the laboratory to paperless processes. The expertise it offers is a powerful combination of technical know-how, profound managerial understanding of laboratories’ workflows, and international networking.

www.nl42.com

About Industrial Lab Automation

Industrial Lab Automation provides services to address harmonization, integration and consolidation of business processes in life-science development and manufacturing. Industrial Lab Automation enables cross-functional collaboration between research, development, quality assurance, and manufacturing corporations.

www.industriallabautomation.com

To contact NL42 Consulting:

Roberto Castelnovo

Email: Roberto.castelnovo@NL42.com

Phone: +39 340 456 3204

To contact Industrial Lab Automation:

Peter J. Boogaard

Email: peterboogaard@industriallabautomation.com

Phone +31 654 263516

MT logo

Rainin TerraRacks™ ideal for clean working practices

author2017-01-26authorposted by Becca,

 The Sysmex Inostics training center in Barcelona, Spain, is discovering the benefits of METTLER TOLEDO’s Rainin pipettes and TerraRack™ pipette tip racks at first hand, as Dr Laia Freixa, training center manager, explained: “Sysmex opened the Spanish training center in June this year, so it is a very recent initiative. Current and potential clients from around the world come to the laboratory to learn about OncoBEAM® RAS CRC test, a liquid biopsy technique that helps cancer specialists determine the most effective treatment for patients with metastatic colorectal cancer.”

 “We use a range of laboratory equipment during training, as well as in our R&D department, including a variety of Rainin pipettes – single and multichannel, manual and electronic – ranging from two to 1,000 microliters, as well as TerraRack pipette tip racks. We are routinely performing PCR so clean working processes are essential, and the use of sterile consumables, such as TerraRacks, is a key part of this. TerraRacks offer several advantages; they are good quality, light weight, easy to store, and can be recycled. Our Rainin pipettes are excellent too, combining robustness with accuracy. Customer service is equally important to us, and we receive good support from METTLER TOLEDO; our contact person is very responsive.”

Biofortuna logo

Biofortuna expands its immunoassay development and manufacturing services

author2017-01-24authorposted by Raquel,

 

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits.

 

Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven by the success of current customer projects and increasing demand from the market. These enhanced manufacturing capabilities will further strengthen the company’s existing immunoassay service and offer more flexibility to clients.

 

This focus on immunoassay products will complement Biofortuna’s highly successful molecular IVD services, which include ISO 13485 accredited and FDA registered contract research, lyophilisation, air-drying, manufacturing, dispensing and kitting of diagnostic products.

 

Dr Simon Douglas, Biofortuna CEO, commented: “The success and growth of current projects has fueled the desire to increase our immunoassay offering. This expansion will allow for large scale manufacturing of ELISA-based kits to meet our customers’ growing needs.”

Point-of-care ultrasound helps emergency care at King's College Hospital

author2017-01-24authorposted by Caroline,

The Emergency Department at King's College Hospital NHS Foundation Trust is a busy trauma centre dealing with over 400 cases every day. Point-of-care ultrasound has been used in the department of over 10 years, and now forms an integral part of many patient assessment pathways. Emergency Medicine Consultant Dr George Nada explained: “We currently use ultrasound for four main activities: FAST scans, insertion of peripheral lines, AAA screens and basic echocardiography, but it also has applications in many other areas, such as guiding the placement of chest drains, ascetic taps and femoral nerve blocks.” 

 

“We first started using ultrasound in late 2004, just for FAST scans and, approximately 18 months later, for pneumothoraces too. Around the same time, our ICU began using it for central line placement, and we soon followed suit for peripheral lines. We have used point-of-care ultrasound systems for almost all of this time, and the improvements – particularly in image quality – have been very impressive. Our latest system has the added advantage of a large screen which makes it very easy to see the structures of interest during a procedure. Its built-in learning modules are also excellent; new registrars coming into the department can simply work through the tutorials, and don’t need any specific training on how to use the instrument.”

 

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

eraf-sales@fujifilm.com  www.sonosite.com/uk

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

RDT to unveil a new approach to defibrillation monitoring at MEDICA

author2017-01-19authorposted by Becca,

The Sysmex Inostics training center in Barcelona, Spain, is discovering the benefits of METTLER TOLEDO’s Rainin pipettes and TerraRack™ pipette tip racks at first hand, as Dr Laia Freixa, training center manager, explained: “Sysmex opened the Spanish training center in June this year, so it is a very recent initiative. Current and potential clients from around the world come to the laboratory to learn about OncoBEAM® RAS CRC test, a liquid biopsy technique that helps cancer specialists determine the most effective treatment for patients with metastatic colorectal cancer.”

 

“We use a range of laboratory equipment during training, as well as in our R&D department, including a variety of Rainin pipettes – single and multichannel, manual and electronic – ranging from two to 1,000 microliters, as well as TerraRack pipette tip racks. We are routinely performing PCR so clean working processes are essential, and the use of sterile consumables, such as TerraRacks, is a key part of this. TerraRacks offer several advantages; they are good quality, light weight, easy to store, and can be recycled. Our Rainin pipettes are excellent too, combining robustness with accuracy. Customer service is equally important to us, and we receive good support from METTLER TOLEDO; our contact person is very responsive.”

Abbott Vertical

Abbott Announces CE Mark for its "Alinity s" Blood and Plasma Screening System

author2017-01-11authorposted by Raquel,

INNOVATIVE SOLUTION DESIGNED FOR BLOOD AND PLASMA SCREENING MAINTAINS HIGHEST LEVELS OF ACCURACY WHILE SUBSTANTIALLY INCREASING PRODUCTIVITY


 ABBOTT PARK, Ill., Jan. 10, 2017 — Abbott announced today its Alinity™ s System for blood and plasma screening received CE Mark and is now available in Europe and other countries that recognize CE Mark. The new testing solution is designed to screen blood and plasma faster and more efficiently within a smaller footprint than Abbott’s current systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of the
Alinity s System helps blood and plasma centers improve productivity and maintain the highest levels of accuracy, without expanding the instrument footprint.

 

"The Alinity s System is a significant leap forward when it comes to speed, automation and efficiency for blood and plasma screening," said Louis Morrone, divisional vice president and general manager for Abbott’s Transfusion Medicine business. "These elements are important to blood and plasma services of all sizes, supporting Abbott’s overall mission to help people live longer, healthier lives by keeping the global blood and plasma supply safe."

 

The Alinity s System will help transform the blood and plasma screening process in terms of speed, capacity and "walk-away" time (i.e., when lab professionals are free to manage other responsibilities while the instrument processes samples without direct interaction) as a result of a number of new features[i]:

     - Expands capacity to run up to 600 tests per hour, at least twice as much as competitive standalone instruments.

     - Improves centers’ ability to track all activities and actions associated with the testing and processing of each donation in accordance with relevant legislation and requirements.

     - Increases walk-away time to a minimum of three hours.

     - Gives laboratory professionals the ability to continuously load and unload samples and supplies without pausing or stopping the system.

     - Features an intuitive software interface, menu design and sample loading layout, shared with other Alinity instruments, making it easy for lab technicians to learn and use.

 

"When Abbott developed the Alinity s system, we considered the challenges that blood and plasma centers face today as well as in the future, such as adequate space, easier training, and more time for lab professionals to work away from the instrument," said Daman Kowalski, divisional vice president of research and development in Diagnostics at Abbott. "In addressing these challenges, the Alinity s System has the potential to transform how quickly and accurately these centers can screen blood and plasma, which means we can deliver life-saving blood components to the people who need it the most." 

 

[i] Abbott "Alinity s" System Operations Manual.

PRISM walk away time is limited by the sample capacity.  PRISM sample capacity = 280 samples maximum (10 racks x 28 samples/rack)

Up to 160 samples can be processed per hour

280/160 = 1.75 hours (105 minutes)

Compared to 180 minutes on the Alinity s

 

Abbott Vertical

Abbott Announces CE Mark for its Alinity ci-series Diagnostic Systems

author2017-01-11authorposted by Raquel,

NEXT GENERATION OF HARMONIZED SYSTEMS, COMBINED WITH RECENTLY LAUNCHED ALINIQ PROFESSIONAL SERVICES, PROVIDE A UNIQUE SOLUTION TO HELP LABS AND HOSPITAL SYSTEMS ACHIEVE MEASURABLY BETTER HEALTHCARE PERFORMANCE

THE ALINITY FAMILY DELIVERS UNPRECEDENTED INTEGRATION IN DIAGNOSTIC TESTING TO HELP SOLVE THE LAB’S MOST PRESSING CHALLENGES

    - New clinical chemistry and immunoassay technologies allow for cost-effective volume growth in a footprint half the size of Abbott’s current diagnostics systems[1]

    - Error-proof design elements help prevent costly mistakes in the lab

    - Easy-to-use software, common across all Alinity systems, helps labs simplify training and manage strained staffing resources

    - Scalable system design enables labs to address current and future needs

 

ABBOTT PARK, Ill., Jan. 10, 2017 — Abbott announced today its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics have obtained CE Mark and are now available in Europe and other countries that recognize CE Mark. These innovative testing solutions help labs run more tests in less time, reduce human error and increase testing productivity.

"Better healthcare begins with a high performing lab. Abbott’s Alinity family is an unprecedented approach to providing a more efficient, complete lab solution that no competitor in the industry can match," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Abbott is bringing meaningful innovation to diagnostic testing, elevating the role it plays in improving clinical decision making and delivering high quality care to patients."

 

Offering a flexible, modular design, the "Alinity c" clinical chemistry system, and the "Alinity i" immunoassay system, can operate individually or as an integrated Alinity ci-series unit, all within half the size of current diagnostics systems.

 

"The Alinity ci has the potential to be a game-changer for our lab, as it is designed to solve many of the issues that we face," said Mario Plebani, M.D., Professor of clinical biochemistry and clinical molecular biology, School of Medicine, University of Padova – Italy. "Every day we see greater demand for tests with fewer resources. The new Alinity systems are easier to use, helping to prevent errors and increase staff efficiency."

 

In addition to greater capacity in a smaller footprint, the Alinity ci-series maintains the high quality performance of Abbott’s current systems and has a number of new features based upon customer insights. Features include:

      - Increased loading capacity for samples and tests, and separate lanes to run urgent tests without interrupting lab workflow.

      - Continuous access to solutions and supplies, which gives labs the ability to reload solutions without pausing or stopping instruments or testing cycles for prolonged periods of time.

      - Solution bottles designed to work like a lock and key to ensure the right solutions can only be inserted into the right location.

      - Intuitive menu design and user-friendly interface, common to the Alinity family of instruments, which simplifies training for lab technicians.

 

"To design the Alinity ci systems, we spent countless hours with our customers in the design phase to ensure that we built a solution for the issues they face every day–including higher testing volumes, a lack of staffing and space, and complex, time-intensive processes and instruments," said Dennis Gilbert, Ph.D., vice president, research and development, Diagnostics, Abbott. "The Alinity family of systems simplifies diagnostic testing while delivering results that drive better patient outcomes."

 

Abbott will launch clinical chemistry and immunoassay tests for the Alinity ci-series in phases, with a complete menu of tests available within a year of launch.* Clinical chemistry tests detect the presence of different chemicals in the blood and include tests such as sodium, potassium, glucose and calcium. Immunoassay methods use antibody or antigen recognition to detect complex molecules and provide information related to infectious diseases, hormone levels, cardiac risk factors, cancer, thyroid issues and therapeutic drugs.

 

1 Abbott internal data.

 

mettler-toledo

A service you can rely on

author2017-01-11authorposted by Becca,

The Coates Lab at the University of California Berkeley focuses on environmental and fossil fuel microbiology, and relies on Rainin to maintain its large pool of pipettes. Laboratory manager Anna Engelbrekston explained: “Our group’s research concentrates on oil reservoir microbes, specifically looking at inhibiting the production of hydrogen sulfide by sulfate reducing microorganisms, which causes oil reservoir souring. We perform a wide range of DNA and RNA studies, as well as colorimetric assays, HPLC and ion chromatography, and have in the region of 90 manual single channel pipettes, plus a dozen or so multichannels. A number of our pipettes are Rainin LTS, which are popular with everyone in the lab, as they are very comfortable and easy to use.”

 

“It is important that pipettes are serviced correctly to ensure accurate, reproducible results, and so, once a year, Rainin’s technicians visit our site to carry out the necessary servicing and calibration. As we use corrosive chemicals, one big advantage of Rainin’s service is that the technicians replace the pipette seals annually. Not all companies do this, and it makes a big difference; since we started using Rainin for our pipette servicing about three years ago, far fewer of our pipettes need to be sent for maintenance in between service visits. Everything is going very well.”

dolomite-bio

Dolomite Bio launches Injection Valve and Sample Loop for scRNA-Seq

author2017-01-10authorposted by Violeta,

Dolomite Bio has launched a new Injection Valve and Sample Loop for single cell RNA sequencing workflows. This option enables straightforward, gentle introduction of evenly distributed mRNA capture beads into the company’s RNA-Seq System for individual encapsulation of cells.

The Injection Valve and Sample Loop is a complete module allowing barcoded mRNA capture beads in lysis buffer to be efficiently flowed through the RNA-Seq Chip without clustering or blockages. Bead damage prior to encapsulation is negligible as harsh mechanical stirring is unnecessary, and its four-way valve and simple, compact microfluidic connections enable seamless switching between the injection of the bead suspension and pumping of a driving fluid, with minimal dead volume and bead wastage compared to traditional syringe pump methods. The integrated mirror and chip holder enable easy visualization via the RNA-Seq System’s high speed microscope and camera, and the module also incorporates a Falcon®/Eppendorf® tube holder for easy collection of the droplet emulsion.

For more information, visit www.dolomite-bio.com

 

About Dolomite Bio

Dolomite Bio creates innovative products for high throughput single cell research. By encapsulating single cells in microfluidic droplets, our products enable rapid analysis of thousands or millions of individual cells and their biological products.

Dolomite Bio is a brand of Blacktrace Holdings Ltd (www.blacktrace.com), a world leader in Productizing Science®. Our Head Office is based in Royston (near Cambridge), UK and we have regional offices in the USA, Japan, India and Brazil.

Dolomite Bio’s products include μEncapsulator System and RNA Seq system, suitable for use in many applications such as isolating antibody coding sequencing, profiling T cell receptors, droplets for FACS-sorting libraries and encapsulating cells in gel microbeads. To find out more about Dolomite Bio, please visit www.dolomite-bio.com

tecan

Improved pipetting performance for biobanking and diagnostics

author2017-01-10authorposted by Becca,

Tecan is simplifying handling of biological fluids with the introduction of a wide bore version of its popular 1,000 μl Liquid Handling Arm™ (LiHa) disposable tip. Initially available for use with the Air LiHa™ air displacement pipetting option on Freedom EVO® workstations, this new filtered tip has been developed to help alleviate some of the issues associated with handling complex liquids for applications such as biobanking and clinical diagnostics.

                                                          

The introduction of a wide bore tip option for the Air LiHa is in direct response to customer requests, and is aimed at users routinely working with viscous or non-homogenous biological fluids. Supplied in Tecan Pure purity in Tecan’s standard hanging tray format, the larger diameter aperture of this tip should help to eliminate tip occlusion errors, reducing the need for manual intervention and improving laboratory productivity. The new tip is currently supported for capacitive liquid level detection (cLLD) and Pressure Monitored Pipetting (PMP™) in the latest version of Freedom EVOware®, and will soon be available for use with both the Freedom EVO’s liquid-displacement LiHa and the Fluent® Laboratory Automation Solution’s Flexible Channel Arm™, allowing it to be easily introduced into existing workflows.

                                                                                                                       

To learn more about Tecan’s new wide bore 1,000 μl LiHa disposable tip, visit www.tecan.com/consumables  

mettler-toledo

Rainin TerraRacks™ provide a greener alternative for pipetting

author2016-12-15authorposted by Becca,

METTLER TOLEDO’S Rainin TerraRacks™ have enabled the European Institute of Oncology in Milan, Italy, to adopt a more environmentally-friendly approach to manual pipetting. Dr Bronislava Matoskova, Molecular Medicine Program Manager, explained: “As well as regular biochemistry and molecular biology studies, we analyze human tissue, blood and serum as part of a molecular medicine research program. We use large numbers of pipette tips and are keen to reduce the environmental impact of our work as much as possible. When I saw the TerraRack, I was immediately captivated by its green concept, which minimizes the waste produced. It was love at first sight!”

                                              

“TerraRacks are transparent and the hinged lid ensures that the tips remain clean and free from contaminants, which is crucial for any application where sterility is important. I’m particularly pleased about the environmental benefits. The TerraRack is lightweight and can be compressed so that it takes up less space, and its companion TerraBase™ is reusable, reducing the amount of waste generated. Whether you dispose of laboratory waste by weight or volume, it’s a win-win situation.”

dolomite-bio

Dolomite Bio’s Single Cell RNA-Seq System accelerating cancer research

author2016-12-09authorposted by Violeta,

Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer. Karolina Nowakowska, a PhD student at The Institute of Cancer Research, explained: “Our team is focused on studying treatment resistance in prostate cancer patients, looking at the biochemical mechanisms responsible. My project is based on using single cell sequencing to help identify the specific genes which lead to treatment resistance, trying to identify biomarkers and, in the longer term, treatments which will allow a more personalized approach to therapy.”

 

“Initially I was using FACS to perform manual sorting of cells into individual wells, but this is both time consuming and laborious, limiting me to a maximum of 20 cells per experiment. As throughput is crucial in biomarker discovery, we wanted to perform our investigations on a much larger scale and, following the publication by Macosko et al1, we decided that microfluidics was the way forward. After a demonstration of the system at Dolomite Bio’s headquarters near Cambridge, we chose the Single Cell RNA-Seq System, and can now run over 1,000 cells per experiment. Although we have only just finished optimizing our protocols, the throughput is very impressive and the system offers good reproducibility. The beauty of this technique is that it allows you to view many cellular events simultaneously and, once optimized, it’s more cost effective than manually sorting and sequencing cells.”  

 

For more information, visit www.dolomite-bio.com

Disclaimer: The views stated are that of the individual, and not The Institute of Cancer Research

1 Macosko E et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161(5), 1202-14.

mettler-toledo

Simplifying environmental microbiology research with Rainin Pos-D pipettes

author2016-12-08authorposted by Becca,

Researchers at the University of Alaska Fairbanks are using a METTLER TOLEDO Rainin Pos-D™ positive-displacement pipette to investigate the role of chemical dispersants in the biodegradation of oil in Arctic marine environments. Taylor Gofstein, a PhD student, explained: “Little is known about the fate of oil or oil spill response chemicals – like dispersants – in Arctic waters, since most studies regarding dispersants are performed in temperate regions. There is currently a pretty hot debate in the environmental microbiology community about the role dispersants play in the biodegradation of oil; one hypothesis suggests that they increase bioavailability to microorganisms – speeding up the process – while a few researchers suggest they are degraded in preference to petroleum contaminants, slowing the process. This is a key question we are interested in answering, and we recently performed a major incubation experiment using Arctic seawater.”

 

“Starting with 250 liters of water from just off Barrow – the northern-most point of the USA – this investigation included 180 one liter bottles and 165 stirrer plates. Our target was to achieve an oil-in-water concentration of around 50 ppm, requiring just 47 μl of crude oil per bottle. Pipetting oil accurately with a traditional air displacement pipette would be an exercise in futility, so we were lucky to have a Rainin Pos-D pipette available for this work. Unlike with some other positive-displacement pipettes, the Rainin tips come pre-assembled, meaning we can autoclave them and just use them as we would for a standard pipette, without worrying about sterility and contamination. The pipette is also ergonomically designed and has a very smooth mechanism, making it quick and easy to use.”

glass-solutions

Glass Solutions delivers high quality glassware for laboratory applications

author2016-12-06authorposted by Violeta,

Glass Solutions, a world leader in the manufacture of high quality, precision glassware, is the supplier of choice for a wide variety of laboratories, providing specialist scientific glassware backed by unrivalled service and support. With extensive in-house expertise, combined with the UK’s largest advanced glass-blowing facility, the company is ideally placed to produce exceptional quality, precision manufactured glassware to suit a wide variety of laboratory applications.

 

Based in a modern, purpose-built facility, Glass Solutions offers an extensive portfolio of ready-made laboratory glassware – including test tubes, beakers, separating funnels, condensers and reaction vessels – established over many years in response to customers’ demands. Each design can be rapidly reproduced and tailored to individual client’s particular needs, whether a one-off piece or a batch of glassware is required. For those occasions when a custom solution is required, the company also offers a bespoke design and glass-blowing service, using its knowledge and skills to turn novel ideas from a scale drawing into carefully crafted laboratory items. Whether you require routinely used equipment from the standard catalog or a unique individual piece, Glass Solutions is perfectly positioned to deliver on time, at a competitive price.

 

About Glass Solutions

Glass Solutions is the world leader in the manufacture of high quality, precision glassware, custom-made for scientists, architects, designers, instrument makers and engineers. Based in Sutton, near Cambridge, UK, it has the largest advanced glass-blowing facility in the country, as well as offices in the US, Japan, Brazil and India. The company manufactures a wide range of glassware, including standard laboratory and sophisticated custom-made glassware, glass tubing and rods, and provides design assistance, prototype and small batch manufacturing services, as well as large-scale production of thousands of items. www.glass-solutions.com.

dolomite

Dolomite’s Fluidic Factory recognized with R&D 100 Award

author2016-11-24authorposted by Raquel,

Dolomite, a world leader in microfluidics innovation, is celebrating the success of its Fluidic Factory 3D printer in the ‘Processing and Prototyping’ category this year’s R&D 100 Awards. This innovative system – the first commercially available 3D printer for fluidically-sealed devices – offers rapid, straightforward and reliable prototyping of microfluidic components, including chips, manifolds, connectors and other devices. Using cyclic olefin copolymer (COC) makes it easy and affordable to 3D print devices for almost any application.

 

The prestigious R&D 100 Awards are the ‘Oscars of Invention’, providing a benchmark of excellence and identifying the top technology products of the past year. The winners are chosen by an independent panel of judges and the editors of R&D Magazine, who this year recognized the significant contribution the Fluidic Factory is making to the fast growing field of microfluidics. Its success highlights the potential of this system to further research and development in areas such as medical diagnostics, drug development, chemical synthesis, enzymatic bioconversion, biomedical assays and education.

 

Mark Gilligan, CEO of Blacktrace Holdings, commented: “The entire Blacktrace Group is delighted that we have once again been successful at the esteemed R&D 100 Awards, highlighting our strengths in innovation and developing novel technologies with real world applications. This award recognizes how the Fluidic Factory is helping to push the boundaries of microfluidics, enabling faster and more cost-effective prototyping and opening up new avenues of research.”

 

To find out more, please visit www.dolomite-microfluidics.com/webshop/fluidic_factory

Broughton Software

Wockhardt introduces LabHQ LIMS for quality control

author2016-11-11authorposted by Violeta,

Global pharmaceutical and biotechnology company Wockhardt has chosen the latest version of Broughton Software’s LabHQ LIMS for its new quality control laboratories in Wrexham. This intuitive software solution is specifically designed to support the activities of busy quality control laboratories, and has been developed with input from Broughton Software’s clients and network of regulatory, quality and laboratory professionals.

 

Wockhardt selected LabHQ LIMS to meet a number of key business needs, including facilitating data integrity for regulatory compliance, increasing operational efficiency and reducing costs. Together with its purpose-built quality control laboratories, this will support Wockhardt’s business well into the future, helping to improve the working environment, optimise testing efficiency and meet regulatory expectations. The success of this installation with its intuitive user interface means that the system also has the potential to be deployed across Wockhardt’s global sites in India and Ireland.

 

Peter Sheppard, Quality Standards Manager at Wockhardt, explained: “When we were considering upgrading our LIMS, it was imperative that any new system would satisfy the growing regulatory demands of the pharmaceutical industry, as well as deliver further efficiency improvements and cost savings to our business operation. Working with Broughton Software on a new version of LabHQ LIMS has enabled us to achieve this goal. The go live is perfectly timed as it coincides with the move into our new ‘state of the art’ QC and R&D laboratories in Wrexham.”

 

Broughton Software CEO Paul Moran added: “We are delighted that Wockhardt has joined our growing list of client partnerships. Working with one of the world’s largest generic pharmaceutical manufacturers gives us a priceless insight into the increasing demands of regulatory bodies such as the MHRA and FDA.  As a result, the latest version of LabHQ LIMS provides pharmaceutical companies with the technology to ensure regulatory compliance and enhance the value of their global supply chains.”

 

To learn more about Broughton Software’s innovative LIMS solutions, visit www.broughtonsoftware.com

 

About Wockhardt

Wockhardt is a global pharmaceutical company employing over 10,000 people and 27 nationalities, with a presence in USA, UK, Russia and many other countries. It has manufacturing and research facilities in India, the USA and the UK, as well as a manufacturing facility in Ireland. Wockhardt has a significant presence is USA, Europe and India, with 62 % of its global revenues coming from international businesses. Wockhardt is home to 850 scientists, of whom 100 are doctorates. Wockhardt is the only company in the world that the US FDA has given QIDP status (Qualified Infectious Diseases Programme) for five of its antibacterial discovery programmes – two of them are gram negative and three gram positive. Wockhardt’s anti-infective portfolio targets bacterial organisms where resistances are high and breakthrough antibiotics are needed.

 

About Broughton Software

Broughton Software is a development company specialising in the regulated pharmaceutical and healthcare industries. The company holds a UKAS-accredited certification to ISO 9001:2015 for the design and development, deployment and support of electronic data management systems for use in regulated environments. Broughton Software’s focus has been on building strategic partnerships and delivering competitive advantage for pharmaceutical and healthcare companies.

 

dolomite

From microcapsules to heavy industry

author2016-11-10authorposted by Violeta,

Researchers at the Lawrence Livermore National Laboratory (LLNL) are using a Dolomite Fluidic Factory to help develop a novel carbon capture technology intended for industrial applications1. Mindy Simon, postdoctoral research associate, explained: “Carbon capture is important for power generation and other heavy industries, reducing the amount of carbon dioxide released into the atmosphere. Here at LLNL, we have developed an innovative microcapsule technology which consists of a highly permeable polymer shell surrounding a CO2-absorbing liquid core. These microcapsules can be loaded into columns which can then be placed into a smoke-stack or other industrial outlet, capturing the CO2 before it is released into the environment.”

 

“We use microfluidics to manufacture the microcapsules, and initially used custom glass microfluidic chips from Dolomite for this application. However, because we are a research lab, we are constantly tweaking and updating our designs, and manufacturing glass prototypes by hand is both laborious and complex; it’s as much art as science. We wanted a 3D printer to allow rapid prototyping of new microfluidic devices, and our local Dolomite representative told us about the Fluidic Factory. We were immediately interested, and became a beta tester for the system.”

 

For more information, visit www.dolomite-microfluidics.com.

 

1)  Vericella, J, et al.  Encapsulated liquid sorbents for carbon dioxide capture, Nature Comms, 2015, 6:6124

mettler-toledo

A pipetting (r)evolution

author2016-11-10authorposted by Becca,

Rainin LTS pipettes are helping scientists at the University of California, Santa Barbara to perform research in the fields of ecology and evolution. Danielle Black, a graduate student in the Department of Ecology, Evolution and Marine Biology, explained: “Our lab is focused on the study of fungal communities associated with plant leaves. As part of this research, we use PCR to amplify certain regions of fungi DNA for analysis, and this involves a lot of pipetting. Our Rainin LTS pipettes are ideal for this work. They are very comfortable to hold and smooth to operate, and so your hands don’t get as tired. This is a real benefit for repetitive pipetting tasks.”

 

“When you are doing sensitive molecular assays, sterility is important. We use both filtered and unfiltered tips, and find the Rainin TerraRacks an advantage. Previously, we used refillable tip boxes which had to be autoclaved each time. TerraRacks are ready to use – eliminating the need to autoclave and refill tip boxes – and this saves a lot of time. The lab is also tidier, as we no longer have empty boxes waiting to be autoclaved and refilled and, since TerraRacks use less plastic, it is better for the environment too. They are just so much more convenient.”

glass-solutions

Brazing ahead with Glass Solutions

author2016-11-09authorposted by Raquel,

Innoval Technology – a global aluminium consultancy company – relies on Glass Solutions to supply precision-manufactured bodies for glass tube brazing furnaces. Adam Nadin, a metallurgical engineer at Innoval, explained: “Many of the companies that manufacture aluminium components do not have in-house laboratories, so rely on our expertise to provide process support and product-related solutions. Using a glass tube brazing furnace, our Materials Testing Team can quickly and accurately simulate industrial conditions on a small scale.”

 

“We initially looked at purchasing a ready-made glass tube brazing furnace, but had trouble sourcing equipment that met our needs, and so decided to create our own. We approached Glass Solutions to produce the glass outer body and replaceable inner sleeve, because the company had considerable experience in manufacturing complex and robust glassware for scientific instruments. We simply supplied the technical drawings, and they produced exactly what we required; it really was that easy. Glass Solutions has since manufactured a number of additional furnace bodies for us to supply to customers around the world, and we’ve always been very happy with the quality of the service we receive.” 

 

bulgin

Bulgin to launch M Series interconnects at electronica 2016

author2016-11-08authorposted by Raquel,

Bulgin will be unveiling a new range of industrial automation components on stand B2.271 at this year’s electronica exhibition. This bi-annual event, which takes place from the 8th to the 11th of November in Munich, will be the first opportunity to see the new M Series interconnects, which have been designed to offer flexible connectivity solutions for a variety of rugged automation applications.

 

The M Series includes a range of sizes and pin configurations – from 3 to 19 pins – and is designed for use in industries requiring exceptionally reliable and robust connections, from automotive production and machine building to food and beverage processing. A variety of connector types and keying options are available – as well as both straight and right-angled versions – providing end-to-end automation connectivity for almost any situation.

 

To find out more about the M Series interconnects, as well as the complete range of Bulgin products, visit Bulgin on stand B2.271 or go to www.bulgin.com.

mettler-toledo

Rainin TerraRacks enhance process security for CROs

author2016-11-03authorposted by Caroline,

Pelago Bioscience in Solna, Sweden, is taking advantage of the enhanced process security and convenience offered by METTLER TOLEDO’s Rainin TerraRack™ pipette tip racks. Dr Charlotta Norling, Project Leader at Pelago, explained: “We perform contract research activities for the pharmaceutical industry, with a particular focus on drug-target interactions in early drug discovery. We use high quality Rainin pipettes throughout the company, because we only have a very limited amount of each drug candidate, and our studies are time sensitive, meaning we cannot afford any pipetting issues which may compromise results for our customers.”

 

“To save on bench space, we generally use stackable pipette tips for most of our work, but we have recently switched to Rainin TerraRacks in our cell biology laboratory. Sterility is vital for this work, and the risk of contamination when using stackable tips was unacceptable. The TerraRacks are ideal, as they come pre-sterilized. This saves a lot of work in terms of sterilizing the tips in house, and each rack has a hinged lid to ensure they stay clean – we’ve had no sterility issues with TerraRacks. The color-coding also makes it very easy to see which tip size you have – they are ideal for our cell lab and complement our Rainin pipettes well.”

 

For more information, please contact:

METTLER TOLEDO AG,

Laboratory & Weighing Technologies,

Im Langacher, 8606 Greifensee, Switzerland

 

T +41 44 944 2211

F +41 44 944 3320

http://www.mt.com

 

About Rainin

Rainin, a METTLER TOLEDO Company, is the leading provider of advanced pipetting solutions for life scientists worldwide. We offer a wide selection of manual and electronic pipettes, BioClean pipette tips, and expert services that work together as a complete pipetting solution – Pipetting 360°. Rainin has long been the largest selling brand in North America and consistently rank among the top premium pipette brands in Europe, Asia and the Middle East. Top quality, innovative design and state-of-the-art production result in superior pipetting products with years of reliable operation.

BBI_Solutions

Up to 10-fold increase in assay sensitivity - discover Morffi™ at MEDICA 2016

author2016-11-03authorposted by Violeta,

BBI Solutions will be showcasing its Morffi™ signal enhancement technology on Stand F26 in Hall 1 at MEDICA 2016. This year’s exhibition, which takes place in Dusseldorf from the 14th to the 17th of November, will give delegates a chance to explore this innovative technology and learn about the complete range of high quality raw materials and services the company offers to the IVD industry.

 

Morffi technology can improve performance for lateral flow immunoassays by increasing signal intensity and sensitivity up to 10-fold, as well as offering a faster time to result. Visitors to the stand will be able to discuss the potential of this novel conjugate blocking method, which is offered as part of BBI’s lateral flow development and OEM manufacturing services. The event will also be one of the first chances for customers to see the company’s recently extended portfolio, including a range of disease-specific antibodies and the new CellAdvance™ range of cell culture reagents. This expanded product offering represents an unparalleled source of high quality raw materials for the IVD market, backed by 30 years of BBI expertise in the lateral flow market. And if you still can’t find what you’re looking for, speak to the team about the company’s custom end-to-end assay development services, helping you to go from initial concept to final manufacture and beyond.

 

Join BBI Solutions on Stand F26 in Hall 1 at MEDICA 2016 to learn more about the future of lateral flow technology, or visit http://www.bbisolutions.com/events/medica-2016/ to pre-book an appointment with the team.

 

 

About BBI Solutions

BBI Solutions is a leading manufacturer of biological reagents and finished test platforms for the in vitro diagnostics market. BBI is a global business with manufacturing sites spanning three continents.

 

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

 

BBI Solutions offer lateral flow development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

 

BBI Solutions is part of the BBI Group.

 

www.bbisolutions.com

cepheid

30 Minute or Less Molecular Flu/RSV Test Now Available

author2016-11-01authorposted by Raquel,

 

With the flu season fast approaching, healthcare providers no longer need to choose between a fast test result or an accurate test result for patients suspected of influenza infection. Now, they can have both, with Xpert® Xpress Flu/RSV from Cepheid, a new test that delivers reference-quality molecular test results in as little as twenty minutes.1

 

"For too long, clinicians have been asked to treat suspected cases of influenza empirically, since gold-standard RT-PCR based tests took too long to process in the critical first 24 hours of symptom onset," said David H. Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "With the arrival of fast molecular tests like Xpert Xpress Flu/RSV, patients and their healthcare providers can now expect an accurate diagnosis, and access to targeted therapies substantially more quickly. Unnecessary treatment with antimicrobial agents can also be avoided. This supports clinical efforts to improve the patient experience, and further streamlines workflow in the laboratory, which can be particularly challenging in the midst of a busy respiratory virus season."

 

Upper respiratory infections are among the most common reasons for outpatient visits in the United States and worldwide.2,3 Early symptoms for a wide variety of viral and bacterial respiratory infections are often clinically indistinguishable, yet treatment is different depending on the cause of infection, highlighting the importance of accurate diagnostic tests like Xpert Xpress Flu/RSV. With this development, hospitals and clinics can reliably diagnose influenza and respiratory syncytial virus (RSV) infection in 30 minutes or less.

 

Xpert Xpress Flu/RSV is twice as fast as its predecessor, Xpert Flu/RSV XC, but has comparable performance characteristics. The new assay features a novel design, which employs multiple targets for each virus. The built-in redundancy provides very high test sensitivity, avoiding the impact of seasonal drift that has been a problem historically with molecular tests, while maintaining high specificity. This assay is the first in a series of tests from Cepheid that will deliver results in 30 minutes or less.1

 

The new test is available immediately in the EU and all countries recognizing the CE-Mark.

For more information, visit http://www.cepheid.com/en/

dolomite-bio

Dolomite Bio offers flexible single cell encapsulation for autoimmune disease research

author2016-10-27authorposted by Violeta,

Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at the single cell level. Dr Päivi Saavalainen, Principal Investigator, explained: “We are primarily interested in the genetics and immunopathogenesis of these diseases, and the ability to study the molecular biology of individual lymphocytes is an important part of our work. I became interested in microfluidics for single cell encapsulation around a year ago, following the publication of the Macosko paper1. At the time, there was no bespoke system for performing the Drop-seq method but, by the time I had secured funding, Dolomite Bio was offering the purpose-made Single Cell RNA-Seq System.”

“I’m not an expert in microfluidics, so being able to purchase a complete package – without needing to select my own chip design, pumps and tubing configuration – made the choice very easy. We have had the system since May, and I’m pleased with the throughput it offers. There was a bit of a learning curve, as we were not familiar with microfluidics technology, but we can now produce a few thousand individually encapsulated and barcoded cells in a single 15 minute run. Another nice feature of the Dolomite Bio system is that it’s quite flexible. This allows you to develop your own protocols, and we have been able to optimize the chemistry and our libraries to perfectly match our downstream processes.”

For more information, visit www.dolomite-bio.com

1 Macosko E et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161(5), 1202-14.


About Dolomite Bio

Dolomite Bio creates innovative products for high throughput single cell research. By encapsulating single cells in microfluidic droplets, our products enable rapid analysis of thousands or millions of individual cells and their biological products.

Dolomite Bio is a brand of Blacktrace Holdings Ltd (www.blacktrace.com), a world leader in Productizing Science®. Our Head Office is based in Royston (near Cambridge), UK and we have regional offices in the USA, Japan, India and Brazil.

Dolomite Bio’s products include μEncapsulator System and RNA Seq system, suitable for use in many applications such as isolating antibody coding sequencing, profiling T cell receptors, droplets for FACS-sorting libraries and encapsulating cells in gel microbeads. To find out more about Dolomite Bio, please visit www.dolomite-bio.com.

dolomite

Dolomite and Lab on a Chip Video Competition winner cooks up a treat

author2016-10-25authorposted by Violeta,

This year's MicroTAS Video Competition has been won by Enrica Rollo from EPFL (École polytechnique fédérale de Lausanne) in Switzerland, for her entertaining comparison between cleanrooms and kitchens. The annual competition – run by microfluidics specialist Dolomite and Lab on a Chip, and supported by the Chemical and Biological Microsystems Society – embraces the lighter side of life sciences and chemistry, while giving delegates a chance to win €2,500 worth of Dolomite microfluidics equipment.

 

Enrica's winning entry was a recipe for a 'Micropillars Chocolate Cake', providing an imaginative yet informative explanation of how micropillar electrodes are created and used to monitor the passage of single cells. Substituting silicon dioxide, platinum and titanium for chocolate, hazelnuts and coconut, her entry certainly had the judges’ interest! Enrica picked up her prize voucher from Dolomite's Mark Gilligan and Sam Keltie, Executive Editor of Lab on a Chip, at the event, and is now busy designing her new microfluidic system.

 

To see the winning video, visit https://www.youtube.com/watch?v=1c-sRzp4syg&feature=youtu.be

sonosite-fujifilm

Using point-of-care ultrasound to train the intensivists of the future

author2016-10-21authorposted by Caroline,

West Suffolk Hospital in Bury St Edmunds is using the latest generation point-of-care ultrasound system to help intensive care trainees develop their skills in cardiac and lung ultrasound, as consultant anaesthetist Dr Kaushik Bhowmick explained: “My main focus is point-of-care echocardiography, while one of my colleagues is particularly interested in lung ultrasound. We have a strong focus on training – we are the first district general hospital in the eastern region to offer a FICE training course – and wanted a good teaching device for our intensive care trainees. FUJIFILM SonoSite’s X-Porte® ultrasound system is ideal for these purposes. I also use it in theatre if an echocardiogram is required, complementing the SonoSite Edge® that we routinely use for vascular access and nerve blocks.”

 

“In real-time situations, there may be occasions when a trainee cannot get the view they want and are not sure why. This is where the X-Porte can really help, as the trainee can review the steps in acquiring the image from the teaching module embedded within the machine and find out where they went wrong. Interpretation of the data is even more important, and so we also use the system for seminars, showing the trainees different slices from various patients, and talking through a range of cases. I am also actively promoting FICE accreditation to other consultants, as I think it is an important technique to learn. Ultimately, the more people who can use point-of-care ultrasound, the better it will be for our patients.”           

rainin

Delivering a first-class service

author2016-10-19authorposted by Becca,

Researchers at the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute in La Jolla, USA, rely on Rainin Pipet-Lite™ XLS pipettes and filter tips for studies to identify disease-driving genes and pathways in autoimmune and infectious diseases, and cancer. Antje Rhode-Kurnow, senior laboratory manager and scientific specialist in the center’s Laboratory of Molecular Immunology, Carl Ware Lab, explained: “We do a lot of virus work, particularly experiments involving DNA and RNA studies, and it is essential to avoid any potential for contamination. Everything we use in our BSL-2 tissue culture room must be sterile, and one of the main reasons for choosing Rainin is that it offers sterile DNase/RNase-free filter tips for its pipettes.”

 

“We have a mix of manual and electronic, single and multichannel pipettes. Everybody loves the Pipet-Lite XLS pipettes because they are light weight and it is very easy to change the volume settings. The multichannel pipettes are ideal for ELISAs, and the electronic single channel pipettes are really popular for RT-PCR. Rainin’s customer service is fantastic too; once a year, the company’s technicians visit our laboratory and calibrate our pipettes on site. If a pipette needs attention between these visits, we simply contact the service center and it is collected, repaired and returned to us very quickly. It’s a great system and, together with the company’s trade-in scheme, is another good reason to stay with Rainin. I’m a very happy customer.”

particle-works

Particle Works offers bespoke microencapsulation for drug development

author2016-10-11authorposted by Violeta,

Particle Works – the nano- and microstructured material specialist – provides microencapsulation services for drug development applications, including controlled drug release, solubility enhancement or targeted drug delivery. Using its expertise in microfluidics and nanoparticle synthesis, the company can create bespoke PLGA formulations and coatings to alter drug release profiles, enhance the efficiency of targeted drug delivery and more precisely control dosing regimes.

 

Microencapsulation of active pharmaceutical ingredients (APIs) is increasingly being employed in the drug development arena to improve the solubility of candidate drugs or protect biopharmaceutical agents (DNA, proteins, etc) from degradation, as well as to provide more controlled release of APIs over time. Functionalization of the particle surfaces with specific binding species – such as antibodies, aptamers and peptides – also allows the particles to be targeted to a specific location or tissue, increasing the efficacy of many drugs. PLGA is commonly used for drug microencapsulation, and precise control over particle size, shape and architecture is extremely important to the efficacy of the candidate drug. Particle Works can use its expertise in nanoparticle development to improve the targeting efficiency, distribution and lifetime of the particles in vivo. From the encapsulation of candidate APIs in custom PLGA configurations to the creation of unique functionalized coatings, the company can provide high quality development and scale-up of highly monodisperse nanoparticles (typical CV values of <5 %) offering improved targeting efficiency, efficacy and reproducibility.

 

For more information, visit: http://www.particle-works.com/applications/targeted-drug-delivery/

biofortuna

Biofortuna reaches key milestones for ReadyPlex™ blood group genotyping product family

author2016-10-03authorposted by Raquel,

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has successfully achieved key milestones in the development of its new blood group genotyping product family – ReadyPlex™. This breakthrough has released the second tranche of its 2015 funding – totalling £1.5m – which will be used for final development and commercialisation of this innovative product line.

 

The ReadyPlex range is aimed at the transfusion market, and will offer rapid genomic analysis of erythrocyte blood groups, human platelet antigens (HPAs), human neutrophil antigens (HNAs) and coagulation polymorphisms. A product design freeze has now been achieved, and this additional funding – supported by all the company’s current investors, including Foresight VCTs, Catapult Ventures, Enterprise Ventures, Merseyside Special Investment Fund, private investors and management – will enable verification and validation of the product family as it moves towards clinical trials. In addition, the funding will be used to increase the capabilities and production capacity of Biofortuna’s manufacturing and development contract services division, helping to meet the demand of current and future contracts.

 

Dr Simon Douglas, Biofortuna CEO, said: “The new investment will be used to increase the portfolio of tests currently offered by Biofortuna. These new funds and the confidence of all of our investors shows the potential of Biofortuna as a leading diagnostic kit provider, as well as a world-class contract service manufacturer.”

syrris

Syrris creates Orb Pilot for effortless reaction scale-up

author2016-09-28authorposted by Rebecca Quine,

Syrris, a world leader in chemistry product innovation, is launching the Orb Pilot jacketed reactor this fall. This unique system, which offers flexible and cost-effective pilot scale batch chemistry, will be unveiled at P-MEC Barcelona from the 4-6 October 2016.

 

The Orb Pilot is a user-friendly, floor standing scale-up jacketed reactor providing an exceptional combination of performance, versatility and value for money. It offers a choice of vessel sizes from 10 to 50 liters on a single system, and is precision engineered to withstand temperatures from -40 to +235 oC.

 

Available with a selection of single and vacuum jacketed vessels, plus a wide range of accessories and stirring options, the Orb Pilot can be easily configured to match your exact requirements. It features a unique clamp, easy motor lift and rapid oil drain mechanism – offering fast vessel changes – while a spring-loaded base avoids the need for frame adjustments to accommodate different vessels or thermal expansion. Combined with an incredibly robust and durable design, this will ensure the Orb Pilot provides years of continuous, cost-effective service for virtually any batch chemistry application.

 

To find out more, please visit www.syrris.com/news  or email info@syrris.com.

 

 

Syrris Limited

Syrris is world renowned for excellence in chemical reactor systems and is a world leader in flow chemistry systems. Established in 2001, Syrris employs over 30 scientists and engineers at its facility in Royston (near Cambridge, UK) and has offices in the US, Japan, India and Brazil plus over 30 distributors worldwide.

 

Syrris develops laboratory automation products for research and development chemists in industries such as pharma, petrochem, agrochem, fine chemical synthesis etc. as well as academia. Syrris products are used in a wide variety of applications and laboratories including process, discovery, crystallization, process safety, scale-up and many more.

 

Syrris products include the innovative range of fully automated batch reactor products (Atlas), a manually operated jacketed reactor platform (Globe) and flow chemistry systems (Asia and Africa). In recognition of its technological achievements, Syrris has been awarded the “Eastern Region’s UKTI Best Established Exporter” and the “Most Outstanding Export Achievement” at the Global Opportunity Conference on International Trade. Syrris’ Asia Flow Chemistry system was the recipient of a prestigious 2012 R&D award.

radiometer

Radiometer becomes a gold sponsor of the European Congress on Emergency Medicine

author2016-09-21authorposted by Caroline,

Radiometer is proud to be a gold sponsor of this year’s European Congress on Emergency Medicine organized by the European Society for Emergency Medicine (EuSEM) in Vienna, Austria, October 1-5. Visitors to Booth 52 in the Hofburg Galerie will have the opportunity to see live demonstrations of Radiometer’s point-of-care (POC) testing solutions; the AQT90 FLEX analyzer, ABL90 FLEX PLUS analyzer and the HemoCue® WBC DIFF System. Radiometer will also be hosting a lunchtime symposium – POWER UP YOUR ED: 3 ways to implement change for faster diagnostic decisions – on Tuesday October 4, featuring three keynote speakers delivering presentations on sepsis management, elderly patients and lean processes for point-of-care testing in the emergency department (ED).

 

Radiometer is committed to helping ED clinicians make crucial decisions as quickly as possible, offering a range of POC testing solutions that provide immediate access to fast, reliable results. This enables earlier diagnosis and initiation of treatment, helping to save more lives. Lab-quality quantitative results for a wide range of critical parameters – including troponin, NT-proBNP, D-dimer, CRP, PCT – as well as rapid analysis of blood gases and lactate plus accurate white blood cell counts, are delivered at the point of patient care in minutes.

 

Henrik Schimmell, President of Radiometer, commented: “We are delighted to be sponsoring this year’s EuSEM Congress with an impressive scientific program covering a range of important topics in the field of emergency medicine. We look forward to demonstrating our point-of-care testing solutions and welcoming delegates to the lunchtime symposium.”

 

For more information about Radiometer’s lunchtime symposium, visit www.radiometer.com/powerup

 

For more information about the EuSEM Congress, visit www.eusemcongress.org/en

syrris

Syrris to preview Titan continuous processing scale-up system at P-MEC

author2016-09-21authorposted by Violeta,

Syrris, a world leader in chemistry process innovation, is previewing its revolutionary Titan system at P-MEC in Barcelona, Spain, from the 4th to the 6th of October. This modular continuous chemical processing system is designed to enable straightforward scale-up, from kilo lab through pilot plant to manufacturing.

 

Titan is an easy to use, high performance turnkey system designed for long-term use in demanding manufacturing environments. It comprises a wide range of seamlessly integrated, rapidly reconfigurable modules, enabling simple or sophisticated continuous flow processes to be performed on a lab scale, or at rates of up to a tonne per day. Titan offers flexibility and scalable functionality – extra modules can easily be added – allowing the type and complexity of processes to be easily modified, or multiple processes to be combined into a single system. Reactors are available in 64 and 250 ml volumes, and may be connected together when larger scale systems are required. Reliable and robust, Titan offers extremely high chemical resistance. It can accommodate reaction temperatures from -40 to +250 °C and pressures up to 20 bar, at flow rates between 1 and 250 ml/min per channel. Process parameters can be controlled manually from the modules, or automated via Titan or pre-existing PLC or plant software.

 

For more information, visit www.syrris.com

BBI_Solutions

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays

author2016-09-20authorposted by Violeta,

BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September. The technology, developed in-house by BBI Solutions scientists, improves the limit of detection of an assay, providing an increase in sensitivity of up to ten times and a faster time to result.

 

Lateral flow immunoassays (LFIs) rely on the specific interaction between the analyte of interest and an immobilised binding partner, such as an antibody, antigen or enzyme. To improve performance, a ‘blocking’ agent is bound to unoccupied conjugation sites on the reporter label, preventing non-specific binding. However, the most commonly used conjugate blocker, BSA cross-reacts with human serum albumin-binding antibodies, bovine and other animal-origin targets, and exhibits lot-to-lot variability. Its relatively large size can also lead to steric hindrance affecting the detection of the target molecule. The proprietary Morffi technology overcomes these issues1. Due to its size in comparison to BSA, it improves the availability of analyte-specific binding partners on the surface of the reporter label, increasing the signal intensity and sensitivity of the assay. Morffi has been successfully tested with over 30 conjugates to date, clearly demonstrating its suitability for a range of LFIs. Find out more in the BBI Solutions whitepaper entitled Morffi, Enhanced performance of a lateral flow assay.

 

1 Morgan West, Ffion Walters, Shaun Phillips and Darren Rowles; Enhanced performance of a lateral flow assay. Use of a novel conjugate blocking technology to improve performance of a gold nanoparticle-based lateral flow assay. http://bit.ly/morffiwhitepaper

 

 

About BBI Solutions

BBI Solutions is a leading manufacturer of biological reagents and finished test platforms for the in-vitro diagnostics market. BBI is a global business with manufacturing sites spanning three continents.

 

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

 

BBI Solutions offer lateral flow development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

 

BBI Solutions is part of the BBI Group.

 

www.bbisolutions.com

cepheid

Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On The Market

author2016-09-19authorposted by Raquel,

Particularly perilous Clostridium difficile strains are now potentially easier to detect, thanks to expanded reporting of binary toxin (CDT) gene presence with the leading molecular test for C. difficile from Cepheid.    

The presence of binary toxin-producing C. difficile has been linked to increased disease severity, mortality and disease recurrence1,2. In addition, strains of C. difficile have been documented that appear to cause disease when they are negative for the well known toxins A and B but positive for binary toxin3,4. With the addition of Xpert C. difficile BT, Cepheid continues to offer one of the most comprehensive molecular C. difficile test portfolios on the market. 

"Binary toxin (CDT) is associated with more severe C. difficile infection (CDI)," says Thomas V. Riley, Ph.D. and Microbiology Professor at The University of Western Australia.  "In addition, CDT has been linked to an increase in the prevalence of community-acquired CDI, a high rate of recurrent CDI, and the need for hospital admission due to reinfection3.  The detection of strains of C. difficile with the ability to produce CDT will provide valuable prognostic information."

"Recent studies indicate that some patients with suspected C. difficile harbour binary toxin producing strains that do not carry the genes for toxins A and B4," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer.  "While the clinical significance of such strains is not yet fully understood, the vast majority of current C. difficile tests will miss these cases completely.  Xpert C. difficile BT reports binary toxin status independently, which allows for detection of a wider range of hypervirulent strains and tracking of novel variants that are negative for toxins A and B.

C. difficile infection is the result of C. difficile bacteria overgrowth, commonly caused through exposure to antibiotics for treatments of other illnesses.  Binary toxin is produced by a number of C. difficile strains, including PCR-ribotype 027 (Nap1/BI) and other strains associated with severe outcomes.

Xpert C. difficile BT is Cepheid's current Xpert C. difficile test, with modified result reporting that makes the additional information on the presence of binary toxin available.  Xpert C. difficile BT is available immediately in countries accepting the CE-mark.

 

1 Bacci et al, 2011. Emerg Infect Dis. Jun; 17(6):976-82
2 Stewart et al 2013. J Gastrointest Surg. 17:118–125
3 Androga et al JCM 2015; 53: 973-5.
4 Eckert, et al. New Microbes New Infect. 2014:8;(3):12-7

sonosite-fujifilm

Point-of-care ultrasound helps enhance maternity services in Africa

author2016-09-15authorposted by Caroline,

A unique collaboration between the charity Health Improvement Project Zanzibar (HIPZ) and the Zanzibar government has seen point-of-care ultrasound systems introduced into the country’s hospitals, helping to improve maternity services. Dr Ru MacDonagh, founder of HIPZ and a consultant urologist at Musgrove Park Hospital in Taunton, Somerset, explained: “In a drive to improve healthcare services, the Zanzibar government approached HIPZ to run its Makunduchi Hospital and, later on, the larger hospital at Kivunge. One big problem was the lack of ultrasonography, which is particularly important in a maternity unit. The large cart systems we used initially were not practical for use in Africa, and so we looked for an alternative solution.”

 

“SonoSite point-of-care ultrasound systems are used at Musgrove Park, and an anaesthetist colleague had also used them in the earthquake zone in Nepal during the 2015 disaster relief effort, describing them as ‘bullet proof’. This robustness made them ideal for use in Africa. We bought two NanoMaxx® systems, which deliver exactly what we need. They are compact, lightweight and portable, with good image quality. They are also straightforward to operate, and I learned how to use them in a very short period of time. Point-of-care ultrasound has made a dramatic difference to our maternity unit. Patients really appreciate seeing the baby, and attendance rates at our antenatal clinics have now grown from just 20 to 30 % to around 70 %. Ultrasound has proved a huge success. It’s a real life saver”

          

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

ukresponse@sonosite.com  www.sonosite.co.uk

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

dolomite-bio

Dolomite Bio’s Single Cell RNA-Seq System enables high speed encapsulation

author2016-09-05authorposted by Violeta,

Dolomite Bio has developed the Single Cell RNA-Seq System for efficient, high throughput single cell transcriptomics. This compact, scalable system enables rapid, reproducible droplet encapsulation of individual cells, allowing up to 10,000 single cell libraries to be generated in one 15-minute run.

 

The Single Cell RNA-Seq System allows up to 500 µl samples of cells and oligo-barcoded beads to be encapsulated in extremely monodisperse droplets, each containing a single cell. It incorporates all the components required to encapsulate individual cells, including the hardware – pumps, flow sensors, connectors and a high speed camera and microscope – advanced Flow Control Center software and accessories. The system uses a glass Single Cell RNA-Seq Chip – a commercially available version of the prototype PDMS Drop­seq chip described by Macosko et al1 – offering faster run time, longer life and greater ease of use. Installation and user training is included with each system, ensuring straightforward implementation and rapid initiation of droplet encapsulation experiments. Following encapsulation, the cell is lysed, allowing the mRNA to be captured on the beads for downstream recovery and sequencing.

 

For more information, please visit, www.dolomite-bio.com/product/rna-seq-system

 

1 Macosko E et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161,

particle-works

Particle Works launches range of high quality magnetic nanoparticles

author2016-08-31authorposted by Violeta,

Particle Works – the nano- and microstructured material specialist – has developed magnetic nanoparticles offering superior performance and physical characteristics. The particles are composed of cobalt protected by a thin shell of iron oxide, offering up to five times the performance of other commercially available products. Supplied with a choice of functional coatings, they are suitable for organic and aqueous solvents, as well as for functionalization with, for example, antibodies.

 

Drawing on the Blacktrace group’s expertise in microfluidics, Particle Works magnetic nanoparticles are precision manufactured using continuous flow techniques to offer very narrow size distributions and low batch-to-batch variation. Each product is supplied with full characterization data, simplifying data analysis and offering enhanced process security for applications in the diagnostic imaging, pharmaceutical, biomedical and industrial sectors. Backed by Particle Works’ quality guarantee and expertise in nanomaterials, the company’s magnetic nanoparticles are ideally suited to proof of principle, materials optimization and scale-up studies.

 

For more information, visit: www.particle-works.com

 

About Particle Works

Particle Works manufactures high-performance nano- and microstructured materials with precisely controlled particle size, shape and architecture. Particle Works is a brand of Blacktrace Holdings Ltd (www.blacktrace.com), a world leader in Productizing Science®. Our Head Office is based in Royston (near Cambridge), UK and we have regional offices in the USA, Japan, India and Brazil. Our range of products include Metal Nanoparticles (Gold and Cobalt Nanoparticles), Quantum Dots, Hydrogels (Alginate Beads) and PLGA Beads (custom microencapsulations) suitable for  use in many applications such as lateral flow assays, bioimaging, targeted drug delivery, cell growth etc. To find out more about Particle Works, please visit: www.particle-works.com.

syrris

Syrris launches Asia Automated Reagent Injector at ACS

author2016-08-30authorposted by Violeta,

Syrris, a world leader in the field of flow chemistry, launched its Asia Automated Reagent Injector at the 252nd American Chemical Society National Meeting and Exposition in Philadelphia, USA, from the 21st to the 25th of August. This latest innovation is designed for use with Asia flow chemistry systems, enabling fully automated experiments with multiple reagents.

 

Driven by the Asia Syringe Pump module, the compact Asia Automated Reagent Injector offers high performance, fully automated sample injection via two independent channels, allowing complex matrixed libraries to be synthesized. Gas blanketing provides the inert sampling conditions required for safe handling of air and moisture sensitive reagents and, with sample pre-pressurization up to 20 bar, dispersion and pressure drops during reactions can be avoided, enabling even very small volumes to be injected. For maximum flexibility, sample loops from 0.1 to 10 ml are available, as well as a selection of removable racks for 2, 8 and 40 ml vials. Complete process automation is provided by connection to the Asia Manager PC Software, enabling sophisticated multiple sample injections and experiments to be performed, including key applications such as synthetic library generation, reagent screening, reaction optimization, kinetic and degradation studies, and LogD screening.

 

For more information, visit http://syrris.com/flow-products/asia-modules/asia-auto-injector

 

Syrris Limited

Syrris is world renowned for excellence in chemical reactor systems and is a world leader in flow chemistry systems. Established in 2001, Syrris employs over 30 scientists and engineers at its facility in Royston (near Cambridge, UK) and has offices in the US, Japan, India and Brazil plus over 30 distributors worldwide.

Syrris develops laboratory automation products for research and development chemists in industries such as pharma, petrochem, agrochem, fine chemical synthesis etc. as well as academia. Syrris products are used in a wide variety of applications and laboratories including process, discovery, crystallization, process safety, scale-up and many more.

Syrris products include the innovative range of fully automated batch reactor products (Atlas), a manually operated jacketed reactor platform (Globe) and flow chemistry systems (Asia and Africa). In recognition of its technological achievements, Syrris has been awarded the “Eastern Region’s UKTI Best Established Exporter” and the “Most Outstanding Export Achievement” at the Global Opportunity Conference on International Trade. Syrris’ Asia Flow Chemistry system was the recipient of a prestigious 2012 R&D award.

radiometer

Radiometer to sponsor World Sepsis Day 2016

author2016-08-30authorposted by Caroline,

Radiometer is proud to announce that it is sponsoring this year’s World Sepsis Day on the 13th September, continuing its commitment to the fight against this life-threatening medical condition. This initiative is a key part of the drive to improve outcomes for sepsis – the number one cause of preventable deaths worldwide – highlighting the significant diagnostic challenges and importance of early intervention.

 

Sepsis affects over 25 million people every year, proving fatal in almost a third of cases. The Global Sepsis Alliance aims to save 800,000 lives a year by promoting events such as World Sepsis Day. This sponsorship agreement is part of Radiometer’s ongoing pledge to improve global healthcare, by increasing awareness of sepsis and providing medical professionals with the tools to help identify and treat the condition sooner, improving the odds of recovery.

 

Radiometer offers the broadest point-of-care diagnostic menu to support the current guidelines for the diagnosis and treatment of sepsis. Last year, the company launched a rapid procalcitonin (PCT) assay – the biomarker of choice to aid the diagnosis of sepsis – which offers results in less than 21 minutes with the AQT90 FLEX analyzer. Together with Radiometer’s portfolio of other relevant diagnostic and prognostic markers – including white blood cell count, CRP, creatinine, bilirubin, lactate and blood gases – this is helping to significantly improve turnaround times for sepsis diagnosis, improving the odds of patients making a full recovery.

 

Henrik Schimmell, President of Radiometer, commented: “We are delighted to be sponsoring the World Sepsis Day, as it complements our ongoing commitment to help improve global healthcare by providing reliable, fast and easy patient diagnosis. By raising awareness of sepsis, we can help to ensure that more people survive this potentially fatal condition.”

 

To find out more about World Sepsis Day, visit http://www.world-sepsis-day.org.

To find out more about Radiometer’s portfolio of acute care tests, please contact radiometer@radiometer.com or visit http://www.radiometer.com/en/diagnostics/sepsisdetection

tecan

Tecan increases application flexibility for genomics

author2016-08-30authorposted by Caroline,

Tecan has increased application flexibility and walkaway times for genomics workflows. The launch of a new generation of 10 μl LiHa disposable tips will improve labware access on Fluent® and Freedom EVO® workstations, as well as offering more options for on-deck tip storage.

 

The redesigned, 10 μl tips are 3.6 mm longer and have been developed to improve access to PCR plates and common 384-well microplate formats, helping to minimize dead volumes and waste of precious samples and reagents. Ideal for genomics applications – such as next generation sequencing and human identification (HID) – the tips are available in both Tecan Pure and Tecan Sterile purity levels, with a choice of both filtered and non-filtered options. The new tips are available in both standard trays and SLAS formats, offering users more choice in terms of deck set-up and storage options, and nested options, maximizing on-deck capacities and walkaway times.

 

Severin Heynen, product manager for consumables at Tecan, commented: “This completely redesigned tip is optimized for genomics workflows and other applications requiring high throughput and accurate low volume pipetting. Offering sterile tip purity and a range of storage options gives our customers even more choice in how they automate their protocols, helping to streamline laboratory workflows and maximize the return on their investment in our liquid handling solutions.”

 

To learn more, visit www.tecan.com/consumables

                                                                                                                 

                                                                                                                          

For more information please contact

Tecan Trading AG

Antonietta Allocca

Tel  +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12

info@tecan.com  www.tecan.com

 

 

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2015, Tecan generated sales of CHF 440 million (USD 459 million; EUR 411 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

 

 

 

Über Tecan

Tecan (www.tecan.com) ist ein weltweit führender Anbieter von Laborinstrumenten und Lösungen für die Branchen Biopharma, Forensik und Klinische Diagnostik. Das Unternehmen ist auf Entwicklung, Herstellung und Vertrieb von Automatisierungslösungen für Laboratorien im Life-Science-Bereich spezialisiert. Die Kunden von Tecan sind Pharma- und Biotechnologieunternehmen, Forschungs-abteilungen von Universitäten sowie forensische und diagnostische Laboratorien. Als Originalgeräte-hersteller (OEM) ist Tecan auch führend in der Entwicklung und Herstellung von OEM-Instrumenten und Komponenten, die vom jeweiligen Partnerunternehmen vertrieben werden. Tecan wurde 1980 in der Schweiz gegründet. Das Unternehmen verfügt über Produktions-, Forschungs- und Entwicklungs-stätten in Europa und in Nordamerika. In 52 Ländern unterhält es ein Vertriebs- und Servicenetz. Im Jahr 2015 erzielte Tecan einen Umsatz von CHF 440 Mio. (USD 459 Mio.; EUR 411 Mio.). Die Namenaktien der Tecan Group werden an der SIX Swiss Exchange gehandelt (TECN; ISIN CH0012100191).

mettler-toledo

A simple choice for pipette calibration

author2016-08-25authorposted by Caroline,

BD Biosciences relies on METTLER TOLEDO Rainin for calibration and servicing of all the pipettes used by its Greater San Diego facilities. Omar Richards, Instrumentation Supervisor, explained: “Our operations in the San Diego area cover everything from R&D to manufacturing and quality control, and pipettes are used across virtually every area of the business. They account for almost half of our total equipment list – we have around 2,500 pipettes at any time – making careful management of pipette servicing and calibration both essential and challenging. I have worked with Rainin for around 22 years in various roles and, in my opinion, the company’s pipette service is unmatched. When I came to BD Biosciences, and saw the level of service we were receiving from our incumbent provider, it was a very easy decision for me to switch to Rainin.”

 

“We now ship all our pipettes out to Rainin for servicing, as there are certain aspects of the calibration that really cannot be performed outside of a controlled metrology lab environment. All pipettes used in our R&D and manufacturing groups are calibrated every 12 months, and our QC areas have recently switched from three- to six-month calibrations, as the data showed that the risk of a failure between calibrations was very low. The Rainin team really are the subject matter experts when it comes to pipettes, and using the company’s services ensures complete process security and peace of mind.”

 

For more information, please contact:

Mettler Toledo Rainin, LLC

7500 Edgewater Drive, Box 2160

Oakland, CA 94621


T +1 800 472-4646

http://www.mt.com/rainin

 

About Rainin

Rainin, a METTLER TOLEDO Company, is the leading provider of advanced pipetting solutions for life scientists worldwide. We offer a wide selection of manual and electronic pipettes, BioClean pipette tips, and expert services that work together as a complete pipetting solution – Pipetting 360°. Rainin has long been the largest selling brand in North America and consistently rank among the top premium pipette brands in Europe, Asia and the Middle East. Top quality, innovative design and state-of-the-art production result in superior pipetting products with years of reliable operation.

syrris

Syrris marks 15 years of chemistry innovation

author2016-08-24authorposted by Raquel,

Syrris – a Blacktrace Holdings brand – is celebrating 15 years of creating pioneering chemistry solutions. Founded in August 2001 to address some of the technology challenges faced by the pharmaceutical industry, the company’s focus on improving productivity in R&D chemistry has ensured that it rapidly became a leading provider across various sectors, such as the pharmaceutical manufacturing, petrochemistry, agrochemistry and fine chemical synthesis industries.

 

Today, Syrris has grown into a world leader in the field of flow chemistry, with a dedicated and highly capable team of engineers and scientists. Offering a versatile range of automated flow and batch chemistry solutions for a broad range of applications – from synthesis, process optimization and reaction analysis to crystallization, calorimetry and scale-up – it continues to deliver innovative products combining cutting-edge technologies with ease of use.

 

Mark Gilligan, Chief Executive Officer and Chairman of Blacktrace Holdings, commented: “We are very pleased to reach this milestone, and continue to enjoy year on year growth. Our industry-focused approach has ensured we can deliver solutions to meet the day-to-day challenges faced by research and development chemists and chemical engineers, while continuing to combine our science and product engineering capabilities to develop innovative products.”

 

To find out more, please visit www.syrris.com/news/news or email info@syrris.com.

syrris

Syrris introduces fully automated synthesis

author2016-08-18authorposted by Raquel,

 

Syrris, a world leader in chemistry product innovation, is launching the Atlas HD automated jacketed reactor system at the upcoming American Chemical Society (ACS) National Meeting and Exposition in Philadelphia. This event takes place from the 21st to 25th of August, and will give visitors the opportunity to explore how this modular, touch screen-controlled platform could simplify process development, reaction optimization, advanced syntheses, reaction calorimetry and crystallization activities.  

 

The Atlas HD is designed to offer supreme flexibility and ease of use, combining intuitive touch screen control with a wide range of options to suit virtually any reaction set-up. It is available with a choice of easily interchangeable reaction vessels – from 50 ml to 5 l – and a selection of sensors to allow fully automated monitoring of temperature, turbidity and pH. Reaction parameters can be easily programmed and monitored in the system’s firmware, as well as adjusted in real time, helping to achieve unrivalled reproducibility and performance. For complete process automation, the Atlas HD’s PC software offers straightforward third party device integration, providing a truly modular solution for a variety of laboratory workflows.

 

To find out more, please visit www.syrris.com/news/news or email info@syrris.com.

ingenza

Ingenza celebrates EU H2020 SME Instrument success

author2016-08-16authorposted by Raquel,

Ingenza is pleased to announce it has successfully applied for EU H2020 SME Instrument funding of €50,000 for Phase 1 of its innovative SYNBIOMAN project, allowing the company to forge ahead with the development of this novel synthetic biology-driven biomanufacturing platform. Successful completion of the Phase 1 study could open the door to additional funding for Phase 2, valued at €2.5 million.

 

SYNBIOMAN will build on Ingenza’s proprietary industrial synthetic and systems biology tools, helping small and medium-sized biotechnology enterprises to close the gap from lab to market by developing GMP biomanufacturing capabilities that target the production of therapeutic proteins. Frequently, these drug candidates are sourced from low yielding organisms, have highly complex structures, or are very toxic. As a result, they can be challenging to manufacture, preventing the development of new therapies for currently unmet clinical needs. Dr David McElroy, Chief Business Officer at Ingenza, said: “We are delighted to have secured EU H2020 SME Instrument support for this project. The Horizon 2020 programme receives thousands of funding applications each year, and fewer than five per cent of applicants are successful. It is a real achievement for our scientific research to be recognised in this way.”

 

For more information, visit www.ingenza.com or email sarah.scott@ingenza.com

syrris

Syrris creates Orb Pilot for effortless reaction scale-up

author2016-08-10authorposted by Raquel,

Syrris, a world leader in chemistry product innovation, is previewing its Orb Pilot jacketed reactor at the 252nd American Chemical Society (ACS) National Meeting and Exposition. This event, which takes place in Philadelphia from the 21st to 25th of August, will give delegates the first chance to see the unique Orb Pilot, which is designed to offer flexible and cost-effective pilot scale batch chemistry.

 

The Orb Pilot is a user-friendly, floor standing scale-up jacketed reactor providing an exceptional combination of performance, versatility and value for money. It offers a choice of vessel sizes from 10 to 50 liters on a single system, and is precision engineered to withstand temperatures from -40 to +235 oC.

 

Available with a selection of single and vacuum jacketed vessels, plus a wide range of accessories and stirring options, the Orb Pilot can be easily configured to match your exact requirements. It features a unique clamp, easy motor lift and rapid oil drain mechanism – offering fast vessel changes – while a spring-loaded base avoids the need for frame adjustments to accommodate different vessels or thermal expansion. Combined with an incredibly robust and durable design, this will ensure the Orb Pilot provides years of continuous, cost-effective service for virtually any batch chemistry application.

 

To find out more, please visit www.syrris.com/news/news  or email info@syrris.com.

dolomite-bio

Dolomite lends a helping hand to synthetic biology research

author2016-07-28authorposted by Raquel,

Dolomite microfluidic chips are helping researchers from the Biodesign Institute at Arizona State University (ASU) to develop novel enzymes capable of polymerising synthetic nucleotides. Using these chips, the team has created a droplet-based optical polymerase sorting (DrOPS) technique allowing rapid screening for novel polymerase activities in uniform water-in-oil microcompartments. The team’s leader, Professor John C. Chaput – formerly at ASU and currently at the University of California, Irvine – explained: “The creation of synthetic nucleic acids is of great interest to synthetic biologists but, because they are not found in nature, wild type polymerases struggle to process them. To overcome this issue, we are developing novel polymerases using directed evolution in water-in-oil microcompartments. The DrOPS methodology has significant advantages over traditional methods, which are both labour intensive and impractical to perform on a large scale due to the amount of precious artificial nucleotide reagents required for screening.”

 

The Biodesign Institute turned to microfluidics to allow rapid sorting and screening of novel polymerases, taking advantage of the technique’s single-cell encapsulation capabilities and picolitre reaction volumes. Dr Andrew Larsen commented: “We needed very reproducible microfluidics, and so using commercially available chips was preferable. We already had experience with Dolomite’s chips for a variety of applications within the institute, and they have always been very consistent, so the choice was obvious. These chips give us the ability to consistently generate uniform droplets – both single and double emulsion droplets – offering spatial separation between cells and allowing fluorescence-based sorting using conventional FACS technologies. Dolomite has also been very supportive of our efforts, helping to accelerate this area of research.”

 

For more information, visit www.dolomite-bio.com.

glass-solutions

Glass Solutions help ALS to maintain laboratory supplies

author2016-07-26authorposted by Violeta,

ALS Food and Pharmaceutical, based in Chatteris, UK, relies on Glass Solutions to maintain its laboratory glassware. The Section Head of the company’s Vitamins and Additives department explained: “Our laboratory is responsible for the analysis of vitamins in a wide range of food and nutritional products, and clients rely on the integrity of our results. As a busy analytical laboratory, we need to make certain that we always have sufficient glassware available for our analyses and, because degradation of the analyte is a potential problem, we often use amber glassware to provide protection from light.”

 

“While clear glass tubes are readily available, amber ones are not. Instead of buying clear tubes and sending them away to be amber coated, we have them custom made by Glass Solutions, which is just as cost effective and far easier. The company also has the capability to repair qualitative glassware – for example, replacing damaged tops on Quickfit® apparatus or taps and spouts on separating funnels – helping to prolong lifespans. Glass Solutions is very flexible and always willing to help; they give us exact lead times so that we know when the order will be ready, and our drivers collect the glassware during their daily routine, ensuring rapid delivery and minimising breakages during transit. It’s an ideal situation.”

 

 

About Glass Solutions

Glass Solutions is the world leader in the manufacture of high quality, precision glassware, custom-made for scientists, architects, designers, instrument makers and engineers. Based in Sutton, near Cambridge, UK, it has the largest advanced glass blowing facility in the country, as well as offices in the US, Japan, Brazil and India. The company manufactures a wide range of glassware, including standard laboratory and sophisticated custom-made glassware, glass tubing and rods, and provides design assistance, prototype and small batch manufacturing services, as well as large-scale production of thousands of items. www.glass-solutions.com.

radiometer

Radiometer sponsors FREE online World Sepsis Congress

author2016-07-21authorposted by Anna,

Radiometer is proud to announce that it is sponsoring the 1st World Sepsis Congress, from the 8th to the 9th of September 2016. Organized by the Global Sepsis Alliance, this free online event will give participants the chance to hear experts from around the world discuss the challenges and opportunities in the battle against this life-threatening illness.

 

Sepsis is the number one cause of preventable deaths worldwide, affecting over 20 million people every year. Radiometer is committed to raising awareness of the importance of early intervention, as well as providing the tools to help medical professionals identify and treat sepsis at the earliest possible opportunity. Last year, the company launched a rapid procalcitonin (PCT) assay – the biomarker of choice to aid the diagnosis of sepsis – which offers results in less than 21 minutes with the AQT90 FLEX immunoassay analyzer. Together with Radiometer’s portfolio of other relevant diagnostic and prognostic markers – including lactate, white blood cell count, CRP, creatinine, bilirubin and blood gases – this is helping to significantly improve turnaround times for sepsis diagnosis, improving the odds of patients making a full recovery.

 

Radiometer’s President, Henrik Schimmell, commented: “We are very pleased to be sponsoring the 1st World Sepsis Congress. This free online event fits well with our ongoing commitment to help improve global healthcare by providing reliable, fast and easy patient diagnoses. We encourage all healthcare professionals to sign up to this free event, which will highlight how early recognition and appropriate treatment can save lives.”

 

Register free for the 1st World Sepsis Congress at www.worldsepsiscongress.org

mechelec-automation

MECHELEC unveils new trolley packer

author2016-07-21authorposted by Anna ,

Bedfordshire-based MECHELEC AUTOMATiON has developed a revolutionary new trolley collation and packing system for the dairy industry. The TP1002 Trolley Packer is designed to provide fully automated, cost-effective trolley loading, at faster operating speeds than current systems.

 

The TP1002 is intended for use in both major and provincial dairies, offering flexible throughput for NIS, INFINI and ECO dairy bottles. It uses a robotic arm to quickly and efficiently load two static trolleys simultaneously, offering double the packing speed of conventional systems from a comparable footprint. This elegant solution eliminates the need to manipulate trolleys, avoiding the common compatibility issues arising from differing designs or damaged trolleys. The simplicity and open construction of the robotic system also allows easier access and maintenance, as well as faster switching between bottle sizes and product streams, e.g. shrink-wrapped products. 

 

John Salisbury, Director at MECHELEC, commented: “This innovative solution is a direct result of many years of industry experience across the food and beverage, and dairy industries. By identifying the major issues affecting mechanised trolley packing, we have been able to develop a novel solution which is well suited to dairies large and small, providing a robust and cost-effective alternative to conventional options.”

rainin

Rainin Service team delivers high quality with rapid turnaround times

author2016-07-21authorposted by Anna,

Rainin’s pipette maintenance and calibration service is helping EKF Life Sciences in Elkhart, Indiana, USA, to maintain the high quality standards its customers have come to expect. Quality Assurance Manager Adam Crocker explained: “We use a variety of air and positive displacement pipettes for our quality control processes, and accurate and precise pipetting is essential to ensure that our enzymes and in vitro diagnostic reagents are of a high standard. To work properly, pipettes must be correctly maintained and calibrated, and so we turned to Rainin.”

 

“We chose Rainin because it is a well-known company with a good reputation, and we have over 20 years’ experience of using its pipettes. The company services and calibrates our pipettes on an annual basis, and we schedule additional checks in house. If a problem is detected, we simply send the pipette to Rainin and it is usually repaired and returned within the week. The company always does a thorough job – even when the problem is not specified – and provides us with a calibration certificate, helping us to meet regulatory requirements. When you look for a service provider, you often find that some companies deliver quality and other companies offer fast turnaround times. Rainin provides both.”

dolomite-bio

Blacktrace focuses on biology with the launch of Dolomite Bio

author2016-07-19authorposted by Raquel,

Blacktrace Holdings Limited, a leading group of companies focused on Productizing Science®, is pleased to announce the launch of its latest brand, Dolomite Bio. This biology-focused brand – spun out from sister company Dolomite Microfluidics – is dedicated to the development of innovative products for high throughput single cell research.

 

Dolomite Bio specializes in microfluidic droplet applications, offering a range of microfluidic systems and individual modules, as well as control software and reagents, for cell biology applications. Its core droplet technology is fully scalable, enabling microdroplet encapsulation of individual cells and molecules – from a few cells to millions or more – in just a few minutes. It is ideal for a wide variety of high throughput, single cell research applications, including:

  • Single cell RNA-Seq
  • Direct isolation of functional antibody coding sequence libraries
  • Profiling natively-paired T-cell receptors
  • Directed evolution by FACS sorting
  • Functional antibody screening in droplets
  • Cell encapsulation in hydrogels

 

Mike Hawes, CEO of Dolomite Bio, said: “We are delighted to announce the launch of Dolomite Bio, which will focus on developing novel products for high throughput single cell research. This new brand takes advantage of Dolomite Microfluidics’ underlying technology and the Blacktrace group’s understanding of the market to serve customers in this rapidly growing field.”

 

For more information, visit www.dolomite-bio.com.

sonosite-fujifilm

Healing little hearts with the aid of point-of-care ultrasound

author2016-07-19authorposted by Hannah,

Surgical teams from the UK-based charity Healing Little Hearts are using point-of-care ultrasound to help accelerate recoveries and improve outcomes for paediatric patients with congenital heart defects. Healing Little Hearts provides life-saving heart operations to babies and children across India who would not otherwise have access to treatment, as well as helping to develop local paediatric surgical programmes. Dr Sanaulla Syed, a paediatric cardiac anaesthetist with the charity, commented: “Obtaining vascular access in small children can be difficult, and the availability of point of care ultrasound systems has revolutionised this practice. As the technology has improved, this has led to other applications, and we now use ultrasound for a range of diagnostic applications before, during and after cardiac surgery. Ultrasound-guided regional anaesthesia – specifically bilateral paravertebral blocks – can also significantly reduce the amount of opiates required for surgery, considerably shortening post-operative recovery times and offering improved analgesia.”

 

“When travelling to India with Healing Little Hearts, UK surgical teams are keen to maintain the same high standards we have in the NHS, and so we are grateful for SonoSite’s ongoing support in providing point-of-care ultrasound systems – such as the NanoMaxx® – which we can easily take with us. The local surgical teams have been very interested in this approach and, with some teaching and guidance from visiting teams, have now begun to adopt the same practices in their own procedures.”

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

 ukresponse@sonosite.com www.sonosite.co.uk                                              

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

dataracks

Dataracks launches new fire safety solutions at DT Manchester

author2016-07-13authorposted by Caroline ,

Dataracks – the pioneer of cold aisle containment – is showcasing the latest fire detection and suppression solutions at DataCentre Transformation Manchester on the 12th of July. Visit the Dataracks stand to learn more about the company’s complete range of fire safety equipment for data centres, including the new Optex HSSD aspiration sensor and the Stat-X family of aerosol-based fire suppression systems from Nobel Fire Systems Ltd.

 

Dataracks has been rewriting the book on data centre design for over 25 years, and is now partnering with Nobel Fire Systems and Optex to introduce the latest fire safety solutions to the market. Optex’s HSSD dust particles sensor sets new standards for early warning of fires, with exceptional sensitivity and a built-in fan to provide active sampling. Its compact, standalone design allows it to be mounted inside cabinets and racks, helping to ensure much more rapid detection than traditional smoke sensors, potentially avoiding a fire from breaking out in the first place.

 

If the worst should happen, Dataracks now also supplies Nobel Fire Systems’ revolutionary Stat-X range of fire suppression systems, which can be installed into virtually any rack. Using technology developed specifically for high risk areas, each compact, self-contained aerosol unit offers strategic fire control to prevent escalation. This limits the damage associated with whole-room fire suppression, as well as offering significant cost savings by minimising installation and maintenance requirements. These latest offerings are compatible with both the Micro Data Centre and Dataracks’ aisle containment solutions, complementing the company’s existing fire safety solutions, such as the Active Roof and remote monitoring options.

 

Jeremy Hartley, Managing Director of Dataracks, commented: “As an innovation-focused company, we are pleased to be able to offer these state-of-the-art fire safety solutions to our customers. Our new agreements with Optex and Nobel Fire Systems will ensure that we remain at the forefront of data centre improvement, setting new standards within the industry.”

 

To find out more about Dataracks’ solutions, visit www.dataracks.com

                                                                                                                          

For more information please contact

Dataracks

Jeremy Hartley

Tel  +44 (0)1954 252800

sales@dataracks.co.uk   www.dataracks.com

 

 

About Dataracks

Dataracks (www.dataracks.com) is a leading manufacturer of data centre hardware solutions. Established in 1989, the company has a strong history of innovation in server cabinet and rack technology, introducing the industry’s first purpose-built IT data racks over 25 years ago. The company rewrote the book on cooling and efficiency in data centres again in 2007, when it pioneered cold aisle containment, and continues to set new standards in the industry today.

bulgin

Bulgin extends its reach with the incorporation of Arcolectric

author2016-07-06authorposted by Raquel,

Bulgin – an Elektron Technology brand – has announced the strategic incorporation of sister company Arcolectric into its business offering, bringing together two complementary connectivity portfolios. By combining these leading product ranges under the highly respected Bulgin brand, the company is looking to the future, evolving into a more comprehensive and wider reaching component manufacturer and provider of engineered solutions to meet the needs of the industry.

 

The integration of the Arcolectric product range will further strengthen the Bulgin portfolio, broadening the selection of components and value-added solutions available, as well as increasing the company’s credibility across a wider customer base drawn from diverse sectors of industry. German Casillas, Group Sales Director and Head of Connectivity, said: “The fusion of Arcolectric with Bulgin will allow us to focus our efforts on a single leading brand, streamlining our operations and improving efficiency. This will significantly benefit our customers, enabling them to purchase both product ranges from a single source, making the procurement process far easier.”

particle-works

Blacktrace launches Particle Works, a nano- and microstructure specialist brand

author2016-07-04authorposted by Raquel,

Blacktrace Holdings Limited, a leading group of companies focused on Productizing Science®, will be launching its latest brand, Particle Works, at the NANOTEXNOLOGY 2016 conference in Thessaloniki, Greece, from the 4th to the 8th of July. The Blacktrace group’s many years of expertise and world-leading capabilities in the design, development and manufacture of automated microfluidic continuous flow equipment provide the perfect foundation for this newly created brand specializing in high performance nano- and microstructured materials.

 

Particle Works designs and fabricates a wide range of metal nanoparticles, quantum dots and hydrogels with tight control of critical parameters such as particle size, shape and architecture and supplies them with comprehensive characterization data. These standard products are designed to maximize material performance – including catalytic activity, magnetic strength and optical resonance – helping to standardize processes and accelerate development across a wide range of disciplines. The Particle Works team can also provide customer-specific services to simplify and accelerate proof of principle, materials optimization and scale-up studies.

 

Omar Jina, Chief Commercial Officer at Blacktrace Holdings, commented: “We are delighted to announce the launch of Particle Works. This newest addition to our group of companies perfectly complements our world-leading capabilities in the design, development and manufacture of continuous flow and automated chemistry equipment, and extends our global range of products and services to include precision manufactured nano- and microstructured materials.”

 

For more information, visit: www.particle-works.com

syrris

Syrris launches Titan Syringe Pump for continuous processing scale-up

author2016-06-28authorposted by Violeta,

Syrris, a world leader in chemistry product innovation, has launched the Titan Syringe Pump, a continuous flow chemical processing module. Suitable for lab, pilot and production scale applications, this extremely chemically-resistant single channel pump combines powerful drive motors, clever valve design and software control to deliver ultra-smooth flow rates from 1 to 250 ml/min.

 

The Titan Syringe Pump is designed for safe and reliable scale-up. Carefully constructed from long-life materials, it operates effortlessly at pressures up to 20 bar and viscosities up to 1,000 cP, delivering precisely controlled flow rates for extended periods. Removable cassettes allow straightforward servicing of syringes and enable seals to be rapidly changed with minimal tools required. A built-in backwash feature prolongs seal lifetime and maintains the cleanliness of pistons and cylinders, which also helps to prevent degradation of air-sensitive chemicals and protect users. Process safety can be further enhanced by immersing syringe cassettes in a gas blanket. The Titan Syringe Pump can be controlled manually via the intuitive Titan Remote Display touch screen or fully automated through PC software, and it is compatible with a wide range of chemical reaction systems.  

 

For more information, visit http://syrris.com/flow-products/titan-syringe-pump

glass-solutions

Glass Solutions offers unmatched custom glass blowing

author2016-06-23authorposted by Raquel,

Glass Solutions is the world leader in high quality, precision glassware for scientific, architectural and engineering applications, and offers bespoke design and glass blowing capabilities to match individual customer needs. Combining extensive in-house expertise with the UK’s largest advanced glass blowing facility, the company is ideally placed to produce high quality, precision manufactured glassware to suit the specific requirements of designers, instrument makers and engineers.

 

With an extensive portfolio of tubes and rods, laboratory glassware, instrument components and microfluidic chips, the company has many years of experience in the manufacture of high quality glass products using a broad range of precision processes and techniques, ensuring complete satisfaction for its large customer base. Advanced facilities, coupled with a knowledgeable in-house design team, allows Glass Solutions to fulfil virtually any customer requirement, from the design and creation of individual pieces or prototypes based on customer concepts to the low to medium volume production of OEM components from existing CAD drawings.

 

Omar Jina, Chief Commercial Officer at Glass Solutions, commented: “We pride ourselves on the high quality and exceptional precision of all our products, from our standard portfolio through to unique pieces for individual applications. Our in-house team of design engineers can support the creation of one-off or small batch products to precisely match our customers’ glassware needs, eliminating the need for compromise.”

radiometer

Radiometer launches the next generation of transcutaneous monitoring

author2016-06-22authorposted by Anna,

Radiometer has unveiled its CE-marked TCM5 transcutaneous monitor, addressing the critical care needs of neonatal, pediatric and adult patients, as well as sleep clinic and home care environments. With a sleek appearance, intuitive color touchscreen interface and clear visual display, this all-new device has been designed with the end user in mind, offering continuous, non-invasive monitoring of tcpO2 and tcpCO2, as well as Masimo SET® SpO2, perfusion index and pulse rate in real time. The unique gold-plated sensors automatically recalibrate when placed in the calibration chamber, enabling highly reliable measurements even with prolonged use, and on-board interactive tutorials minimize training requirements.

 

Initially available in Australia, Austria, Belgium, France, Germany, Japan, Luxembourg, New Zealand, South Africa, Switzerland, the Netherlands, the United Arab Emirates and the United Kingdom, the TCM5 monitor offers a choice of two distinct versions tailored to different customer and patient needs. The TCM5 BASIC monitor is ideal for diagnostic investigations in sleep clinics and respiratory care in the home environment. Lightweight and compact with a clear numeric display, it enables accurate determination of ventilation and oxygenation status overnight and the dedicated sleep mode offers silent operation and a dark screen, ensuring that patients are not disturbed.

 

The premium TCM5 FLEX monitor is designed for critical care departments. It is particularly beneficial in neonatal intensive care due to its non-invasive nature. Numeric and trend displays, together with audible and visual alarms, instantly alert clinicians to any change in a patient’s status, enabling immediate intervention. For round-the-clock monitoring of neonates, a special NICU mode automatically monitors the duration of contact with the skin and controls the sensor temperature, helping to prevent damage to sensitive skin.

cepheid

Cepheid Announces World Health Organization Prequalification Of Xpert HIV-1 Qualitative Test

author2016-06-17authorposted by Raquel,

Broadens Access to Critical Diagnostic Results for Infants Born with HIV

Cepheid today announced that its Xpert® HIV-1 Qual (Qualitative) test has been awarded World Health Organization (WHO) prequalification, making it one of the first molecular point of care tests designed for HIV to be given this designation.  The test can detect HIV-1 in whole blood and dried blood spots from individuals suspected of HIV infection, including infants.  Inclusion in the prequalification list signifies that Xpert HIV-1 Qual meets WHO's stringent performance, quality, safety and reliability standards, and fulfills a performance measure established for many developing countries and global health participants before they can allow broad deployment of a new technology.  

Without timely HIV testing and therapy initiation, one-third of HIV-infected infants will die before their first birthday, and more than 50% will die before their second birthday.1  Globally, an estimated 110,000 children died of AIDS-related causes in 2015.2  HIV infection in infants can only be diagnosed by molecular testing since immunoassay tests can be ambiguous given the presence of maternal HIV antibodies in the infant's bloodstream up to 18 months of age.3  

"Early detection of HIV in infants can be life-saving, particularly if these children are placed on antiretroviral therapy (ART) in the first twelve weeks of life," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer.  "Current central laboratory testing methods are slow, delays in initiation of ART for HIV-positive infants are all too common, and many patients are lost to follow up.  In fact, for as many as half the infants tested for HIV, results are never received."4

"Having rapid quantitative results available for assessment of maternal transmission risk on the day of delivery, along with a sensitive qualitative test to determine neonatal infection status, could together represent significant leaps forward in HIV prevention strategies," said Jeanne Jordan, Ph.D., Professor, School of Public Health at The George Washington University.

Xpert HIV-1 Qual is part of a comprehensive portfolio of Xpert tests available internationally, including Xpert HIV-1 VL, Xpert CT/NG, Xpert Ebola and Xpert MTB/RIF, which run on the GeneXpert® System, the world's most prevalent molecular diagnostics platform. 

Xpert HIV-1 Qual is available outside the United States.  For more information on Cepheid's GeneXpert Systems or the complete menu of Xpert tests, visit www.cepheidinternational.com

dataracks

Dataracks helps Hydro66 to break the mould

author2016-06-16authorposted by Caroline,

Hydro66 has created the world’s first purpose-built hydroelectric powered co-location data centre in Sweden, choosing Dataracks for all its racks, cages and aisle containment solutions. Andy Long, Chief Executive Officer of Hydro66, explained: “There are three main advantages to locating data centres in Scandinavia; a favourable climate, abundant renewable energy and local expertise. Although these benefits were recognised by the major internet drivers several years ago, co-location providers have – for the most part – continued to develop the traditional city locations, with their associated high costs, limited space and unstable power supplies.”

 

Christiaan Keet, Chief Technical Officer, took up the story: “When choosing a rack provider, we visited various manufacturers, and were immediately impressed by the way we were received at Dataracks’ factory in Cambridgeshire. They were extremely professional and responsive, and it was clear – as far as I’m concerned – that the engineering of their solutions is far above most of the other products on the market. Dataracks’ designs make it as straightforward as possible to work with their products; they are extremely easy to access, adjust and tailor, while still being really solid and secure. They also provide very good airflow management, with a range of blanking plates to ensure the most efficient air pathway.”

 

“Although we had concerns over the logistics, I’m pleased to say that Dataracks proved my fears over not using locally sourced racks completely wrong; everything ran smoothly and nothing has ever been late. The company’s installation team were also top notch – extremely professional and very good at what they do. The company has been a pleasure to work with, and we look forward to future projects together,” Christiaan concluded.

 

To find out more about Dataracks’ solutions, visit www.dataracks.com

quotient

Quotient Clinical hosts formulation development and drug delivery seminar series

author2016-06-15authorposted by Raquel,

Quotient Clinical, the Translational Pharmaceutics® company, is holding a series of formulation development and drug delivery seminars this June and July. The seminars will take place at major life science hubs in the UK and USA, and will address the most pressing challenges currently faced by pharmaceutical and biotechnology companies in early drug development.

Starting in San Diego, the series will bring together a team of industry experts for insightful presentations and discussions, giving attendees the chance to explore innovative approaches for optimizing drug product formulations; from strategies and technologies to enhance oral bioavailability to the use of spray drying to overcome solubility challenges.

Speakers include prominent biotech consultant and entrepreneur Nick Barker and Richard Johnson, CEO and Founder of Upperton Ltd, and they will be joined by representatives from Quotient Clinical’s experienced scientific team, including John McDermott, Dr Kieran Crowley and Dr Kevin Kane. The presentations and discussions will be followed by a complimentary lunch, providing an informal networking opportunity to further examine these issues with leading industry figures.

For the full list of seminars including locations and dates, please visit www.quotientclinical.com/seminar-roadshow

mettler-toledo

Rainin TerraRacks™ help advance neurological research

author2016-06-14authorposted by Anna,

The neuroimmunology laboratory at Nuovo Ospedale S. Agostino Estense di Baggiovara in Modena, in Italy, is taking advantage of METTLER TOLEDO's Rainin TerraRack™ pipette tip racks for research into neurological disorders. Biologist Dr Roberta Bedin explained: “Most of the laboratory’s work is specialist diagnostic testing of cerebrospinal fluid from patients suffering from neurological diseases, but we also carry out research into conditions such as multiple sclerosis, Alzheimer’s disease and epilepsy.”

 

“I have used Rainin LTS pipettes – single and multichannel – for many years, and find them easy to handle, light weight and accurate. The multichannel pipette is especially useful for ELISAs. The LTS tips are well made and not too rigid, and the design of the pipettes allows them to be picked up without using a lot of force. Recently, our stockist suggested we tried TerraRacks. I like the fact that the racks are transparent so that you can see what you are doing and, as the plastic is recyclable, the environmental impact is taken into account. In general, the larger the volume of waste, the greater the cost of disposal. TerraRacks are not only recyclable, they can also be compressed so that the waste takes up very little space, which is a definite advantage.”

visualsonics

Second University of Naples installs world'S first Vevo® MD from Fujifilm Visualsonics

author2016-06-14authorposted by Caroline,

Toronto, Canada FUJIFILM VisualSonics Inc., a world leader in ultra high frequency ultrasound imaging systems and subsidiary of FUJIFILM SonoSite, Inc., today announced a significant milestone in its history with the installation of the first Vevo® MD Ultra High Frequency (UHF) clinical ultrasound system at the Second University of Naples in Italy. With multiple successes in preclinical research over the last decade, the Vevo® MD is FUJIFILM VisualSonics’ first foray into the clinical market.

 

According to Dr. Roberto Grassi, Professor of Radiology at the F. Magrassi and A. Lanzara Department at the Second University of Naples, the institution has used VisualSonics ultra high resolution ultrasound systems for preclinical studies for approximately 10 years. These UHF systems have enabled the research team to study the anatomy of small animals, such as mice and rats, with a resolution down to 30 microns. The addition of Vevo® MD—which has been in use at Second University for about a month now—brings the team’s capabilities to a whole new level and shows great potential for developing novel applications in the clinical sector.  

 

“Preclinical research is a crucial step toward establishing clinical applications, but until the launch of the Vevo MD, there were no clinically-approved ultra high frequency systems for human studies,” said Dr. Grassi. “The Vevo MD is the world’s first CE-marked, ultra high frequency ultrasound imaging system—up to 70 MHz—for clinical use, and will transform our clinical studies, enabling visualization of superficial structures in the human body.”

 

First commercialized in Europe, the Vevo MD is truly a unique ultrasound system, as it operates at much higher frequencies than any conventional ultrasound system currently available. It allows medical professionals to see what they have never seen before—unparalleled image resolution down to 30 microns. The Vevo MD system is compatible with FUJIFILM VisualSonics UHF series of transducers. This patented transducer technology is capable of operating in a range of frequencies up to 70 MHz, a tremendous increase in resolution compared to conventional ultrasound systems.

 

The Vevo MD was designed to play a role in a range of clinical application areas including neonatology, vascular, musculoskeletal, dermatology, and other small parts that are within the first 3 cm of the body.

 

“The beauty of the Vevo MD is that it is non-invasive for our patients and allows us to examine the superficial strata, visualizing structures that we could not see using conventional ultrasound. It has enabled us to determine the finer upper limb damage that occur in arthritis, allowing us to investigate the effectiveness of human drug treatments for these conditions,” said Dr. Grassi. “We are now starting to perform vascular assessment of diabetic patients, and also plan to study dermatological and systemic diseases.”

tecan

Simple PCR set-up from Tecan

author2016-06-02authorposted by Caroline,

Tecan is making it easier than ever before to set up and miniaturize qPCR reactions. In direct response to customer requests, the company has launched an updated software package for its D300e Digital Dispenser, offering new functionality and extending this innovative device’s flexibility for genomics workflows.

 

The D300e provides picoliter to microliter non-contact dispensing of liquids directly into assay plates, and the software now features a PCR Wizard that guides the user through qPCR set-up. Offering accurate and reproducible plate generation, the exceptional low volume dispensing capabilitiy of the D300e provides a convenient solution for the miniaturization of qPCR assays, allowing up to a five-fold reduction in assay volumes without any loss of data quality. Simplifying workflows and significantly saving reagent costs, this major step forward for qPCR is complemented by a range of other user-driven software updates. These include the ability to use the instrument’s high capacity D4+ cassette for reagent dispensing – increasing the capacity from 10 μl to 200 μl for small molecule and biomolecule dispensing – and the addition of a number of new fluid classes, as well as extra normalization options.

 

Dr Manuel Bauer, Product Manager for the Tecan D300e, commented: “We are extremely pleased with the latest developments of our software. These new options ensure that the D300e continues to provide the most flexible low volume dispensing solution on the market, helping our customers to get more done, more quickly, and without any changes to either the instrument hardware or consumables.

cepheid

Cepheid Xperience coming to the UK

author2016-05-31authorposted by Raquel,

Molecular diagnostics specialist Cepheid is bringing its Xperience mobile virtual laboratory to the UK, showcasing the advantages of the company’s innovative GeneXpert® technology. Molecular diagnostics provides unparalleled sensitivity and speed for pathogen identification and susceptibility testing, and the Cepheid’s GeneXpert systems offer fully automated, on-demand molecular testing in a scalable and easy to use format.

 

The Cepheid Xperience will be touring England and Northern Ireland this June and July, giving hospital staff – from laboratory technicians and clinicians to chief executives and finance directors – the chance to explore the potential benefits of this technology for their own hospitals, from improving turnaround times and streamlining patient pathways to helping combat antibiotic resistance. This series of events coincides with both Medtech Week and the release of the Tackling Drug-Resistant Infections Globally report by Lord Jim O’Neill, which contains the latest recommendations on rapid diagnostics and reducing the unnecessary use of antimicrobials. The Cepheid Xperience gives healthcare professionals a perfect opportunity to discover how GeneXpert technology can help them to tackle antimicrobial resistance and improve the delivery of patient care.

 

For more information, visit www.cepheidinternational.com

tecan

Tecan and CellSpring collaborate to automate novel 3D cell culture platform

author2016-05-26authorposted by Caroline,

Tecan and CellSpring, a biotech spin-out from ETH Zurich, have announced a co-marketing agreement to automate the 3D Bloom® platform on a Freedom EVO® workstation. This latest collaboration will further extend Tecan’s automated 3D cell culture portfolio, allowing scientists to take advantage of a high throughput technology with an extended cell viability period of at least seven days in the assay matrix.

 

The adaptive 3D Bloom Biopolymer Platform is compatible with all cell types and is ideal for both mono and co-culture assays. 3D microtissues can be prepared in microplate format within minutes, and analysis carried out while still in the culture matrix. Kevin Moore, Manager of Liquid Handling Products and Application Management, commented: “As a leader in the field of automated 3D cell culture, Tecan is delighted to be working with CellSpring to implement its microplate-based 3D Bloom platform on the Freedom EVO. This will allow scientists to benefit from straightforward, high throughput automation of a 3D cell culture process offering long-term cell viability.”

 

Dr Chris Millan, Chief Technology Officer at CellSpring, added: “CellSpring is excited to partner with Tecan to bring automated, simple 3D cell culture solutions to customers. The benefits of our 3D Bloom Platform – versatility and reliability – are now available at scale using the Freedom EVO.

tecan

Tecan and CellSpring collaborate to automate novel 3D cell culture platform

author2016-05-25authorposted by Caroline,

Tecan and CellSpring, a biotech spin-out from ETH Zurich, have announced a co-marketing agreement to automate the 3D Bloom® platform on a Freedom EVO® workstation. This latest collaboration will further extend Tecan’s automated 3D cell culture portfolio, allowing scientists to take advantage of a high throughput technology with an extended cell viability period of at least seven days in the assay matrix.

 

The adaptive 3D Bloom Biopolymer Platform is compatible with all cell types and is ideal for both mono and co-culture assays. 3D microtissues can be prepared in microplate format within minutes, and analysis carried out while still in the culture matrix. Kevin Moore, Manager of Liquid Handling Products and Application Management, commented: “As a leader in the field of automated 3D cell culture, Tecan is delighted to be working with CellSpring to implement its microplate-based 3D Bloom platform on the Freedom EVO. This will allow scientists to benefit from straightforward, high throughput automation of a 3D cell culture process offering long-term cell viability.”

 

Dr Chris Millan, Chief Technology Officer at CellSpring, added: “CellSpring is excited to partner with Tecan to bring automated, simple 3D cell culture solutions to customers. The benefits of our 3D Bloom Platform – versatility and reliability – are now available at scale using the Freedom EVO.”

glass-solutions

Merging materials for unique lighting installations

author2016-05-24authorposted by Raquel,

Glass Solutions is working with bespoke furniture and lighting designers FRD Ltd to produce individual lighting installations for both private and public spaces. Jane Kavanagh, Operations Manager at FRD, explained: “FRD creates unique lighting and furniture for the high end interior design market, from restaurants and public areas to private dwellings and super yachts. We have a strong global reputation, working with architects, designers and private clients in the UK, Europe, Middle East, Far East and USA to produce truly bespoke pieces. Although we are known for our metalwork, our designers often use glass to complement specific aspects of our pieces, and we have worked with Glass Solutions for a number of years to help us achieve the right aesthetic for individual projects.”

 

“We originally contacted the company to manufacture a series of large diameter glass tubes for chandeliers, as we couldn’t find any other supplier capable of producing something on the scale we required. They pulled out all the stops on that project – the service we received was truly exceptional – and we have since gone back to them a number of times, for everything from simple chandelier components to large complex pieces. We often push the boundaries of what is possible, but the Glass Solutions team is always up for the challenge, and we rarely have to compromise. You live and die by tolerances in this industry and, when we supply a design to Glass Solutions, we can always be confident that the glass is going to match the metalwork precisely.”

sonosite-fujifilm

Point-of-care ultrasound indispensable for elite sport in Wales

author2016-05-24authorposted by Caroline,

Point-of-care ultrasound is an essential tool for Dr Mark Ridgewell, an early pioneer for sports and exercise medicine (SEM) and, for the past 13 years, consultant sports physician at the Sport Wales Institute. He explained: “Point-of-care musculoskeletal ultrasound has developed into an extremely useful tool for SEM, particularly in the last 10 years; it has certainly become indispensable for me as an extension of my clinical examination. Patients these days are well read and aware – consultations often take the form of a discussion about managing a condition – and the ability to explain things to individuals with the help of ultrasound is a real advantage. It is excellent, for example, for assessing tendons during rehabilitation and recovery following an injury, or for looking at injuries dynamically, to work out what’s happening when a joint or tendons move. Soft tissue overuse injuries are often a lot more subtle and more difficult to explain, and the ability to use ultrasound is a huge benefit here. I also use ultrasound regularly for guiding injections, particularly in shoulders, hips and around the ankle.”

 

The High Performance Area at the Sport Wales National Centre in the centre of Cardiff is now equipped with a SonoSite X-Porte® system on Mark’s recommendation: “It is fantastic, I’m very happy with it, for ease of use, clarity of picture and the size of the screen. Even some of my patients have commented on the image quality and that, in itself is very important; patients will simply take themselves elsewhere if there isn’t access to this sort of state-of-the-art technology. Keeping up to date is extremely important; the elite sports world is constantly changing and you can’t be left behind.

biofortuna

Record year for Biofortuna Contract Services division

author2016-05-18authorposted by Raquel,

Biofortuna Ltd is pleased to announce a record year of growth for its IVD Contract Services division. This growth has been driven by the expansion of its service portfolio, together with increased demand for its core lyophilisation services.

 

Biofortuna’s success stems from its specialist freeze-drying expertise and proprietary cryo­preservation technologies, allowing the stabilisation of complete PCR, isothermal amplification and immunoassay reactions into instantly soluble freeze-dried pellets. This lyophilisation technique provides a simple solution for ambient temperature shipping and storage, and offers single-step set­up protocols for end users.

 

The success of this approach has led to significant expansion of the company’s ISO 13485 accredited and FDA registered services, which now include contract research and development, lyophilisation, air-drying, manufacturing, dispensing and kitting of diagnostic products. Its analytical stabilisation offerings have also been extended, with the addition of Karl-Fischer titration and DSC instrumentation.

 

Over the next year, Biofortuna plans to further expand its customer base by investing in state-of-the-art immunoassay manufacturing facilities. Dr Simon Douglas, Biofortuna CEO, commented: “I’m delighted by the performance of our Contract Services division. This success is a testament to the quality of the services we offer, and I look forward to further growth over the next 12 months.”

  

About Biofortuna Ltd

Biofortuna Ltd is a leading diagnostics company offering both custom manufacturing services and molecular diagnostic products. Biofortuna provides a complete solution for diagnostics companies looking to outsource elements of development and manufacture.

 

Biofortuna’s lyophilisation technology provides easy-to-use diagnostics whilst increasing laboratory productivity and improving quality in clinical testing and patient care.

 

Biofortuna currently offers molecular diagnostic products for HLA disease identification and HLA pharmacogenetics, and is currently developing a range of real-time blood group genotyping kits.

 

bulgin

Bulgin launches new miniature anti-vandal switch range

author2016-05-12authorposted by Raquel,

Bulgin – an Elektron Technology brand – has extended its popular range of anti-vandal products to include a 12 mm miniature push button variant. The latest addition to the company’s anti-vandal portfolio is the smallest of its kind and one of the most versatile, offering multiple actuator options and a long life expectancy, guaranteed to 200,000 cycles. Compact and durable, it is ideal for applications where space is at a premium.

 

The IP65- and IK08-rated miniature anti-vandal range (IP67-rated switches available to order) is perfect for demanding environments where reliability is vital, with an operating temperature ranging from -25 to + 55 °C and shock resistance greater than 10g. Screw and pin terminal options with ratings up to 36 V DC, 2 A, are available in a wide variety of actuator and body types, including:

      - nickel-plated brass, stainless steel, zinc-aluminium and chrome-plated bodies

      - domed, flush and raised actuator options in stainless steel or polybutylene terephthalate (PBT)

      - dot and ring LED illuminated variants

 

Robust and sealed, the miniature anti-vandal switches are suitable for a wide range of demanding applications in fields as diverse as defence and security, commercial, recreation and leisure, transport and infrastructure, scientific and medical, marine and industrial manufacturing.

 

For more information, visit http://www.bulgin.com/news/12mm-switch-news.html

tecan

Essential QC tools for GLP/GMP environments

author2016-05-03authorposted by Anna ,

Tecan has unveiled a novel solution to help laboratories meet the stringent requirements of regulatory authorities such as the FDA and the EMEA. The new MultiCheck™ QC package for Spark® 10M and Spark 20M multimode readers comprises a reusable QC plate and accompanying data analysis software, and is designed to aid laboratories striving to fulfill increasingly strict regulatory demands including GLP, GMP, ISO 9001, ISO 13485 or Title 21 CFR Part 11.


Enabling verification of the correct functionality of all major components and key measurement modes over time, the new MultiCheck QC package for Spark readers allows complete Installation Qualification and Operational Qualification (IQOQ) of the reader in a single step. For fast, simple operation, the MultiCheck plate uses solid samples, eliminating tedious preparation and pipetting of test liquids. The plate’s absorbance reference is also traceable to NIST, ensuring the highest level of quality control. The powerful MultiCheck software guides the user through the entire process, documenting the operator identity, QC plate and reader serial numbers for audit purposes. All QC measurements performed using the Spark reader are rapidly analyzed, with detailed results for each test parameter documented in a comprehensive report.


To learn more, visit www.tecan.com/qctools

quotient

Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs

author2016-04-29authorposted by Raquel,

Quotient Clinical, the Translational Pharmaceutics® company, and Upperton, the UK spray drying specialist, have announced a partnership to address drug delivery challenges.  This venture will combine Upperton’s formulation development services with Quotient’s GMP manufacturing services.

Over 40% of candidate drugs in development are poorly soluble which leads to low oral bioavailability. Spray drying is a widely adopted and successful approach to addressing this issue.

Mark Egerton, CEO of Quotient Clinical said “Spray drying is a key technology and is an established capability within our service portfolio. Upperton has more than 20 years’ spray drying expertise and this partnership will both reinforce our existing spray drying know-how and extend our capabilities into biologics, offering new and exciting opportunities”.

Richard Johnson, CEO and Founder of Upperton added “We are really pleased to announce this partnership with Quotient. It allows us to streamline the transfer of formulation development projects into pilot GMP manufacturing, better supporting our customers’ preclinical and clinical development needs. Our first joint program has already been successfully delivered and has demonstrated the time savings that can be achieved for our customers through our close working relationship with Quotient”.

cepheid

Using 'Diagnostics First' Could Help Preserve Effectiveness Of Life-Saving Antibiotics

author2016-04-20authorposted by Raquel,

Cepheid Highlights Role of Diagnostics as Valuable Tool in Growing Fight Against Antibiotic Resistance

Cepheid (Nasdaq: CPHD) have announced the launch of its 'Diagnostics First' campaign to raise awareness for the use of accurate and fast diagnostic tests to inform optimal treatment decisions and avoid over-prescription of the world's limited arsenal of antibiotics.

"Since the introduction of antibiotics in the 1940s, doctors have had to rely on their expertise, intuition, and experience to diagnose patients and initiate antibiotic therapy well before diagnostic test results were available," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer.  "Many lives have been saved by empiric therapy, but we are now seeing the rise of drug-resistant bacteria that may soon be resistant to all known antibiotics. Fortunately, advances in technology have enabled the accurate and fast diagnostics needed to support real-time decision making by healthcare providers to provide the right drug at the right time."

According to the United States Centers for Disease Control and Prevention (CDC), up to 50% of all prescribed antibiotics are not needed, or are not effective as prescribed.1 Over-use of antibiotics has led to the global rise of drug-resistant infections such as carbapenem-resistant Enterobacteriaceae (CREs) and ceftriaxone-resistant Neisseria gonorrhoeae, as well as an upsurge of Clostridium difficile infections.  All of these have been deemed urgent threats by the CDC.  Multi-drug resistant tuberculosis (MDR-TB) and methicillin-resistant Staphylococcus aureus (MRSA), among others, are also cited as serious threats by the CDC and major global health concerns by the World Health Organization.2 Infections from these bacteria lead to over 25,000 deaths annually and 2.5 million additional hospital days in the EU, and over 23,000 deaths per year and 2 million cases of illnesses in the US.3

"Cepheid strongly endorses the important work being done by the CDC, the White House, the World Health Organization and the United Kingdom's Review on Antimicrobial Resistance, among others, to address the rapidly growing threat of drug-resistant organisms while there is still time to act," said John Bishop, Cepheid's Chairman and Chief Executive Officer.  "The objective of Cepheid's 'Diagnostics First' campaign is to further escalate the discussion about the importance of accurate and fast diagnostics as part of the best 'prescription' in this important fight."

Mr. Bishop adds, "It's critical that we all play our part to help target antibiotics where they are needed more precisely, so that we can preserve their value for future generations.  If the improper use of antibiotics continues, it is possible that minor infections could become deadly, much like they were in the pre-antibiotic era."

"As noted in the O'Neill Review on Antimicrobial Resistance, rapid point-of-care diagnostic tests are a central part of the solution to the problem of unnecessary antibiotic use," said Dr. Thierry Naas, Associate Professor in Medical Microbiology at the University of Paris South Medical School, who is currently coordinating the European Joint Programming Initiative on Antimicrobial Resistance.  "We welcome the efforts of Cepheid and others as they continue to innovate and bring these accurate and fast diagnostics into routine clinical use to help ensure patients receive the most appropriate antibiotic therapy."

For more information on the Diagnostics First campaign, visit www.diagnosticsfirst.com.  

(For more information on Cepheid's GeneXpert Systems or the complete menu of Xpert tests, visit www.cepheid.com.)

 

1 www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf 
2 www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdfwww.who.int/mediacentre/factsheets/fs194/en/ 
3 www.cdc.gov/drugresistance/pdf/antibiotic_resistant_fs.pdf

.

sonosite-fujifilm

High flying point-of-care ultrasound

author2016-04-20authorposted by Anna ,

Ultrasound technology is taking to the skies with the Essex & Herts Air Ambulance Trust, a charity that provides a free, life-saving Helicopter Emergency Medical Service for the critically ill and injured of Essex, Hertfordshire and the surrounding areas.

 

Stuart Elms, Clinical Director of the Trust, explained: “We operate two helicopters crewed by full-time pre-hospital care doctors and critical care paramedics who can be rushed to the scene of an incident with highly specialised and advanced life-saving equipment and pharmacy. As part of our practice, we are moving towards using ultrasound for management of cardiac arrest and advanced life support. Working with expert sites such as the Essex Cardiothoracic Centre at Basildon, Harefield Hospital  and SonoSite, our aim is to train our critical care paramedics to use point-of-care ultrasound, allowing us to tailor our cardiac care even more accurately.”

 

“SonoSite is a world leader in point-of-care ultrasound, and its hand-carried iViz instrument lends itself perfectly to pre-hospital use, both in the aircraft and at the scene. The system is small and portable with a good screen that gives a brilliant view, and can be used one handed. The preset views allow rapid set-up and scanning, and are supported by a training mode that allows comparison of normal and abnormal pathology. Ultimately, we also hope to take advantage of the system’s mobile computing capacity to automatically upload data to electronic patient report forms prior to arrival at the hospital. Our aim is to make as much use of ultrasound as we currently do of stethoscopes – whether they are cardiac, medical or trauma patients – helping to improve outcomes.”

glass-solutions

Glass Solutions provides a clear line of sight

author2016-04-13authorposted by Raquel,

Bolton-based PTFE Developments Ltd. specialises in the production of fluoropolymer-lined chemical process equipment for the chemical and pharmaceutical industries, relying on Glass Solutions to supply the high quality glass used in its tubular sight glasses. David Howarth, Managing Director, explained: “We chose Glass Solutions as our supplier because the company maintains substantial stocks of the SCHOTT Duran range of borosilicate glass that we use. This helps to ensure the availability of top-end glass tubes made to our specifications, which is vital for reliable production.”

 

“Quality, particularly in the pharmaceutical industry, is a very important factor. Glass Solutions’ workmanship is excellent, and the glasses we receive are always accurately cut. We simply place an order for the size and length of tube that we need, and the company delivers a custom solution ready to build in to our products. We have a good working relationship with the company, and the service we receive is excellent; Glass Solutions is both flexible and efficient, which is particularly beneficial if we need something urgently. We have been working with the company for several years now, and find the team really easy to deal with.”

quotient

Quotient Clinical extends spray drying capabilities for poorly soluble molecules

author2016-04-12authorposted by Raquel,

Quotient Clinical, the Translational Pharmaceutics® company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor™ Spray Dryer. Quotient has a proven track record of developing spray-dried dispersions to overcome drug compound solubility issues, and the addition of a larger scale spray dryer will allow the production of a range of batch sizes, from milligrams up to two kilograms.

 

Sited at Quotient’s new GMP facility at MediCity in Nottingham, UK – scheduled to open later in 2016 – this expansion is a direct response to customer requests for ongoing product development support, including toxicology and later stage clinical studies.

 

Nikki Whitfield, VP of Pharmaceutical Sciences, commented: “Poor solubility is increasingly prevalent in drug pipelines across the industry. We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to address these complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimised formulations to support our clients’ downstream clinical development programs.” 

sonosite-fujifilm

FUJIFILM SonoSite announces launch of the new SonoSite SII, the simply smart ultrasound system

author2016-04-12authorposted by Anna ,

FUJIFILM SonoSite Inc., specialists in developing cutting-edge ultrasound solutions and providing world-leading education to enable point-of-care visualization access, announced today CE mark and 510(k) clearance for its new mountable ultrasound system, the SonoSite SII. Developed for regional anesthesia, vascular access and trauma applications, the SII empowers efficiency for clinicians through a simple, yet smart user interface that adapts to the user’s imaging needs. The system is portable and can be used across multiple hospital environments, including a zero footprint option for space-constrained rooms.

 

“SonoSite introduced the first mountable ultrasound system in 2007, providing an unparalleled solution for clinicians who valued and needed to accelerate their clinical workflow,” said Brian Leck, Vice President, Global Direct Sales, FUJIFILM SonoSite Inc. “The new SII ultrasound system expands on the design goals of our mountable legacy system by offering more functionality, and an even better user experience from start to finish. We listened to clinicians, and delivered a product designed to maximize the efficiency of their ultrasound use. The SII captures the epitome of the SonoSite brand, allowing clinicians to confidently use the system from day one.”

 

For regional anesthesiologists, enhancing patient throughput is a critical need, especially as they perform an increasing number of ultrasound-guided procedures on a daily basis. The SII features a new touchscreen user interface with a clinician-driven menu logic that adaptively adjusts to the use case– “what you need, is what you see”. An embedded dual transducer connector also allows quick switching between transducers with two simple taps of the screen, ensuring that the right transducer is always readily available. To further accelerate end-to-end workflow, the SII comes with a new stand, offering elevated transducer holders and additional storage, all while minimizing footprint.

 

For trauma patients, the speed and ease of image acquisition is vital, as a few minutes can alter a patient’s care path. The SII features DirectClear™ technology, a novel, patent-pending process that is available on select transducers. DirectClear™ elevates transducer performance by increasing penetration and contrast resolution. This transducer innovation contributes to an unsurpassed imaging experience for the clinician.

 

The SonoSite SII transforms the pace of patient care for proceduralists or those clinicians requiring a quick answer at a critical moment. To learn more about the SII ultrasound system or for more information about FUJIFILM SonoSite, Inc. please visit: www.sonosite.com.

sonosite-fujifilm

SonoSite X-Porte™ proves a hit with A&E services in Chester

author2016-03-23authorposted by Anna,

The Emergency Department at the Countess of Chester Hospital NHS Foundation Trust was one of the first sites in the UK to benefit from the advanced point-of-care ultrasound capabilities of Fujifilm SonoSite’s X-Porte™ system. Dr Mayooran Thevendra, a consultant in emergency medicine at the trust, explained: “We use ultrasound extensively in the department for FAST scans, ultrasound of aortas, vascular access and basic echocardiography. We were looking to replace our existing point-of-care ultrasound system just as the X-Porte was introduced, and were very impressed by its ease of use. We trialled several other systems, but none of them offered the same combination of simplicity and image quality.”

 

“Its portability and ease of use have also led to us using the X-Porte more than our previous system. The needle visualisation software makes administering nerve blocks for pain relief incredibly easy; you can see exactly where the needle tip is in relation to the nerves and other structures, and we’re even starting to teach junior doctors this technique. The educational videos loaded onto the system are also particularly useful for training our middle grade doctors, as well as registrars rotating through the department as part of the Mersey Deanery of the School of Emergency Medicine, providing helpful insights that make it easier to get good images.”

 

syrris

Syrris showcases Asia Automated Reagent Injector

author2016-03-17authorposted by Raquel,

Syrris, a world leader in the field of flow chemistry, previewed its Asia Automated Reagent Injector at the SCI/RSC Continuous Flow Technology conference in Cambridge, UK, on the 15th of March. This latest innovation is designed for use with Asia flow chemistry systems, enabling fully automated experiments with multiple reagents.

 

Driven by the Asia Syringe Pump module, the compact Asia Automated Reagent Injector offers high performance, fully automated sample injection via two independent channels, allowing complex matrixed libraries to be synthesised. Gas blanketing provides the inert sampling conditions required for safe handling of air and moisture sensitive reagents and, with sample pre-pressurisation up to 20 bar, dispersion and pressure drops during reactions can be avoided, enabling even very small volumes to be injected. For maximum flexibility, sample loops from 0.1 to 10 ml are available, as well as a selection of removable racks for 2, 8 and 40 ml vials. Complete process automation is provided by connection to the Asia Manager PC Software, enabling sophisticated multiple sample injections and experiments to be performed, including key applications such as synthetic library generation, reagent screening, reaction optimisation, kinetic and degradation studies, and LogD screening.

 

For more information, visit http://syrris.com/flow-products/asia-modules/asia-auto-injector

 

quotient

Quotient Clinical incorporates Japanese bridging into a Translational Pharmaceutics® program

author2016-03-15authorposted by Raquel,

 

Quotient Clinical, the Translational Pharmaceutics company, has announced the completion of its first clinical program involving Japanese healthy volunteers.

The Japanese market is one of the leading pharmaceutical markets worldwide, and bridging studies conducted outside of Japan ensure that drugs that are to be marketed in Japan have been thoroughly evaluated in the Japanese population.

 

This program of work was a first-in-human investigation, performed on behalf of a US sponsor, and comprised an integrated four part clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug candidate targeting an important orphan disease.

 

The program was delivered using Quotient’s Translational Pharmaceutics® platform, which integrates formulation development, real-time GMP manufacturing and clinical testing, allowing the drug product to be adapted in real-time, based on emerging clinical data. The inclusion of first generation Japanese volunteers into one part of the study accelerated the transition into downstream clinical trials in Japan.

 

Ian Nisbet, VP Clinical Operations, said “We are delighted to extend our core Translational Pharmaceutics services to now include Japanese volunteers. Recruitment was undertaken in partnership with UK Chiken Services Ltd, an experienced company which specialises in Japanese volunteer recruitment. All cohorts were dosed on time and in full.”

dolomite

Dolomite launches 3D fluidics printer at Lab-on-a-Chip & Microfluidics 2016

author2016-03-15authorposted by Raquel,

Dolomite, a world leader in microfluidics innovation, unveiled its innovative Fluidic Factory at Lab-on-a-Chip & Microfluidics 2016 in Madrid, Spain, on the 15th of March. The first commercially available 3D printer for fluidically-sealed devices, it offers rapid, easy and reliable printing from as little as $1 per device. Using FDA-approved, robust and translucent cyclic olefin copolymer (COC), this makes it easy and affordable to 3D print devices for almost any application.

The Fluidic Factory is designed for ultimate ease of use, enabling rapid prototyping of fluidically-sealed devices such as chips, sensor cartridges, fluid manifolds, valves, connectors and medical devices. Its intelligent software and innovative hardware ensure reliable sealing of fluidic paths, allowing the creation of precise channel geometries and various features not possible using etching, embossing, moulding or machining techniques. Users can choose a design from the Fluidic Factory’s Design Library, or create and print their own unique devices using virtually any CAD software. With this complete design flexibility, the Fluidic Factory is ideal for a wide range of applications, including organ-on-a-chip, point-of-care diagnostics, drug development, education, chemical synthesis, and analytical and biomedical assays.

To find out more, please visit www.dolomite-microfluidics.co.uk/en/news 

 

cepheid

Cepheid delivers milestone 10,000th GeneXpert system

author2016-03-09authorposted by Anna,

Dean Street Express Expanding to Additional Locations using GeneXpert Infinity System

 

Cepheid have announced the delivery of the 10,000th GeneXpert® System to the 10 Hammersmith Broadway Clinic in London, England. The Hammersmith Clinic is the first in a series of new clinics developed by the same team behind the innovative Dean Street Express clinic located in London’s Soho district that has been transforming the model for STD testing and public health since it first opened in February 2014. Dean Street Express, 10 Hammersmith Broadway and the additional planned clinics offer drop-in service and on-site testing, with results delivered to patients within hours, rather than days, for a number of STDs, including CT/NG, HIV, and syphilis. Dean Street Express has adopted Cepheid’s GeneXpert Infinity System to enable rapid, on-site testing for CT/NG using patient-collected specimens. Unlike more traditional molecular systems that can only be operated at centralized testing locations with highly skilled lab technicians, the GeneXpert System allows lab-quality, complex molecular tests to be completed at the point-of-care, in this case with Cepheid’s unique, high-volume GeneXpert Infinity System.

 

“Dean Street has challenged the way we all think about the delivery of diagnostic tests and the workflow and management of important diagnostic results,” said John Bishop, Cepheid’s Chairman and Chief Executive Officer. “As a result, the overall patient experience is dramatically improved, and those patients who need it are started on appropriate therapies faster. I’m very pleased to see the proliferation of this transformational approach to sexual healthcare, and proud to be installing our 10,000th GeneXpert system at the new Hammersmith Clinic.”

 

“We have been thrilled with the response to the Dean Street Clinic, and have been able to test more patients and diagnose more STDs, in part due to the GeneXpert system’s quality, speed, and ease-of-use that enables same-day, non-intrusive STD testing,” said James Beckett, Divisional Director of Operations at the Chelsea and Westminster Trust. “Cepheid is an important partner as we extend our innovative approach into Hammersmith and other new locations in London, offering an exciting opportunity, not just for the UK but for sexual health globally, to improve diagnosis of STIs and to encourage people to screen regularly. We firmly believe that all patients should be able to access sexual health services in this way.”

 

The new Hammersmith site is scheduled to open in April 2016, to be followed by additional clinics later this year.

tecan

Freedom to evolve with Tecan’s Freedom EVO® 75

author2016-03-08authorposted by Anna ,

Researchers at the Complutense University of Madrid are using directed evolution techniques to develop new enzymes for a variety of bioprocessing applications. Taking advantage of the walkaway liquid handling capabilities of a Freedom EVO® 75 workstation, the university’s Enzyme Biotechnology Group – headed by Dr Isabel de la Mata – has been able to investigate ~4,000 Rhodococcus mutants for penicillin acylase and N-acyl homoserine lactone acylase activity, conducting over 190,000 assays in the primary screen alone. Dr de la Mata explained: “We are interested in enzymes with novel activities for use in the production of semi-synthetic antibacterial agents, such as β-lactam antibiotics, to overcome the resistance mechanisms which are becoming increasingly prevalent in nosocomial pathogens. The success of these molecular evolution methods depends on the ability to investigate large numbers of clones and, using our Freedom EVO 75 platform, we have been able to develop a robust high throughput assay for screening Rhodococcus mutants in a 96-well microplate format. This type of project simply wouldn’t have been possible to perform manually, and the technical support has been excellent.”

 

Rodrigo Velasco, a PhD student in the group, commented: “Thanks to the throughput capabilities of the Freedom EVO platform, each sample could be simultaneously assayed under several operational conditions, which would be very complex and difficult to achieve manually. This provides invaluable information to help us design the downstream stages of the research.”

 

To find out more about Tecan’s Freedom EVO 75, visit www.tecan.com/freedomevo75  

sonosite-fujifilm

A long term partner for point-of-care ultrasound

author2016-03-08authorposted by Anna,

The Anaesthesia Department at Queen’s Hospital, part of the Burton Hospitals NHS Foundation Trust, has been using FujiFilm SonoSite point-of-care ultrasound systems since they were first introduced in the UK, and has recently taken delivery of its first X-Porte. Dr TJ Bhatti, Clinical Director of Anaesthesia, Critical Care and Theatres at the trust, explained the benefits of good industry support and ever-advancing ultrasound technology: “We use ultrasound extensively in the department – for everything from nerve blocks and vascular access to peri-operative transthoracic echocardiographs – as well as on the wards and in A&E if necessary. We have even started using it in our physiotherapy department, training members of the team there to perform several simple nerve blocks. With so many users, it is important that the systems are familiar and easy to use, which is why we have always stuck to a single supplier. The user-friendliness and robustness of SonoSite’s systems, together with the very good five year warranty and the company’s support for educational initiatives, has always made it an obvious choice.”

 

“The latest generation X-Porte really is exceptional, offering excellent image quality. The system is also very intuitive to use, and can be easily customized to the user’s preferences, saving a lot of time. One of the most interesting features is its built-in tutorials and 3D anatomy guides. These are ideal for helping less experienced doctors, and I regularly see them being used side-by-side with live imaging to maximum effect.”

quotient

Quotient Clinical showcases Enabled-First-in-Human® programs at ASCPT 2016

author2016-03-01authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® company, will be showcasing its Enabled-First-in-Human® (Enabled-FIH) programs at the upcoming American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting 2016, to be held on the 8th to 12th of March in San Diego, California.

 

As part of the event, Quotient Clinical will be hosting a seminar entitled Accelerating timelines from candidate selection to proof-of-concept with Enabled-FIH programs. This seminar will cover unique and innovative approaches to reaching proof-of-concept (POC), with presentations from Hazel Hunt, VP of Research at Corcept Therapeutics, and Alyson Connor, Executive Director of Exploratory Clinical Pharmacology at Quotient Clinical. The speakers will describe integrated and adaptive clinical protocols which combine healthy volunteer and POC investigations, with case studies to highlight the benefits of using real-time, adaptive GMP manufacturing to adjust drug dose and product composition in response to emerging clinical data.


Alyson Connor commented: “Our Enabled-First-In-Human service is playing a key role in helping our clients to accelerate their early development timelines and achieve significant cost savings. Overall, we believe our service represents an important step forward in solving industry challenges and helping to improve R&D productivity.”

 

 

For further details, visit www.quotientclinical.com/ascpt-annual-meeting-2016

tecan

Automating the development of aptamer-based biological tools with Tecan

author2016-02-24authorposted by Anna ,

The ARNA Laboratory in Bordeaux, France, is using DNA and RNA aptamers to develop novel tools for biological applications. To increase throughput, the laboratory has automated its procedures on two Freedom EVO® platforms, as Inserm Research Director Dr Jean-Jacques Toulmé explained: “Our association with Tecan began when we decided to automate our selection protocols to allow us to screen large libraries of oligonucleotides. We generally perform two selections in parallel, consisting of between 8 and 15 runs. With each run taking around six hours, the selection process is completed in about a week to 10 days. This would be difficult to do manually, and is a tedious, repetitive task for a scientist to carry out. We contacted various suppliers before choosing Tecan, investing in a Freedom EVO platform which enabled the process to be almost completely automated, freeing up staff time and helping us to achieve the desired throughput.”

 

“We then realized that we needed a second automated platform for our production processes, and chose a Freedom EVO with an integrated Infinite® M1000 PRO multimode reader. This gave us the capability to use additional techniques – including AlphaScreen® assays and fluorescence anisotropy – and everything is still working very smoothly. Automation has been a great benefit to our workflow.”

 

To find out more about Tecan’s protein purification and characterization solutions, visit www.tecan.com/proteinscience

syrris

Syrris launches application-focused Asia flow chemistry range

author2016-02-23authorposted by Anna ,

Syrris has updated its revolutionary Asia range of flow chemistry systems, introducing a number of new modules and application-focused solutions. Designed by chemists for chemists, these award-winning systems have been developed to offer exceptional ease of use and enable a wide variety of chemical reactions.

 

The modular Asia range offers configurations to suit everything from beginners with modest budgets and experts who demand the utmost functionality, and now includes preconfigured systems for specific applications, from cryogenic reactions and nanoparticle synthesis to electrochemistry and process optimisation and scale-up. Users can perform manually controlled or fully automated experiments across an extensive range of temperatures, pressures and reaction times – on scales from milligrams to kilograms – ensuring there is an Asia set-up to meet your flow chemistry needs.

 

Catherine Carter, from the Ley Group at the University of Cambridge, UK, commented: “The modular design of the Asia system is very helpful, allowing us to rearrange it into different configurations to suit whatever multi-step synthesis sequence we need to perform. The flexibility to change syringes enables anything from very small scale to large scale synthesis to be achieved.”

 

For more information visit: http://syrris.com/flow-products/asia-systems

dolomite

Dolomite offers high speed imaging for microfluidics

author2016-02-16authorposted by Anna,

Dolomite has developed the Meros High Speed Digital Microscope specifically for microfluidic applications. This high resolution imaging system allows users to conveniently monitor high speed microfluidic events, such as droplet formation, using a built-in stage.

 

The Meros High Speed Digital Microscope features high magnification optics and a zoom lens to ensure that millimetre to micrometre scale features can be visualised clearly, with the added benefit of an extra-long working distance. Coupled with a high speed USB 3.0 camera, this allows clear imaging of moving particles or cells, enabling quantitative analysis of droplet size at low flow rates – typically below 1 kHz – and qualitative evaluation at production speeds of 2-15 kHz or higher, depending on droplet size.

 

The microscope’s easy-to-use stage is designed to securely hold a wide range of Dolomite and third-party microfluidic devices, including chips, connectors and the μEncapsulator 1 module. An integrated LED coaxial lighting system offers exceptional brightness with very low exposure times, with an optional reversible mirror and diffusor, allowing production of publication-quality images. Illumination from above also leaves the underside of the microfluidic device free for temperature regulation systems, such as the Meros TCU-100 temperature controller. To simplify operation, the entire system is controlled by Dolomite’s intuitive Flow Control Centre software, allowing straightforward live imaging, adjustment and image capture.

 

For more information, visit www.dolomite-microfluidics.com

ingenza

inABLE® technology helps unlock the secrets of cyclic peptides

author2016-02-16authorposted by Anna,

Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use. This work is part of a collaboration with researchers at the University of Aberdeen and the University of St Andrews, as Professor Marcel Jaspars of the Marine Biodiscovery Centre at the University of Aberdeen explained: “Small molecule drugs, such as paracetamol, are cheap, easy to administer and readily available. At the other end of the scale are large biologics such as antibodies, which have to be administered by injection and may require patients to attend hospital for treatment. They may need to be stored in a fridge to maintain stability, and tend to be expensive. Consequently, there is a great deal of interest in the production of compounds of intermediate size that have the properties of antibodies but can be taken orally.”

 

“Our aim is to develop a flexible, cost-effective technology platform for the production of drugs based on cyanobactin cyclic peptides. These peptides – which are native to many marine and freshwater species – show excellent promise against diseases such as drug resistant tumours, but their gene clusters are complex and difficult to manipulate. Ingenza’s inABLE technology allows us to shuffle genes very quickly, eliminating laborious, time-consuming manual processes and allowing the generation of large quantities of peptides.”

 

“This technology has been the key to a successful ongoing collaboration between the University of Aberdeen, Ingenza and Professor Jim Naismith at the University of St Andrews, to produce novel cyclic peptides for therapeutic testing. The next step is to expand the number of organisms we are investigating and generate larger quantities of these cyclic peptides, enabling industrial partnerships to be formed to develop new therapeutics targeting specific disease areas.”

quotient

Quotient Clinical celebrates its 100th RapidFACT® program

author2016-02-09authorposted by Anna ,

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues. RapidFACT has been proven to accelerate drug formulation development for all routes of delivery, and over 50 leading pharmaceutical and biotech companies globally have now adopted this approach.

RapidFACT can reduce development timelines by at least 50 % while delivering significant cost savings. This is achieved through Quotient Clinical’s innovative Translational Pharmaceutics platform, which integrates formulation development, GMP manufacturing and clinical testing in one location, allowing the product to be adapted in real-time, based on emerging clinical data. This approach has already been successfully used in programs focused on evaluating solubilisation technologies, optimising modified release systems, changing routes of delivery and developing combination products, with over 300 different formulation prototypes studied to date.

John McDermott, Executive Director of Drug Product Optimisation at Quotient Clinical, commented: “RapidFACT was launched in response to the challenges our customers faced in their development pipelines. We are delighted to announce our 100th program as confirmation of our ability to shorten timelines and save costs in the reformulation and optimisation of drug products. Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today.”

 

 

sonosite-fujifilm

FUJIFILM SonoSite announces launch of the new SonoSite EDGE II system

author2016-02-03authorposted by Anna ,

Providing clear ultrasound diagnostics for critical moments

 

BOTHELL, WA., February 2, 2016 – FUJIFILM SonoSite Inc., specialists in developing cutting-edge ultrasound solutions and providing world-leading education to enable point-of-care visualization access, announced today CE mark and 510(k) clearance for its new portable ultrasound system, the SonoSite Edge II. Designed with emergency medicine and critical care applications in mind, the Edge II features revolutionary transducer technology that delivers a better imaging experience for the most rugged environments.

 

"Since SonoSite introduced the first portable ultrasound system in 1999, it has continued to build solutions that anticipate the bedside provider's needs," said Diku Mandavia, MD, FACEP FRCPC, chief medical officer and senior vice president, FUJIFILM SonoSite Inc. and FUJIFILM Medical Systems U.S.A., Inc.  "The Edge II ultrasound system stays true to the SonoSite legacy of durability, reliability, and ease of use. However, we also incorporated enhancements to accelerate the time to image acquisition, enabling clinicians to make more confident decisions and focus on what matters most, the patient."

 

In the acute care environment, reducing the time to make an accurate diagnosis is a critical need. The Edge II features DirectClear™ technology, a novel, patented process that is available on select transducers. DirectClear™ elevates transducer performance by increasing penetration and contrast resolution. This transducer innovation, combined with a new wide-angle display that offers a 33% increase in viewing angles, contributes to an unsurpassed imaging experience for the bedside clinician.

 

Designed to be truly portable and used in the most rugged environments, the Edge II reinforces FUJIFILM SonoSite’s commitment to reliability and durability with Armored Cable Technology. With an embedded metal jacket, armored cables protect transducers from common abuse accident scenarios, like being rolled over, stepped on, or twisted, and help maintain image quality over the life of transducers built on this cable platform.

 

With these technology innovations, an optimized design to enhance infection control management and efficient use of common controls like gain, the Edge II is the rugged, reliable, and responsive ultrasound solution for point-of-care.

 

For more information about FUJIFILM SonoSite, please visit: www.sonosite.com.

dataracks

Micro Data Centre Launch Event

author2016-01-29authorposted by Anna ,

Join Dataracks and Cambridge Cleantech to discover how micro data centres are helping to shape the edge computing landscape

Unlock the potential of smart technology and data management

Need to store large amounts of data efficiently? Interested in the Internet of Things and smart technologies? Then join Dataracks and Cambridge Cleantech at the Trinity Centre, Cambridge, from 9:30 to 13:30 on Thursday 4th February 2016 to learn more about recent developments in smart technology and edge computing.

 This half-day event, hosted by Dataracks and Cambridge Cleantech, will feature leading industry figures discussing the applications and benefits of the latest technologies, as well as the launch of the Micro Data Centre, the latest innovation from Dataracks. Speakers will include:

  • Tim Murdoch, Cambridge Consultants: Why the Internet of Everything demands that we focus on services.
  • Dan Clarke, Cambridgeshire County Council: The Smart Cambridge programme.
  • Marta Teperek, Cambridge University Library/Research Operations Office: The university’s perspective on data management and sharing: from policy to practice.
  • Jeremy Hartley, Dataracks: Introducing the Micro Data Centre.

 

The session will conclude with a buffet lunch – ideal for networking – and the opportunity to view the revolutionary Micro Data Centre.

Register here: www.dataracks.com

tecan

Empower your research with Tecan’s Spark® 20M multimode reader

author2016-01-25authorposted by Sophie Woodward,

Tecan has launched the Spark® 20M multimode microplate reader*, offering tailor-made solutions to suit virtually any drug discovery or advanced life science research application. This freely configurable system gives researchers access to new techniques and features intended to enhance and streamline biochemical and cell-based workflows. At the heart of the instrument are Spark’s unique Fusion Optics and a powerful, high frequency xenon flash lamp, which can be combined with your choice of high performance detection modules to ensure a perfect match for your workflow. Options include an enhanced fluorescence module designed to improve sensitivity and increase the speed of high throughput screening, and the newly developed Te-Cool™ cooling module that uniquely allows the measurement chamber temperature to be set below the ambient room temperature for more accurate and reliable results.

 

The Spark 20M’s cell handling capabilities have also been extended, with a new automated cell imaging and confluence measurement feature. This allows incubation and monitoring of cell culture microplates within the measurement chamber, enabling the user to define the confluence at which the assay starts/ends or the substrate is injected, for optimal assay results and greater walkaway operation. These new options – combined with the ability to read 6- to 1,536-well microplates – ensure there is a Spark 20M configuration to increase the productivity of your lab, both today and in the future.

 

To find out more about Tecan’s Spark 20M, visit www.tecan.com/spark20m

 

*Spark multimode reader is for research use only.

 

                                                                                                                          

For more information please contact

Tecan Trading AG

Antonietta Allocca

Tel  +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12

info@tecan.com  www.tecan.com

 

 

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2014, Tecan generated sales of CHF 400 million (USD 437 million; EUR 331 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

 

dolomite

Dolomite aids drug encapsulation studies

author2016-01-12authorposted by Sophie Woodward,

A Dolomite microfluidic system is helping Dr Samar Damiati, Assistant Professor in the Biochemistry Department at King Abdulaziz University in Saudi Arabia, perform drug encapsulation studies. She explained: “My work is mainly focused on using different polymers, particularly PLGA – poly(lactic-co-glycolic acid) – for drug encapsulation, generating monodisperse particles for further investigation. I use a Dolomite system for this purpose, preparing particles on an almost daily basis, and find it very straightforward.”

 

“The drugs I am currently working with are hydrophobic and need to be encapsulated in suitable biodegradable polymer carriers to control their release in oral pharmaceutical formulations. The classical method of encapsulating drugs usually involves an extrusion step to produce particles of uniform size, but this can be avoided by using a microfluidic chip. Using the Dolomite chip, I have been able to produce PLGA particles that are uniform in size and shape, which is a huge benefit to my work. The ability to combine microfluidics with complementary techniques, for example electrochemical methods, allows further investigations to be performed, providing a full picture of the system under study. Customer support is important too; Dolomite’s data sheets are available online, making them easy to access, and I can always contact the company if I need further advice. I know that I will always get a quick response.”

 

For more information, visit www.dolomite-microfluidics.com.

mettler-toledo

Rainin TerraRack™ wins Green Apple Environment Award

author2015-12-17authorposted by Sophie Woodward,

METTLER TOLEDO is proud to announce that its Rainin TerraRack™ line of pipette tip racks has achieved success in this year’s Green Apple Awards. The judges clearly recognised the environmental benefits of this innovative product range – which is designed to minimise the problem of plastic tip rack waste – selecting TerraRack from a field of more than 500 entries to receive a Bronze Award for Environmental Best Practice. The award was presented to EU Market Manager Ian Eaton-Taylor at a ceremony held at the Houses of Parliament in London on Monday November 16th.

 

Empty conventional tip racks can take up a large amount of space and represent a significant quantity of plastic waste. Where disposal rates are based on weight, they're also a considerable expense. TerraRacks are composed largely of PETE (polyethylene terephthalate) – an exceptionally strong polyester never previously used to construct pipette tips racks – which is easy to recycle and in high demand as a post-waste commodity. They are 50 % lighter than conventional tip racks, highly compressible when empty, and completely recyclable, significantly reducing their volume and disposal costs. The TerraRack shell is moulded as a single unit which a polypropylene tip deck snaps into, providing structural support with minimal weight. Every rack is presterilised, individually wrapped and sealed for maximum purity, and the hinged lid and secure latch protect tips from damage and potential contamination between uses. For a weightier, more conventional tip rack feel, an optional re-useable TerraBase – made from autoclavable, chemically resistant translucent polycarbonate and with silicone feet – is available.

 

For more information, please contact:

METTLER TOLEDO AG,

Laboratory & Weighing Technologies,
Im Langacher, 8606 Greifensee, Switzerland
T +41 44 944 2211
F +41 44 944 3320

www.mt.com/rainin

quotient

Quotient Clinical expands its formulation development services with the acquisition of Co-Formulate

author2015-12-16authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited.

 

Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics platform, which challenges the conventional industry approach by integrating formulation development, real-time GMP manufacturing and clinical testing. The acquisition of Co-Formulate reinforces and extends Quotient’s existing pharmaceutical development capabilities across solid, semi-solid and liquid formulations. Co-Formulate is based adjacent to Quotient’s new GMP facility in Nottingham, UK, which will enable seamless integration of formulation development and GMP manufacturing services.

 

Mark Egerton, Chief Executive Officer of Quotient Clinical, commented: “We are delighted that Co-Formulate has become part of our business. The company brings a wealth of formulation development experience in areas that complement our existing capabilities. Its expertise in helping customers to manage product life cycles and develop a range of product formats, including age-appropriate paediatric and geriatric formulations, will help us to extend our customer base and service portfolio. These are important areas of our growth strategy over the coming years.”

 

Huw Jones and Nazim Kanji, Directors and founders of Co-Formulate, said: “We are excited to join forces with Quotient Clinical. The co-location of our formulation development laboratories with Quotient’s new GMP manufacturing facility will deliver a real advantage for our customers. We will now be in a position to deliver seamless programs consisting of formulation development, clinical trial manufacturing and clinical testing, all under the umbrella of a single organisation.”

 

Financial terms of the transaction were not disclosed. Quotient Clinical’s legal advisors on the acquisition were Browne Jacobson, and Dow Schofield Watts performed financial due diligence.  The shareholders of Co-Formulate received legal advice from Shakespeare Martineau, and financial advice from Realise Capital Partners.

 

For further information, please contact:

 

 

Gordon Cameron

Chief Financial Officer

Quotient Clinical

Tel: +44 (0)115 931 5148

Gordon.cameron@quotientclinical.com

 

 

Robin Bodicoat

Marketing Director

Quotient Clinical

Tel: +44 (0)115 931 5102

robin.bodicoat@quotientclinical.com

dolomite

High throughput single cell applications set to benefit from Dolomite’s novel µEncapsulator 1 System

author2015-12-16authorposted by Sophie Woodward,

Dolomite, a world leader in microfluidics innovation, has launched the groundbreaking µEncapsulator 1 System, the only microfluidic product specifically designed to meet the needs of research biologists. This user-friendly, high throughput system offers simple, straightforward encapsulation of single cells, DNA and/or functionalised beads in high precision, identically-sized picolitre droplets.

 

The launch of the µEncapsulator 1 System is set to benefit scientists working on an array of applications, including characterisation of natively paired T cell receptors, isolation of monoclonal antibody coding sequences from blood samples, high throughput single cell expression profiling, droplet PCR, high sensitivity digital PCR and encapsulation in hydrogels. The µEncapsulator can individually encapsulate 300,000 cells into monodisperse droplets in 15 minutes. Samples and reagents are loaded into the 100 µl Sample Reservoir Chip for encapsulation using a 2 Reagent Droplet Chip. The microfluidic droplets produced are then collected in a temperature-controllable microcentrifuge tube for easy aliquoting into PCR tubes or cell culture multiwell plates, or imaging under a microscope. A biocompatible oil with a high dissolved gas content is used for dropletisation, enabling encapsulated live cells to be cultured for days. For ease of use, the system can be controlled using Dolomite’s advanced Flow Control Centre software, enabling a range of protocols to be performed, from simple one-click sample processing and dropletisation through to full automation.

 

For more information, please visit: http://www.dolomite-microfluidics.com/webshop/uencapsulator1_system

syrris

Versatile Syrris flow reactors feature in a plethora of publications

author2015-12-15authorposted by Sophie Woodward,

Syrris, a world leader in flow product innovation, has been a driving force in enhancing R&D chemistry productivity ever since the company’s foundation 14 years ago. This achievement is amply recognised by the wealth of impressive publications describing novel flow chemistry applications developed using Syrris reactors.

 

Today, scientists have access to hundreds of flow chemistry papers citing groundbreaking applications established on modular reactors from Syrris, including the Ley group’s Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry1. The group, based at the University of Cambridge, took advantage of the Asia reactor’s continuous analysis and work-up capabilities to synthesise the natural products Spirodienal A and Spirangien A. This pioneering process, using solids, liquids and gases, combines 16 stages of a 21-step synthesis into one flow chemistry sequence, demonstrating just how far flow techniques have advanced.

 

The pharmaceutical industry is also benefitting from continuous flow techniques, as well as microfluidic electrosynthesis, with publications including A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir 2 and Preparative Microfluidic Electrosynthesis of Drug Metabolites3. Scientists worldwide can learn more about these and many other varied applications taking advantage of Syrris flow reactors – ranging from the early days of flow chemistry synthesis through to numerous present-day examples – by exploring the convenient reference guide at http://syrris.com/news/syrris-in-publications

 

  1. Sean Newton, Catherine F. Carter, Colin M. Pearson, Leandro de C. Alves, Heiko Lange, Praew Thansandote, and Steven V. Ley (2014). Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry. Angew. Chem. Int. Ed. 53, 1-7.

 

  1. Luciana Dalla-Vechia, Benedikt Reichart, Toma Glasnov, Leandro S. M. Miranda, C. Oliver Kappe and Rodrigo O. M. A. de Souza (2013). A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir. Org. Biomol. Chem. 11, 6806-6813.

 

  1. Romain Stalder and Gregory P. Roth (2013). Preparative Microfluidic Electrosynthesis of Drug Metabolites. ACS Med. Chem. Lett. 4 (11), 1119–1123.
cepheid

CEPHEID ANNOUNCES INTERNATIONAL COMMERCIAL AVAILABILITY OF NEXT GENERATION BCR‐ ABL TEST

author2015-12-09authorposted by Sophie Woodward,

Cepheid (Nasdaq: CPHD) has announced the commercial availability outside the United States of Xpert BCR‐ABL Ultra, a quantitative measure of BCR‐ ABL1 mRNA transcripts (types e13a2/b2a2 or e14a2/b3a2) that allows physicians to monitor the effectiveness of therapy in their patients with Chronic Myelogenous Leukaemia (CML) with enhanced sensitivity.

 

CML is a cancer of the myeloid lineage of leukocytes (white blood cells) that is characterised by the presence of the "Philadelphia Chromosome", a reciprocal translocation of chromosomes 9 and 22 that results in the generation of the BCR‐ABL fusion gene. The development of Tyrosine Kinase Inhibitors (TKIs) that target BCR‐ABL has transformed CML from a uniformly fatal illness into a manageable chronic disease for many patients, and new data now suggest that for a subset of patients with consistently deep molecular response (at least a 4.5 log reduction from baseline levels of BCR‐ABL1 transcript), TKI therapy might be discontinued altogether without further recurrence of the disease.

 

“Until now, tests for BCR‐ABL were not standardised and could not be reliably compared in one lab, and certainly not across borders, making patient management quite challenging,” said David Persing, M.D., Ph.D., Cepheid’s Chief Medical and Technology Officer. “Because Xpert BCR‐ABL Ultra is aligned to the International Scale on a lot‐to‐lot basis, accuracy and comparability of results is assured no matter where in the world the test is performed. In addition, the added sensitivity provides physicians with the information they need to confidently optimise individual treatment strategies for their patients with CML, including identifying patients who might be considered for a trial of therapy discontinuation.”

 

“The launch of Xpert BCR‐ABL Ultra will further support the mission of The Max Foundation, enabling haematologists to optimise clinical outcomes, and patients to maximise their potential,” added Pat Garcia‐Gonzalez, MS, Chief Executive Officer of The Max Foundation. “The sensitivity, reliability, and benefits of a point of care molecular diagnostic instrument such as the GeneXpert® System cannot be overstated. It has already allowed us to bring molecular diagnostics to regions of the world where none existed before, giving patients a chance of a future for the first time.”

 

“The Xpert BCR‐ABL Ultra assay solves many of the existing challenges in monitoring molecular response in patients with Chronic Myeloid Leukaemia with accuracy, precise international standard calibration, and speed,” added Michael J. Mauro, M.D., head of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center1. “By aligning to the International Scale on a lot‐to‐lot basis, Xpert BCR‐ABL

 

Ultra addresses ongoing concerns about the effect of variability in testing methodologies on the accurate assessment of treatment responses.”

 

Xpert BCR‐ABL Ultra runs on the Cepheid GeneXpert System, the world's leading molecular diagnostic platform with over 9,200 systems deployed globally in both developed and emerging market countries. Xpert BCR‐ABL Ultra delivers results in less than two and a half hours, with minimal hands‐on time, and with the ease of use for which the GeneXpert System is well known.

 

Xpert BCR‐ABL Ultra begins shipping this week as a CE‐IVD Mark product. For more information on Cepheid's GeneXpert Systems or the complete menu of CE‐IVD Xpert tests, visit www.cepheidinternational.com.

 

1Dr. Mauro was part of a multicenter, prospective evaluation of the Xpert BCR-ABL Ultra Assay. Data from this evaluation is included in the clinical data supporting the release of the test outside the US and was recently presented at the 17th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy 2015 (Estoril, Portugal), “Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1 (Abstract #4221).

sonosite-fujifilm

Point-of-care ultrasound can save lives in general practice

author2015-12-03authorposted by Anna ,

The portability and ease of use of the latest generation of point-of-care ultrasound systems mean that they are increasingly being used outside of the traditional hospital setting, with a number of general practitioners now training to use ultrasound for a wide range of applications. Dr Helen Williams, who divides her time between general practice and the Urgent Care Centre at Queen Elizabeth Hospital in Woolwich, explained the benefits: "I first became interested in ultrasound in 1999, when I was working in a TOP (termination of pregnancy) clinic and picked up an ectopic pregnancy during a routine dating scan. That case made me realise that ultrasound has so many potential applications, and so I purchased a small portable machine for use in my general practice. I have since used ultrasound in a variety of settings, both in primary care and in hospitals, and currently have a SonoSite Edge® system which travels everywhere with me."

 

"Although ultrasound use is becoming more widely accepted in primary care, its use is still not widespread, despite the potentially life-saving applications. This is a real shame because, even as a GP, I think that you can genuinely save a life every few years through routinely using ultrasound. For example, a few months ago, I identified a large, potentially fatal liver abscess in a patient complaining of shortness of breath and pain in the right side of his chest. He was taken straight to A&E, had it drained the same day, and was virtually back to normal within a month. It really can make that much of a difference.”

quotient

Quotient Clinical acquired by specialist healthcare investor GHO Capital

author2015-12-02authorposted by Sophie,

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has been acquired by specialist healthcare investor GHO Capital, with financial details of the transaction remaining undisclosed.

 

Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics® platform, which integrates formulation development, real-time GMP manufacturing and clinical testing. This approach has been proven to accelerate timelines and reduce associated costs, driving overall improvements in R&D productivity. With over 280 employees, the company serves an international customer base – including top tier pharmaceutical and biotech organisations – from its UK headquarters, with over 75% of its customers in the USA or mainland Europe.

 

Mark Egerton, Chief Executive Officer of Quotient Clinical, commented: “We are delighted to be partnering with GHO Capital for the next phase of our growth. In the past few years, we have proven the benefits of Translational Pharmaceutics, and its adoption by an ever increasing number of customers continues to drive our business growth. Partnering with GHO Capital, we will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”

 

Mike Mortimer, Executive Partner and Founder at GHO Capital, added: “Outsourced services and contract development and manufacturing is a space that GHO Capital knows extremely well. Quotient Clinical has a highly attractive business model which can be scaled and expanded – particularly across Europe and the USA – making this an excellent investment opportunity for our fund. We look forward to working with the management team to further support the company’s international expansion.”

 

Alan Payne, Partner of Bridgepoint Development Capital, exiting shareholder from Quotient Clinical, said: “Our investment in Quotient was a significant opportunity for the management team to help it grow the company’s capability, grow its market share, as well as refine its international strategy and business model. It has done all of these and more, increasing its market penetration – especially in the large pharma sector – and creating an attractive, high growth platform.”

tecan

Tecan helps Repsol to drive the fuels of the future

author2015-12-01authorposted by Anna ,

The Madrid Technology Center of global energy company Repsol relies on two Freedom EVO® platforms for colony picking and enzymatic assays for research into fossil fuel alternatives, using Tecan’s 350 µl nested LiHa disposable tips to achieve extended walkaway times. Jose Miguel Seoane, a researcher in the biotechnology department, explained: “The investigation of new biological applications involves screening large numbers of mutants of different micro-organisms, enabling the best performing candidates to be selected for further studies. As we test thousands of different mutations, automated high throughput screening is the key to our success.”

“We generate up to 10,000 colonies per week, and long periods of walkaway automation are absolutely essential, making nested tips indispensable; it makes no sense to invest in automation if you need to manually place tips on the workdeck every 20 minutes or so. The release of 350 µl nested LiHa disposable tips, with a novel design incorporating a frame between each tray, was an important development. The trays fit perfectly and the stack remains in perfect alignment, eliminating tip pick-up failures. This makes the workflow more robust and efficient, as well as providing the long walkaway times that we need. Tecan’s field engineers know the systems well and are very responsive, which we really appreciate as a project can be set back weeks, or even months, if the support is not there. It is a pleasure to work with the company.”

dolomite

Dolomite celebrates 10 years of microfluidic innovation

author2015-12-01authorposted by Sophie Woodward,

Dolomite, part of the Blacktrace group of companies, is celebrating a decade of excellence in the design and manufacture of novel, high quality microfluidic products, including individual components such as pumps, chips, connectors, temperature controllers and sensors, software solutions and complete microfluidic systems. The company, based in Royston, UK, was the world’s first microfluidic application centre, and has gone from strength to strength since its formation in 2005, opening offices in the USA, Japan, India and Brazil, and establishing a global distributor network. Today, it serves many thousands of customers in over 50 countries around the world, working in fields as diverse as academia, biotechnology, drug discovery, food and cosmetics, manufacturing, and the petrochemical and pharmaceutical industries.

 

Dolomite’s expertise in Productizing Science® – creating marketable, commercially successful products from scientific discoveries – has enabled the development of many innovative products, including the first microfluidic connector, novel microdroplet systems and the recently showcased Fluidic Factory 3D Printer. Designed to suit a wide range of budgets and functionalities, the company’s modular microfluidic systems offer the flexibility to quickly and easily vary the configuration to accommodate changing day-to-day needs or to upgrade, for example to include automation. System set-up and operation is fast and straightforward, allowing rapid research, optimisation and scale-up of microfluidic processes. For customers requiring a custom-built microfluidic solution, Dolomite also offers a bespoke design service, producing components, modules and systems tailored to specific individual needs.

 

For more information, visit www.dolomite-microfluidics.com.

 

About Dolomite

 

Established in 2005, Dolomite Microfluidics has grown to be the world leader in the design and manufacture of high quality innovative microfluidic products.

The company offers a broad range of modular microfluidic systems, modules and components – including pumps, chips, connectors, temperature controllers, sensors, accessories and custom-made components – as well as software for analysis or automation.

 Modularity, ease of use, innovation and scalability are common to all Dolomite products, which are used across a broad range of applications in biology, drug discovery, chemistry, food, cosmetics and academia.

 Dolomite is a part of the Blacktrace group of companies, a world leader in Productizing Science®, and has offices in the USA, Japan, India and Brazil, as well as a worldwide network of distributors.

 

dataracks

Dataracks launches Micro Data Centre

author2015-11-27authorposted by Anna ,

Dataracks – the pioneer of cold aisle containment – is set to revolutionise the data centre industry again, this time with the launch of the Micro Data Centre (MDC). This innovative solution is designed to offer all the cooling, security and power supply options required for 19” racks in a compact, convenient and cost-effective package.

 

A new concept for the data centre industry, the self-contained MDC provides flexible, readily scalable capacity that can be installed virtually anywhere with a power supply and access for cooling pipework or ventilation. It uses high efficiency cooling technologies to deliver exceptional efficiency and complete environmental independence, lowering the cost of ownership and allowing rack densities to be increased as needs change.

 

Ideal for any business where space or access is limited – such as office blocks, hospitals, GP surgeries, retail, industrial automation and academia – the MDC eliminates the need for bespoke data centre designs, offering a complete solution that simply requires the addition of servers. Jeremy Hartley, Managing Director of Dataracks, commented: “As a company with a strong history of innovation in server cabinet and rack technology, we are proud to be leading the way in data centre miniaturisation. Regardless of their size, most organisations are looking for the same features in a data centre – flexibility, security and cost effectiveness – and the MDC offers all the features and benefits of a complete data centre without the cost and complexity of bespoke installations.” 

mettler-toledo

Rainin TerraRack™ ideal for PCR core facilities

author2015-11-26authorposted by Anna ,

METTLER TOLEDO's recently launched Rainin TerraRack™ pipette tip racks are already proving popular in the Real-time PCR Research and Diagnostics Core Facility at the University of California, Davis. The laboratory, part of the School of Veterinary Medicine, performs molecular diagnostic assays for veterinary practices across the US – as well as nucleic acid extraction and qPCR for external research studies – relying on high quality Rainin pipettes and BioClean™ tips to ensure accurate pipetting and sample security. Lab Manager Samantha Mapes explained: "We have been using Rainin Pipet-Lite™ single- and multi-channel pipettes for around 12 years, and have always been very happy with both the accuracy and ergonomics."

 

"As a Core Facility, we go through very large numbers of tips, and recycling is a very important issue for businesses here in California. METTLER TOLEDO suggested we try the Rainin TerraRack tip racks to reduce the faculty's waste disposal, and they've been ideal for us. They are much lighter and easier to recycle than traditional tip racks and, despite not looking as sturdy, they have stood up to day-to-day activities very well. We haven't managed to crack or collapse a single rack yet, even though we don't use the TerraBase™ holders most of the time. Each box of tips arrives pre-sterilized, and the lid design prevents contamination, even if the tips remain in storage for several months, which is obviously an important consideration in a PCR lab. Overall we've been very impressed, and one of our part-time technicians has already begun switching another lab she works in to TerraRack tip boxes." 

mettler-toledo

Rainin TerraRack™ ideal for PCR core facilities

author2015-11-26authorposted by Anna ,

Rainin's recently launched TerraRack™ pipette tip racks, available in the UK from Anachem, are already proving popular in the Real-time PCR Research and Diagnostics Core Facility at the University of California, Davis. The laboratory, part of the School of Veterinary Medicine, performs molecular diagnostic assays for veterinary practices across the US – as well as nucleic acid extraction and qPCR for external research studies – relying on high quality Rainin pipettes and BioClean™ tips to ensure accurate pipetting and sample security. Lab Manager Samantha Mapes explained: "We have been using Rainin Pipet-Lite™ single- and multi-channel pipettes for around 12 years, and have always been very happy with both the accuracy and ergonomics."

 

"As a Core Facility, we go through very large numbers of tips, and recycling is a very important issue for businesses here in California. Rainin suggested we try the TerraRack tip racks to reduce the faculty's waste disposal, and they've been ideal for us. They are much lighter and easier to recycle than traditional tip racks and, despite not looking as sturdy, they have stood up to day-to-day activities very well. We haven't managed to crack or collapse a single rack yet, even though we don't use the TerraBase™ holders most of the time. Each box of tips arrives pre-sterilized, and the lid design prevents contamination, even if the tips remain in storage for several months, which is obviously an important consideration in a PCR lab. Overall we've been very impressed, and one of our part-time technicians has already begun switching another lab she works in to TerraRack tip boxes." 

glass-solutions

Glass Solutions celebrates a decade of excellence

author2015-11-25authorposted by Sophie Woodward,

Glass Solutions, a world leader in the manufacture of high quality, precision glassware, is the supplier of choice for numerous design agencies, architects and production companies requiring custom-designed, decorative pieces of glassware. Using a range of precision processes and glass handling techniques, the company has established a reputation for excellence over the past decade. Its exceptional craftsmen create unique, specially commissioned pieces of glassware, from hand-crafted awards and display cabinets to staircase balusters and spindles, sculptural glass and lighting. Whatever the location – restaurant, hotel, commercial organisation, museum or even a film set – Glass Solutions has the creative skills and production flexibility to produce decorative glassware to suit the most exclusive establishments.

 

Based in a modern, purpose-built facility, Glass Solutions’ environmentally-friendly manufacturing base allows maximum glassware production – using only the best quality materials from SCHOTT – while minimising the company’s carbon footprint. However unusual or complex the task – single, one-off bespoke pieces, large-scale glassware or multi-thousand part production – Glass Solutions is perfectly positioned to take up the challenge, delivering innovative solutions on time, at a competitive price.

 

For more information, visit http://www.glass-solutions.com

bulgin

Bulgin launches compact Buccaneer® 4000 connectors

author2015-11-25authorposted by Sophie Woodward,

Bulgin – an Elektron Technology brand – has expanded its ever-popular Buccaneer® range of environmentally-sealed power and data connectors with the introduction of the new Buccaneer 4000 Series. Building on the success of the Buccaneer 6000 and 7000 Series of quick locking connectors, this latest offering provides the same twist lock coupling and ‘fit and forget’ connectivity in a more compact format, making it easier for product engineers to integrate into their system designs.

 

The Buccaneer 4000 Series has been developed to provide excellent sealing characteristics to IP67, IP68 and IP69K standards – ensuring true environmental protection in harsh conditions – as well as to withstand vibrations, shocks and corrosion to EN/IEC 60068 requirements. Each unit has a UV-resistant, UL94-V0 flammability-rated plastic body equipped with a simple and efficient twist locking mechanism, allowing a secure connection without the need for specialist tools. Currently available in 3-, 8- and 12-pole configurations rated to 13A, 600V – plus a micro-B USB data connector – it offers a choice of solder and crimp contacts, and can accommodate cables from 3 to 7 mm in diameter. Together with a choice of in-line or panel mounting options, this makes the Buccaneer 4000 Series ideally suited to a wide range of marine, industrial, transport and infrastructure applications, especially where space is at a premium.

cepheid

Cepheid’s Xpert® CT/NG ideal for confirmatory testing at Antrim Area Hospital

author2015-11-24authorposted by Sophie Woodward,

Antrim Area Hospital in Northern Ireland relies on molecular diagnostic testing with Cepheid’s Xpert® CT/NG for confirmation of Neisseria gonorrhoeae diagnoses. Karen Savage, Lead BMS, Microbiology, explained: “Under BASHH guidelines, we are required to confirm all N. gonorrhoeae cases in regions of low prevalence using an alternative technique to the primary screen. Initially, we batch test samples on an automated platform, and then perform confirmatory analysis using the Xpert CT/NG test on the random access GeneXpert® instrument.”

 

“We have been using the GeneXpert for STD confirmation for about two years, and really like its simplicity, versatility and rapid turnaround times. The GeneXpert is very straightforward to use – it has been designed with microbiologists, rather than molecular biologists, in mind – and there is virtually no sample preparation needed. It offers the random access needed for STAT tests, and has the flexibility to accommodate different tests at the same time. For example, we can run tests for CT/NG, C. difficile and MRSA simultaneously. Prior to the launch of the Xpert CT/NG test, we sent confirmatory samples to an external laboratory for confirmation and, although this is an excellent service, there is a turnaround time of several days because of the need for sample transfer between sites. Now, with the Xpert CT/NG test, we provide same day in-house confirmation. I don’t think anything else compares with the GeneXpert.”

tecan

Tecan adds the personal touch to wine microbiology

author2015-11-18authorposted by Anna,

The Wine Microbiology and Microbial Biotechnology Laboratory at the University of Adelaide has developed a customized solution offering fully automated sampling for yeast fermentations. Based on a Freedom EVO® 200 platform, this system frees researchers from the need to manually aliquot samples day and night for up to three weeks. Dr Tommaso Liccioli Watson, a postdoctoral research fellow in the laboratory, explained: “We use approaches such as directed evolution and mutagenesis to develop novel yeast and bacterial strains to improve the winemaking process. However, these methods are often very time consuming, requiring large-scale screening of hundreds or even thousands of candidate strains, often from heterogeneous populations. Monitoring the fermentation process for large numbers of samples is very laborious, requiring sampling of fermentation vessels every six hours or so over the course of several days to several weeks.”

 

“Automation was the solution, and Tecan’s Freedom EVO really stood out. We were able to integrate our own custom hardware solutions onto the platform with relative ease, building a walkaway fermentation monitoring solution to generate 96-well microplates ready for loading onto our various analytical instruments. It only takes half a day to set up a 96-fermentation experiment, which can be remotely monitored via a smart phone from another lab, from home or – because this is Australia – from the beach. Compared to having to be in the lab every few hours, day and night, this is fantastic.”

cepheid

CEPHEID SUPPORTS INAUGURAL ANTIBIOTIC AWARENESS WEEK

author2015-11-17authorposted by Sophie Woodward,

Cepheid has announced its support of World Antibiotic Awareness Week, a global campaign led by the World Health Organization (WHO) to raise awareness of the growing challenge posed by global antibiotic resistance.  As the world's most prevalent molecular diagnostic platform, Cepheid’s GeneXpert® System is already supporting global efforts to diagnose infections quickly and accurately, enabling physicians to make appropriate clinical treatment decisions that preserve patient safety and limit improper antibiotic use.  To date, more than 9,200 GeneXpert Systems have been deployed globally in both developed and emerging market countries.

 

At the sixty-eighth World Health Assembly in May 2015, escalating antimicrobial resistance (AMR) was identified as a global problem by the WHO, which endorsed a global action plan to address this challenge. Concurrently, the CDC identified antibiotic stewardship—the proper administration of the correct antibiotics only when needed—as the most important action in fighting antibiotic resistance.[1]  Antibiotic Awareness Week is expected to become an annual reminder of the importance of antibiotic stewardship programs.

 

According to leading antimicrobial resistance expert Professor Antoine Andremont of the Bichat-Claude Bernard Hopital in Paris, “rapid, easy-to-perform diagnostics have the potential to provide the critical information needed to tailor the right therapy for every patient, limiting unnecessary antibiotic use, deterring the emergence of more drug-resistant pathogens, and preserving the effectiveness of those drugs in the future.“  Cepheid currently offers 23 fast diagnostics tests in its Xpert portfolio globally, targeting MRSA, C. difficile, Mycobacterium tuberculosis, and a variety of other pathogens, making the GeneXpert System an invaluable tool for improving antibiotic stewardship and patient outcomes.

 

“Antibiotic stewardship has been of longstanding interest here at Cepheid, and we continue to develop Xpert tests and broader platform capabilities to support these critical antimicrobial resistance initiatives,” said David Persing, M.D., Ph.D, Cepheid’s Chief Medical and Technology Officer.  “For example, Cepheid is developing the capability to securely aggregate drug resistance results in real-time using innovative data management software.  The analytical capacity of this new software, which successfully collected data from nearly 2.5 million TB cases from 3 countries in initial pilot programs, has the potential to play a critical role in informing antimicrobial public policymaking for WHO member countries and health partners.”

 

For more information on Cepheid's entire menu of Xpert tests, visit www.cepheid.com.

 

[1] http://www.cdc.gov/drugresistance/cdc_role.html

sonosite-fujifilm

FUJIFILM SonoSite launches iViz highly portable ultrasound system at MEDICA

author2015-11-12authorposted by Anna,

MEDICA 2015 – from the 16th to the 19th of November – will give the clinical community the opportunity to explore the latest developments in medicine and healthcare, and visitors to hall 10 booth number 10D58 will be able to see FUJIFILM SonoSite’s complete range of point-of-care ultrasound systems, including the new iViz utrasound system. This highly portable system is designed for use in virtually any environment, combining the imaging capabilities of much larger and heavier systems into a one-hand fit and control, thumb operated UI with advanced connectivity and mobile computing, allowing physicians to take the clinic to the patient.  

 

The FUJIFILM SonoSite team – including Brian Leck, Vice President of Global Direct Sales – will be joined by Dr Wolf Armbruster, a specialist in regional anaesthesia, who will be demonstrating scanning techniques and ultrasound applications. Dr Armbruster, Head of the Anaesthesia Department at the Evangelisches Krankenhaus in Unna, said: “I routinely work with a SonoSite ultrasound system every day, and can make good, extremely fast and informed decisions based on the images I see. I enjoy sharing my enthusiasm for ultrasound, promoting it as a useful and accessible technique, and regularly conduct ultrasound training courses, as well as performing live scanning demonstrations at congresses.”

 

MEDICA 2015 will also give Torsten Walther, newly appointed Country Manager for Germany, the opportunity to meet many of FUJIFILM SonoSite’s loyal customers for the first time. Torsten brings a wealth of experience in the ultrasound market to this new role, and commented: “I am excited to be joining such a forward-thinking, customer-focused company as FUJIFILM SonoSite, and look forward to working with colleagues and customers to continue the rapid development of point-of-care ultrasound applications across the German healthcare sector.”

sonosite-fujifilm

Nepal earthquake victims benefit from ultrasound-guided regional anaesthesia

author2015-11-11authorposted by Anna ,

Point-of-care ultrasound technology proved vital to the Nepal disaster relief effort, as consultant anaesthetist Andreas Brodbeck from the James Paget University Hospital (JPUH) in Gorleston-on-Sea, East Anglia, explained: “In the wake of the disaster, Nepalese doctors faced an overwhelming workload, and so a team of consultants from JPUH offered their services to Kirtipur Hospital in Kathmandu. Knowing that regional anaesthesia would be beneficial to the hospital and its patients, I took a SonoSite point-of-care ultrasound system with me, along with some local anaesthetics and needles.”

 

“Point-of-care ultrasound proved invaluable. The instrument’s robustness, small size and light weight made it easy to transport, and I used it from the first day to the last, administering regional anaesthesia to a patient in the recovery room while another was undergoing surgery. The Nepalese anaesthetists were fascinated and quickly learnt the technique. It’s a wonderful way to give an anaesthetic; patients are pain free, experience fewer side effects and recover faster. You can perform reliable blocks one after the other, eliminating the need for a general anaesthetic. The onset of anaesthesia is also much faster, you quickly find out whether or not it has worked. This quality is something that you can only get using ultrasound guidance.”

dolomite

Dolomite creates unique microfluidics chip for creation of single cell libraries

author2015-11-04authorposted by Sophie Woodward,

Dolomite, a world leader in microfluidics innovation, has launched the Single Cell RNA-Seq Chip for simple, reliable creation of single cell libraries. This new chip allows researchers to use droplet-based microfluidic methods to help explore the behaviour of thousands of individual cells, providing a rapid and easy way to screen for new or cryptic cell types.

 

The Single Cell RNA-Seq Chip – a commercially available version of the prototype PDMS Drop­seq chip described by Macosko et al1 – is manufactured from glass, offering excellent optical transparency and ensuring high precision. Combined with a very gentle sample loop method – to minimise bead shearing and contamination due to premature cell lysis – it enables rapid, straightforward preparation of single cell cDNA libraries. The chip offers robust and reproducible processing of 1 ml samples in approximately 12 hours, allowing cells to be individually encapsulated with uniquely barcoded RNA capture beads for high throughput sequencing.

 

To find out more, please visit http://www.dolomite-microfluidics.com/webshop/microfluidic-chips-droplet-chips-single-cell-rna-seq-chip-c-17_19_126/single-cell-rnaseq-chip-1-100-microetch-depth-fluorophilic-p-419

 

  1. Macosko, Evan Z. et al (2015). Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell, 161(5): 1202-1214.

 

 

About Dolomite

 Established in 2005, Dolomite Microfluidics has grown to be the world leader in the design and manufacture of high quality innovative microfluidic products.

 The company offers a broad range of modular microfluidic systems, modules and components – including pumps, chips, connectors, temperature controllers, sensors, accessories and custom-made components – as well as software for analysis or automation.

 Modularity, ease of use, innovation and scalability are common to all Dolomite products, which are used across a broad range of applications in biology, drug discovery, chemistry, food, cosmetics and academia.

 Dolomite is a part of the Blacktrace group of companies, a world leader in Productizing Science®, and has offices in the USA, Japan, India and Brazil, as well as a worldwide network of distributors.

ingenza

Ingenza and Imperial researchers work together to improve nasogastric feeding tube placement

author2015-11-03authorposted by Sophie Woodward,

Ingenza has teamed up with clinical scientists at Imperial College London to trial an improved diagnostic assay for confirming nasogastric (NG) tube placement. Professor George Hanna, Director of the National Institute for Health Research Diagnostic Evidence Co-operative London at Imperial College Healthcare NHS Trust, which specialises in In Vitro Diagnostics, explained: “Correct placement of NG tubes is vital, as accidental insertion of the tube into the lung instead of the gut can have serious consequences. The current method for determining correct placement – pH testing of a stomach aspirate, with X-ray confirmation if the results are ambiguous – is prone to misinterpretation, and so we were approached by the Department of Health to look at how this could be avoided. We identified the Ingenza solution as an easy-to-implement and low cost option, providing a highly specific and sensitive test with the potential to reduce the number of expensive chest X-rays.”

 

Ingenza’s simple diagnostic assay is based on detecting the activity of human gastric lipase (HGL), a stomach-specific biomarker. By impregnating a modified pH paper with a chemical ester substrate, this test has the potential to be more accurate than currently available alternatives. Prof Hanna continued: “The real strength of this approach is that it does not change the current pathway; it simply replaces one test strip with another. We performed a small pilot study on 38 consecutive patients requiring an NG tube, and the Ingenza assay accurately confirmed placement in every case. We are now developing the test further – with funding from Innovate UK – to provide a simple ‘yes/no’ result, and will conduct a larger study to look at human factors and the cost-effectiveness of the test on a larger scale.”

 

For more information, visit www.ingenza.com or email sarah.scott@ingenza.com

 

 

About Ingenza

Ingenza is a worldwide leader in the application of industrial biotechnology and synthetic biology, providing efficient scalable bioprocesses to manufacture chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources. Its scientific and commercial activities are led by a management team with over 25 years’ experience in applied bioscience and the development and commercialisation of bio-based products. In addition to engaging in strategic partnerships to tailor its bioprocess services for clients, the company also licenses its proprietary bioprocess technologies.

 

About NIHR

The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).

sonosite-fujifilm

SonoSite’s X-Porte® helps provide continuity of care

author2015-10-28authorposted by Anna ,

The intensive care unit at the Royal Surrey County Hospital in Guildford has recently invested in a SonoSite X-Porte® point-of-care ultrasound system, complementing its existing SonoSite Edge® instrument. Consultant intensivist and anaesthetist Dr Justin Kirk-Bayley explained: “As a major cancer centre, we treat some very difficult and complicated cases, typically using ultrasound to guide line placement and the insertion of chest drains. Since the establishment of FICE – Focused Intensive Care Echocardiography – the use of echocardiography has grown, and there is also interest in performing lung ultrasonography. We invested in the X­Porte to help us perform these more advanced examinations. With X-Porte systems also in use in the radiology and A&E departments, this ensures continuity for the critical care outreach team and radiologists when attending seriously ill patients who are unable to be moved.”

 

“The X-Porte has proved very popular, enthusing my colleagues and becoming the ‘go-to’ instrument. It offers an image quality previously seen only in the hands of an echocardiographer or a radiologist, and is simply a generation ahead. The user interface is intuitive, the large screen is fantastic, and the system is very mobile. Another important feature is that the platform is heavily software-based, and therefore dynamic. This effectively future-proofs the instrument, allowing it to evolve with us, as any subsequent enhancements are not limited by hardware constraints. And when you factor in the level of warranty and quality of service, it just leaves everything else standing.”

dolomite

Dolomite to preview 3D fluidics printer at MicroTAS 2015

author2015-10-23authorposted by Sophie Woodward,

Dolomite, a world leader in microfluidics innovation, will be previewing its innovative Fluidic Factory at MicroTAS 2015 in Gyeongju, Korea, on the 25th of October. The first commercially available 3D printer for fluidically-sealed devices, it offers rapid, straightforward and reliable printing from as little as $1 per chip. Using FDA-approved, robust cyclic olefin copolymer (COC), this makes it easy and affordable to 3D print devices for almost any application.

 

The Fluidic Factory is an intelligent 3D desktop printer that enables the production of truly unique microfluidic devices, such as three-dimensional mixers and non-rectangular chips. By offering reliable sealing of fluidic paths, it allows users to reliably create bespoke channel geometries and various features not possible using etching, embossing, moulding or machining techniques. The print head, print bed and software are designed to be upgradeable, ensuring future functionality for printing different polymers, ultra-high definition printing, micro-milling, fluid dispensing or bioprinting. Users can choose from the wide selection of designs in the Fluidics Factory’s Drawings Library – including microfluidic chips, manifolds and connectors – or create and print their own custom devices using virtually any CAD software files, giving complete design flexibility.

 

To find out more, please visit http://www.dolomite-microfluidics.com/webshop/fluidic_factory 

sonosite-fujifilm

Trice Imaging, Inc. and FUJIFILM SonoSite Announce iViz Portable Ultrasound Device Integration at Health 2.0

author2015-10-23authorposted by Anna ,

The cloud-based mobile technology is embedded in all iViz devices, leading the healthcare industry into a new connected age

 

San Francisco, Calif., (October 5, 2015) —Trice Imaging, a leading provider in the medical image management industry, announced today at Health 2.0 the integration of Tricefy into FUJIFILM SonoSite’s latest portable ultrasound device. The iViz, which was recently CE marked for sale in Europe and currently pending FDA 510(k) clearance, is the latest point-of-care visualization solution by FUJIFILM SonoSite and includes Trice sharing, collaboration and routing software embedded in the device. Both Trice Imaging Inc. and FUJIFILM SonoSite will together demonstrate the technology during a session, covering care delivery platforms for provider media, at the conference on Tuesday, October 6th.

 

Trice Imaging is a web-based medical image sharing, collaboration and routing platform that sends medical image information directly from imaging devices. Trice is changing the way medical images are being shared and stored by medical professionals and patients. The solution gives physicians the ability to share images with their patients and colleagues for fast and cost-effective referrals and consultations. Doctors can now use iViz embedded with Trice technology to streamline patient experience and improve communication with referring physicians, in and out of the hospital.

 

As part of an existing relationship, Trice Imaging Inc. and FUJIFILM SonoSite most recently worked together on a project in Morocco that was awarded with the 2015 GSMA Global Mobile Award. Funded by Qualcomm, the project used portable ultrasound units and 3G connectivity to improve care for women in developing countries through early detection and treatment of major causes in maternal mortality; proving the power of connected mobile ultrasound. 575 exams were wirelessly transmitted to clinicians, resulting in lowered costs per patient and a decrease in time from 2 weeks to less than 24 hours per diagnosis.

 

“We are honored to be working with FUJIFILM SonoSite,” says Trice Imaging Inc. CEO and co-founder Asa Nordgren. “As global pioneers in the portable ultrasound industry, they are at the forefront of the changes in the medical imaging market. Imaging devices are getting smaller, smarter and connected, making it possible to provide ultrasound outside the hospital environment. Equipped with Tricefy, iViz enables instantaneous sharing and collaboration between nurses, doctors, home-care providers and paramedics, so that diagnoses can be made remotely, saving precious time and resources. Imaging devices with embedded communication modules are the future of ultrasound technology, soon to be as common as having Wi-Fi and email embedded in your computer!”

 

FUJIFILM SonoSite iViz is a highly portable ultrasound machine, augmented with mobile computing and advance connectivity. Providers can make an ultrasound exam or procedure while simultaneously accessing patient records, storing exams, submitting reports and consulting with remote providers for near real-time diagnoses. Each device is embedded with Trice subscription plan and its patented encryption and authentication software, making it possible to share images on the run, wherever you are.

 

“We’re looking forward to seeing the impact iViz holds for the future of point-of-care by empowering providers to practice visual medicine when and where needed,” says FUJIFILM SonoSite president and CEO Masayuki Higuchi. “Both clinician and patient are at the center of our solution thinking.  By integrating Tricefy into the SonoSite iViz ultrasound workflow we are able to provide a much simplified experience for patient and care provider with immediate medical image sharing and clinical collaboration.”

 

Both Trice Imaging, Inc. and FUJIFILM SonoSite will be attending the Health 2.0 conference in Santa Clara, California on October 4-7, 2015. The conference promotes, showcases and catalyzes new technologies in health care through a worldwide serious of conferences, code-a-thons and more. The conference this year features Chelsea Clinton, Bob Wachter, the CEO of the American Medical Association and more.

 

syrris

Profiling polymerization reactions with the ChemiSens Calorimeter

author2015-10-15authorposted by Sophie Woodward,

A ChemiSens Calorimeter is helping researchers at Germany’s Max Planck Institute of Colloids and Interfaces to quantitatively evaluate polymerization reaction profiles and accurately determine end points. Klaus Tauer, Leader of the Department of Colloid Chemistry’s Heterophase Polymerization – Polymer Dispersions Group, explained: “We do a lot of fundamental research, studying the heterophase polymerization processes used to produce latexes. We rely on a ChemiSens Calorimeter for this work, using it almost daily for three main purposes; heterophase polymerizations, to follow reaction kinetics, and as a tool for polymer synthesis. Particle nucleation is a crucial step in heterophase polymerization, and we can detect its onset using the instrument. It is also a useful tool for measuring the heat of polymerization, as well as the reaction rate and overall profile, which is very important in reaction kinetics.”

 

“We chose the ChemiSens Calorimeter for its sensitivity and flexibility. It gives us very reliable, reproducible data, and is easy to use – which is essential when you are teaching students about calorimetry. Once a piece of equipment has been installed in the laboratory and staff have become familiar with its operation, you will keep it for as long as it continues to fulfil your needs. This is definitely the case with the ChemiSens Calorimeter. We have had the system for over 20 years now, and are extremely happy with it.”

quotient

Quotient Clinical showcases Translational Pharmaceutics and RapidFACT at AAPS 2015

author2015-10-13authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® company, will be highlighting the benefits of its unique, integrated approach to formulation development, real-time adaptive manufacturing and clinical testing on booth 1662 at this year’s American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. Held in Orlando, Florida, from the 25th to the 29th of October, this meeting provides attendees with an opportunity to see some of the latest developments in the pharmaceutical sector. Quotient Clinical will be presenting six posters describing projects which have benefited from the reduced costs and shorter development timelines offered by the company’s pioneering Translational Pharmaceutics.

 

Quotient will also host the 4th Annual RapidFACT User Group Meeting in Orlando on the 27th of October. Delegates at this event will have the chance to learn more about how this innovative approach is helping pharmaceutical development teams to accelerate drug production optimization. RapidFACT has already been used in hundreds of early development and life cycle management programs, and a number of customers – including Upsher-Smith Laboratories and Stealth BioTherapeutics – will present case studies illustrating how it has enhanced their development projects. This will be followed by a discussion on emerging applications and a complimentary lunch, providing an informal opportunity to network with leading industry figures.

 

To register for the RapidFACT User Group Meeting, visit booth 1662 or go to www.quotientclinical.com/usergroup2015.

 

For further information, please contact:

Robin Bodicoat

Marketing Director

Quotient Clinical

Tel: +44 (0)115 931 5102

robin.bodicoat@quotientclinical.com

quotient

Quotient Clinical CEO Mark Egerton a winner at UK EY Entrepreneur of the Year 2015 awards

author2015-10-07authorposted by Sophie Woodward,

Quotient Clinical has announced that CEO Mark Egerton has received an EY Entrepreneur of the Year® 2015 UK Award. Chosen by a panel of independent judges, the award acknowledges outstanding entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance and personal commitment to their businesses and communities. Dr Egerton was one of 13 business leaders recognised for their achievements, and received his award at a special dinner held at The Brewery, London on the 5th of October.

 

Dr Egerton commented: “I am delighted to receive this honour in recognition of the high level of success that Quotient Clinical has achieved in recent years. The award acknowledges all of the hard work and dedication from everyone within the company. Thanks to an incredible team, we have repeatedly demonstrated that Translational Pharmaceutics® can deliver significant time and cost savings for our customers, helping them to increase their overall R&D productivity.”

dolomite

Dolomite and Lab on a Chip launch Video Competition to win $2,500 of microfluidic equipment

author2015-10-06authorposted by Sophie Woodward,

Microfluidics specialist Dolomite has teamed up with Lab on a Chip and the Chemical and Biological Microsystems Society to create the first ever MicroTAS Video Competition. Now in its 19th year, MicroTAS (the International Conference on Miniaturized Systems for Chemistry and Life Sciences) runs from the 25th to 29th of October at the Hwabaek International Convention Center in Gyeongju, Republic of Korea. This exciting competition will give anyone registered for the event the opportunity to win Dolomite microfluidics equipment worth $2,500 by creating a scientific or educational short film on micro- or nanofluidics.

 

Videos can be fun, artistic, surprising or just unusual, and need to be uploaded to the MicroTAS website (www.microtas2015.org) by the 9th of October to be eligible. Assessment by an international panel of judges will take place at MicroTAS 2015, with the winner receiving a voucher for $2,500 worth of equipment from microfluidics innovator Dolomite.

 

For more information, or to upload your video, go to http://blogs.rsc.org/lc/2015/07/29/2015-microtas-video-competition/.

cepheid

Cepheid Xpert® rapid tests – your complete Winter Care Bundle

author2015-10-05authorposted by Sophie Woodward,

Cepheid’s updated Winter Care Bundle of Xpert® molecular diagnostic tests is an essential tool kit in the battle against virulent infections. Consisting of the Xpert Norovirus, Xpert C. difficile, Xpert Carba-R and Xpert Flu/RSV XC rapid tests for the GeneXpert® System, it offers on-demand RT­PCR testing to help avoid preventable ward closures and avert a winter care crisis.

 

Molecular diagnostic testing with Cepheid’s GeneXpert System provides rapid, accurate diagnoses, minimising the impact on hospital resources by enabling immediate implementation of infection control procedures and initiation of appropriate treatment. Offering results in just 45 to 90 minutes, the Winter Care Bundle can help to prevent the spread of disease and improve patient management, as well as antibiotic and antiviral stewardships, reducing the potential burden of viral outbreaks. Xpert C. difficile is the only rapid test to identify toxin B, binary toxin and tcdC deletion, while Xpert Norovirus can efficiently detect and differentiate between norovirus GI and GII. Xpert Carba-R is designed to identify the most prevalent carbapenemase gene families (KPC, NDM, VIM, IMP-1, OXA-48, OXA-181 and OXA-232), and Xpert Flu/RSV XC – a multiplexed test for fast and accurate differentiation of Flu A, Flu B and respiratory syncytial virus – completes the Winter Care Bundle.

 

For more information, visit www.cepheidinternational.com

ingenza

Ingenza’s proprietary technology produces novel antimicrobial peptide

author2015-09-30authorposted by Sophie Woodward,

Ingenza is collaborating with researchers at Plymouth University to develop an efficient, scalable microbial production system for epidermicin, an exciting new antibiotic that rapidly kills methicillin-resistant Staphylococcus aureus (MRSA) and other harmful bacteria. Mathew Upton, Associate Professor in Medical Microbiology at Plymouth University, explained: “Epidermicin is a stable, 51 amino acid peptide originally found in Staphylococcus epidermidis, which is effective against gram-positive bacteria such as staphylococci, streptococci and enterococci. It is more potent than existing antibiotics, is non-toxic and represents a new tool in the arsenal of antibiotic medications. However, epidermicin is produced in very low amounts in its native biological host and synthetic chemical production of such peptides is prohibitively expensive, which was a big stumbling block for its use in clinical situations.”

 

“We spoke to Ingenza about using its cutting-edge inABLE® technology to produce commercially viable amounts of epidermicin in an alternative biological production host system. The company is very dynamic and wanted to engage with us, showing a real interest in the project and developing a longer term relationship with the university. With the support of an award from the InnovateUK Industrial Biotechnology Catalyst scheme, we are now working together to develop an integrated approach to the efficient production of epidermicin driven by synthetic biology. We aim to establish a method that produces from tens to hundreds of milligrams of peptide per litre of culture grown. By the end of the project, we hope to be producing sufficient quantities of peptide to carry out pre-clinical toxicity, formulation and stability type studies, eventually leading to a phase one clinical trial. That would be the ideal situation, and a perfect conclusion to the project.”

 

For more information, visit www.ingenza.com or email sarah.scott@ingenza.com

 

bulgin

Bulgin launches new options for 6000 & 7000 Series Buccaneer®

author2015-09-17authorposted by Sophie Woodward,

Bulgin – an Elektron Technology connectivity brand – has unveiled the latest additions to its rugged Buccaneer range, introducing solder contact options for the popular Buccaneer 6000 and 7000 series of environmentally-sealed connectors. Featuring quick and convenient locking without the need for specialist tools, these connectors provide rapid installation and a robust interface – even where access is restricted.

 

The Buccaneer range is designed to withstand the harshest environments, meeting IP66, IP68 and IP69K standards to ensure secure power and signal connectivity. These latest updates to the range mean that engineers and product design professionals can now choose between crimp terminals for fast, easy installation, and solder contacts for a more long-term solution with minimal voltage drop.

 

To further increase flexibility, these robust connectors are also now rated for use with up to 16 AWG (1.29 mm) wires, this applied to the 8 pole or 10 pole options for Buccaneer 6000 and 7000 series connectors respectively. Together with fully interchangeable metal and plastic body constructions, the Buccaneer 6000/7000 series can be truly tailored to meet the needs of individual applications, simplifying product design and construction.

 

David Luu, Product Marketing Analyst for Bulgin, commented: “The Buccaneer range is designed for use across a broad range of demanding applications, providing compact, cost-effective and, most importantly, easy-to-use solutions that offers complete environmental protection. These latest offerings are testament to our continued investment in this popular product line, and our ability to adapt quickly to meet customer requirements.”

 

 

For more information about Bulgin products, please contact:

Elektron Technology, Woodland Road, Torquay, Devon, TQ2 7AY, UK

Tel: +44 (0)1803 407700

connectivity@elektron-technology.com

www.bulgin.com

radiometer

Radiometer joins the fight against sepsis

author2015-09-09authorposted by Sophie Woodward,

Radiometer, a leading provider of acute care testing solutions, is helping to promote awareness of the importance of early diagnosis of sepsis, a global medical emergency affecting over 20 million people every year. Symptoms are often unclear and unspecific, making diagnosis extremely challenging. As a result, the condition is often overlooked or recognized too late, with devastating consequences; 30 percent or more of patients who develop sepsis die.

 

As World Sepsis Day on September 13 approaches, Radiometer is highlighting the importance of identifying the condition and initiating appropriate antibiotic treatment at the earliest opportunity. Its broad portfolio of acute care tests provides healthcare professionals with vital tools to monitor key diagnostic and prognostic markers for sepsis, including glucose, bilirubin, lactate, white blood cells, C­reactive protein, creatinine and blood gas. These tests are perfectly complemented by Radiometer’s recently launched procalcitonin (PCT) assay, enabling early and convenient measurement of PCT – the biomarker of choice to aid the diagnosis of sepsis – with results available to treating physicians in less than 21 minutes. Rapid point-of-care testing significantly improves turnaround times, empowering clinicians to diagnose sepsis sooner, because the earlier sepsis is detected, the better the odds for a full recovery.

 

To find out more, please contact radiometer@radiometer.com or visit http://www.radiometer.com/sepsisnews

tecan

Phenomenex and Tecan to Co-Market Automated Sample Preparation Solutions

author2015-09-08authorposted by Anna,

Torrance, Calif. and Männedorf, Switzerland, (September 8, 2015) – Phenomenex, Inc. and the Tecan Group (SIX Swiss Exchange: TECN) today announced a collaboration to co-market automated solid phase extraction (SPE) sample preparation solutions. The two companies will jointly market Phenomenex Strata™ and Strata-X SPE sorbents adapted to Tecan’s Freedom EVO® series of robotics workstations. The solution is especially geared to high-throughput customers in pharmaceutical research, clinical and food testing environments using mass spectrometry detection methods. As part of the global agreement, Tecan will provide the instruments and automation support, and Phenomenex will provide the extraction chemistries as well as application and method development through its PhenoLogixSM group.

 

Solid phase extraction is a widely used sample preparation technique by which compounds in mixtures are separated, prior to chromatographic analysis. Phenomenex Strata and Strata-X SPE sorbents remove unwanted contaminants, including phospholipids, and are offered in a number of unique selectivities to cover a diverse range of analytes. SPE can be a time-consuming manual process that is prone to human errors resulting in additional time and costs for laboratories to confirm or repeat tests. Execution of this process on Tecan automated platforms combined with optimized conditions from PhenoLogix will decrease implementation efforts in the lab, increase throughput while reducing human error and enable sample traceability for regulated environments.

 

“We created this agreement with our high-throughput customers in mind,” commented Michael McGinley, core products manager for Phenomenex. “We can now bring them complete, automated solutions, simplifying the previously daunting task of adapting a manual method to laboratory automation. The engineers at Tecan have an amazing insight on how to optimally automate liquid handling and the Freedom EVO is a proven platform with an established track record for reliability.” 

 

“Phenomenex has a large customer base using their SPE products,” explained James O’Brien, Head of Clinical Diagnostics for Tecan. “By co-marketing our robotic workstations with their chemistries, we expect to expand our reach in these high-volume industries. The experts at Phenomenex and PhenoLogix have enhanced our knowledge of chromatography and enabled us to bring to market a product for mid- to high-throughput laboratories that increases the ROI of their high capital investment in mass spectrometry detection systems.”

quotient

Quotient Clinical expands its data sciences capabilities

author2015-09-08authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® company, has expanded its data sciences services in response to increasing customer demand, doubling the footprint of its facilities in Edinburgh and Nottingham, as well as increasing its specialist headcount and appointing a new Vice President. Data sciences is an integral part of the company’s service, delivering real-time data to customers for review and interpretation, enabling crucial dosing decisions to be made during the course of a study. Greg Johnson, the new Vice President of Data Sciences, joined Quotient in March 2015 and has over 25 years’ industry experience of directing biometrics and data sciences in large contract research organizations.

 

Mark Egerton, CEO of Quotient Clinical said: “Greg brings a wealth of industry experience that will be invaluable as we grow our data sciences offering. Demand for these services is rapidly increasing, and we are now undertaking electronic data capture, data management, pharmacokinetics, modeling and simulation, biostatistics and reporting on over 80% of our customer programs, compared to just 50% a few years ago.”

 

Greg Johnson, the new Vice President of Data Sciences, added: “Translational Pharmaceutics can have a profound impact on reducing development timelines and associated costs, and this is driving an increase in demand for all our services. I look forward to leading the growth of our data sciences capabilities, ensuring that we deliver integrated solutions for our customers.”

radiometer

Radiometer introduces MicroMode measuring for fetal scalp and neonatal capillary sampling

author2015-08-26authorposted by Anna,

Radiometer has launched the advanced ABL90 FLEX PLUS blood gas analyzer, featuring a unique MicroMode measuring function for extremely small volume blood samples. The state-of-the-art analyzer is ideal for the delivery room or the neonatal intensive care unit (NICU), helping healthcare professionals to provide the most effective care possible. MicroMode measuring – combined with the new 45 µl safeCLINITUBES plastic capillary tubes – provides a perfect solution for delicate capillary sampling procedures, enabling immediate assessment of a potentially distressed fetus or critically ill neonate. Up to 17 critical parameters can be determined rapidly at the point of patient care from a single very small volume sample, with results available in just 60 seconds. Operation is both safe and simple, with automatic inlet opening and closing to minimize manual processes and reduce the risk of errors. To ensure data integrity, the analyzer can be connected to the AQURE point-of-care management system.

 

For the ultimate neonatal care package, the comprehensive analytical capabilities of the ABL90 FLEX PLUS blood gas analyzer and safe sampling devices can be complemented with Radiometer’s TCM CombiM monitor, allowing continuous, non-invasive, transcutaneous monitoring of oxygenation and ventilation in real time. This combination of blood gas analysis and transcutaneous monitoring – Radiometer’s NeoOne solution – is particularly beneficial in the NICU, providing a more complete clinical picture for these at risk patients.

glass-solutions

A winning award from Glass Solutions

author2015-08-25authorposted by Sophie Woodward,

Glass Solutions has collaborated with production company Atom Ltd to manufacture a unique high quality glass trophy for a large multinational company. Alan Robinies, Director at Atom, explained: “We had previously produced a number of awards in acrylic for the company to present to its staff in recognition of their achievements. Subsequently, we were approached to recreate these custom-designed awards, this time in high quality glass. Finding a supplier prepared to take on the challenge of creating something a little different to normal was not easy; Glass Solutions was like a breath of fresh air, and did a great job for us.”

 

“Quality is paramount and, while the original acrylic award was good, the glass trophy is far superior. The craftsmanship involved in glass blowing, bonding different pieces of glass together and then creating the bespoke shape of the award, is incredible and cannot be mimicked by a computer or machine. It’s fascinating to watch. Turnaround times are equally important, and Glass Solutions delivered the awards to us in advance of the agreed deadline, ensuring that we had ample time to complete the decoration and engraving. I always had confidence in what the company could achieve and, once the first award was complete, it was plain sailing.”

syrris

Cost-effective Dolomite Flow Chemistry Systems launched at 250th ACS Exposition

author2015-08-20authorposted by Anna,

Syrris’ sister company, Dolomite Microfluidics, has launched new flexible, cost-effective Dolomite Flow Chemistry Systems at the 250th American Chemical Society Meeting and Exposition in August 2015. The three systems are easy to use and can be easily configured to suit different applications, making them ideal for education, continuous large scale reactions, process optimization, scale-up and multi-step reactions.

 

The Dolomite Flow Chemistry Systems are designed to provide excellent control of residence time, reaction temperature, stoichiometry and reagent introduction, for performing detailed flow chemistry experiments. The systems include a choice of glass microreactors or tube reactors in PTFE or stainless steel from 2.5 µl up to 16 ml. The TCU-125 Temperature Controller ensures accurate temperature control of chips from 1 to 125 °C, while the tube reactors can be heated from room temperatures to 250 °C using a hotplate. The high performance and robust Mitos Duo syringe pumps ensure extremely smooth flow rates, from 1.0 µl/min to 10 ml/min, and allow use of the two syringes independently, or in one continuous flow, up to 6 bar. Standard systems can be easily upgraded for additional functionality, such as reaction automation, continuous work-up, small volume sample injection or pressurized inputs.  Dolomite flow chemistry systems allow safer, cleaner, faster reactions and make flow chemistry affordable and easy.

syrris

Effortless reactions with the Orb jacketed reactor system from Syrris

author2015-08-13authorposted by Anna,

Syrris will be launching Orb, a novel jacketed reactor system at the 250th American Chemical Society Meeting and Exposition on the 16th of August 2015. Orb combines exceptional value and high quality construction with unique user-friendly features and reliable performance for batch chemistry. Designed for process development and kilo labs, the compact benchtop system is ideal for numerous applications, including production, crystallizations, process development, work-ups, reaction optimization, distillations and bioreactions.

 

The Orb jacketed reactor system accommodates a broad selection of jacketed and vacuum jacketed vessels from 100 ml up to 10 l, and can be operated over a wide range of temperatures – between -90 and +250 °C – and pressures from 50 mbara to 0.25 barg. Its intuitive, patent-pending clamp mechanism enables vessels to be quickly and easily changed, and is complemented by a simple stirrer motor lift that allows the stirrer motor to be raised and rotated out of the way during vessel changes. Vessel height adjustment is also rapid and straightforward, with no tools required. Together with a comprehensive choice of accessories – including stirrers, circulators, reflux condensers, dropping funnels and distillation assemblies – and optional upgrades to allow automation of reaction parameters and rapid oil drain, Orb jacketed reactor systems can be used in virtually any application.

 

tecan

Tecan takes precision and accuracy in liquid handling to the next level

author2015-08-04authorposted by Anna,

Tecan has launched the next wave of innovation for the Fluent™ laboratory automation solution*, introducing a number of new hardware and software options that enable a much wider range of applications. With the addition of a new air displacement Flexible Channel Arm, Fluent now offers the choice between two pipetting technologies for high definition liquid handling, unmatched precision and greater accuracy. These updates build on the success of the Fluent cell-based assay and compound management workstations, further simplifying key processes and increasing productivity in the lab, as well as being ideally suited to high throughput genomics applications.

 

The workstation’s FluentControl™ software has been further enhanced with the addition of an Application Toolkit providing standard commands for common tasks – such as quantification and normalization workflows – saving application specialists several hours of programming per script compared to current solutions on the market. It also provides a collection of commands allowing programmers to create ‘wizard-like’ interfaces, with special commands for embedding rich user prompts, further simplifying everyday operation of the workstation. A revolutionary Active Stop and Resume function also allows operators to access and, uniquely, interact with the workdeck during a run, simply by opening the door. To restart, the user just closes the door and re-initiates the program, which will pick up where it left off.

 

“We are particularly proud of how the Fluent platform has been received by early users, with some customers already coming back to order additional systems. This new wave of innovation takes our central concepts of user-friendliness and ease of use to the next level for laboratory automation,” commented Dr Stefan Traeger, Executive VP and Head of the Tecan Life Sciences Business.

quotient

Quotient Clinical’s Chief Scientific Officer awarded honorary professorship at the University of Nottingham

author2015-07-29authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, has announced that Dr Peter Scholes, its Chief Scientific Officer, has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham. The award recognizes distinguished individuals who have strengthened links between the University and practical experience in business and industry, through seminars, lectures and research collaborations.

 

Mark Egerton, CEO Quotient Clinical, said: “We are delighted that Peter has received this award and recognition. Peter joined our business in 2007 and has played a key role in developing Translational Pharmaceutics and its application to drug development. He is passionate about the quality of science that we undertake, and holds himself and his colleagues accountable to the highest standards. On behalf of everyone at Quotient, I would like to offer Peter our warmest congratulations”.

 

Peter added: “I am deeply honored to receive this recognition from the University of Nottingham. My six years of studying there had a hugely positive influence on my future, and I hold the School of Pharmacy, the University and its staff in the utmost regard. It has been highly rewarding to maintain my links with the School during my career as I believe that strong relationships between industry and academia are critical, both for developing scientists of the future, and for directing innovative research to improve patient-centred treatment outcomes.  I look forward to maintaining my association with the University in the years ahead”.

 

http://www.quotientclinical.com/

syrris

ChemiSens Calorimeter helps Eurenco put safety first

author2015-07-28authorposted by Sophie Woodward,

 

Explosives manufacturer Eurenco, based in Karlskoga, Sweden, relies on a ChemiSens Calorimeter to ensure the safety of its production processes. Helen Stenmark, R&D manager for explosives and propellants, explained: “Safety is paramount when you are working with explosives. Our reactions involve a great deal of energy, and it is vital to have the right equipment – for cooling and stirring, for example – to safely control the process.”

 

“I have worked with the ChemiSens Calorimeter for over 20 years, beginning with an early prototype, and find it robust, efficient and very easy to use. Calibration is unnecessary, as the system uses heat flow measurement technology that is designed to be unaffected by the ambient temperature. You simply wait for the system to stabilize – about 15 minutes – and then run your experiment, which makes everything so much quicker. For instance, I completed a particular series of experiments in just one and a half days with the ChemiSens Calorimeter, whereas a colleague in another laboratory took five days to perform the same study using a system that had to be calibrated. When we compared the results, they were identical. Real-time data monitoring is another big advantage, allowing me to watch the reaction taking place and perform my calculations immediately, ensuring that everything remains safely under control. We depend on reaction calorimetry to model scaled-up processes and, in such a high risk industry, the accuracy of this data is crucial to safe working practices,” concluded Helen.

 

Syrris Limited

Syrris is world renowned for excellence in chemical reactor systems and is a world leader in flow chemistry systems. Established in 2001, Syrris employs over 30 scientists and engineers at its facility in Royston (near Cambridge, UK) and has offices in the US, Japan, India and Brazil plus over 30 distributors worldwide.

 

Syrris develops laboratory automation products for research and development chemists in industries such as pharma, petrochem, agrochem, fine chemical synthesis etc. as well as academia. Syrris products are used in a wide variety of applications and laboratories including process, discovery, crystallization, process safety, scale-up and many more.

 

Syrris products include the innovative range of fully automated batch reactor products (Atlas), a manually operated jacketed reactor platform (Globe) and flow chemistry systems (Asia and Africa). In recognition of its technological achievements, Syrris has been awarded the “Eastern Region’s UKTI Best Established Exporter” and the “Most Outstanding Export Achievement” at the Global Opportunity Conference on International Trade. Syrris’ Asia Flow Chemistry system was the recipient of a prestigious 2012 R&D award.

cepheid

Patient Safety Awards 2015 highlight the benefits of Cepheid’s GeneXpert® Infinity System

author2015-07-28authorposted by Sophie Woodward,

Cepheid’s GeneXpert® Infinity System lies at the heart of an innovative, award-winning sexual health screening service in Soho, London. Dean Street Express – run by the Chelsea and Westminster Hospital NHS Foundation Trust – was recently declared the winner of the Best New Product, Innovation or Service category at the 2015 national Patient Safety Awards. This latest award further recognises the success of the user-friendly Dean Street Express walk-in sexual health check-up service for symptom-free patients, which has reduced the time taken for a person to have a screen from two hours to 32 minutes, adding to its achievements in the 2014 Health Service Journal and Ehealth Insider awards.

 

The Best New Product, Innovation or Service award acknowledges game changing concepts with the potential to offer significant advances in patient care and safety. Dean Street Express has continued where 56 Dean Street started in bringing sexual health screening into the open, generating discussion and removing much of the perceived stigma attached to attending such a clinic, achieving extraordinary success since opening last year. The time from testing to results and, when necessary, treatment has decreased dramatically, and there has been an impressive five-fold reduction in the number of patients lost to follow-up. The challenge now is for other clinics in the UK and abroad to replicate this efficient, cost-effective model.

 

For more information on Cepheid's GeneXpert Systems or complete menu of CE-IVD Xpert tests, visit www.cepheidinternational.com

 

biofortuna

Biofortuna launches its new approach to custom IVD manufacture and development services

author2015-07-27authorposted by Sophie,

Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market.

 

World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company a strong focus for growth and efficiency. The breadth of the company’s portfolio of IVD manufacturing and development services has expanded to include manufacturing, dispensing, kitting, labelling, capping, as well as design and development of molecular diagnostic kits.

 

Biofortuna is an ISO 13485 certified company based in the UK, with state-of-the-art FDA registered facilities, including molecular biology laboratories. The company uniquely offers a strong scientific basis to its manufacturing services, giving customers a level of understanding and flexibility, in regulatory issues as well as development and manufacturing challenges, that few IVD contract manufacturers can boast.

 

Dr Simon Douglas, CEO of Biofortuna, said: “We pride ourselves on understanding our customers’ requirements and custom designing projects to meet their needs. Our recent expansion and restructuring builds on this successful approach, and we look forward to providing existing and future customers with a broad portfolio of services.”

 

For further information, visit booth #4565 at the AACC, contact services@biofortuna.com or visit www.biofortuna.com.

glass-solutions

Glass Solutions a key contributor to the success of LabPlant spray dryers

author2015-07-22authorposted by Sophie Woodward,

Glass Solutions hand-blown precision glassware is key to the continued success of Yorkshire-based LabPlant UK’s laboratory scale spray dryers. Simon Rowe, sales/purchasing and exports manager, explained: “Spray dryers are popular research tools in industries such as pharmaceuticals, and flavors and fragrances, as well as academia, enabling the conversion of liquids into powders for further analysis. These systems are bespoke items, adapted to individual customers’ requirements, and high quality glassware is a vital part of the unit, whether that’s chambers, collection bottles or cyclones.”

 

“It is important that the glass components of the spray dryers are made reproducibly, and we need to ensure that the tolerances are exactly the same every time. Our systems are designed to enable a degree of movement to either side, allowing adjustments to be made should there be any variance in the glassware, but the quality of Glass Solutions products is such that we almost never need to do this. Although every component is inspected on delivery, I know that this is not necessary since each piece of glassware will be identical, which is excellent. We have worked with Glass Solutions for many years, receiving great service. Our relationship with the company is really good, and we know that it will meet its deadlines, which is key to the timely delivery of our products.”

 

ingenza

Ingenza embarks on GSK collaboration

author2015-07-21authorposted by Sophie Woodward,

Ingenza Ltd, a world leader in the application of industrial biotechnology and synthetic biology, is pleased to announce that it is collaborating with global healthcare company GlaxoSmithKline (GSK) on an innovative research project.

 

A vital part of any collaboration is the selection of a trusted partner. Andrew Collis, Synthetic Biochemistry Lead in GSK Global Manufacturing and Supply, explained why the company chose to work with Ingenza: “In any external collaboration, it is essential to partner with a company that can quickly and efficiently deliver GSK’s proof of concept. It is important to choose a partner that will interact well with our own scientists, with an established track record in the field. We look for a company with the right technical capabilities, that can understand our objectives and the science involved, and is able to engage in productive dialogue with our scientific staff to drive the project forward in a focused manner. Ingenza is a well-established company, which we believe to have the right skill set, attitude and facilities to progress our project and meet our targets and deadlines.”

 

Ian Fotheringham, Managing Director of Ingenza, commented: “Ingenza is delighted to be collaborating with GSK, using its extensive experience in the field to help deliver the project quickly and efficiently. We look forward to establishing an excellent relationship with GSK as the project progresses, working together to advance healthcare developments.”

 

quotient

Quotient Clinical announces expansion of pharmaceutical sciences capacity

author2015-07-14authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories.

 

The new laboratories, based within the company’s existing Nottingham facility, were commissioned in response to an increasing customer demand for Quotient’s formulation development services, and have a footprint of approximately 8,000 square feet. The new GMP manufacturing facility is located in the MediCity innovation hub in Nottingham, and has a footprint of 3,000 square feet. It comprises eight multipurpose suites, offering the opportunity to manufacture drug products on a large scale, with all the necessary containment controls to enable safe handling of high potency molecules. The facility is scheduled to become operational later in 2015 following an MHRA inspection.

 

Mark Egerton, CEO Quotient Clinical said: “This expansion is in direct response to the increasing demand for our Translational Pharmaceutics services. Our approach of integrating formulation development, real-time GMP manufacturing and clinical testing is proving an attractive option to reduce development timelines and associated costs.”

 

Nikki Whitfield, Vice President, Pharmaceutical Sciences, Quotient Clinical, added: “These new facilities form a key component of our strategy to expand our pharmaceutical sciences capacity and capabilities. We will continue to focus on building advanced formulation development approaches to solve important challenges in drug development, and our expanded GMP manufacturing capacity will allow us to support Translational Pharmaceutics programs at Quotient, or to supply drug products to other clinical centres of excellence worldwide.”

tecan

Nanoliter liquid transfers with Tecan’s Freedom EVO®

author2015-07-14authorposted by Anna ,

Researchers at Germany's University of Konstanz have established an innovative technique to allow more cost-effective screening of small molecules. Using the Freedom EVO® workstation’s MultiChannel Arm™ 384, the University’s Screening Center has achieved reliable liquid transfers down to just 80 nanoliters. Silke Müller, a biologist in the screening facility, explained: “We work with a wide range of samples – enzymes, mammalian cells, bacteria – using various high throughput screening assay formats according to the needs of individual research groups. Our Freedom EVO therefore needs to be very flexible in the types of assays we can perform.”

 

With a library of over 38,000 compounds for screening, the center wanted to avoid the need for wasteful pre-dilution of stock solutions to enable large-scale studies to be performed more cost-effectively. Silke continued: “The minimum transfer volume specified for the MCA 384 is 500 nl, but we needed to achieve reliable transfer of just 80 nl of liquid to meet our target final concentration per well. Using fixed steel tips, I developed a technique similar in principle to a pin tool device, relying on the residual liquid volume on the inside and outside of the tips following several aspiration and dispense cycles to provide very low volume transfers. Although the exact aspiration/dispense volume and number of cycles needs to be optimized for each assay buffer, this method has proved highly reliable, with CVs of ~10 % for 80 nl transfers.”

tecan

Fast liquid transfer down to picoliter levels with Tecan’s D300e

author2015-06-30authorposted by Anna,

Tecan has introduced the D300e Digital Dispenser* for applications that need faster, reliable dispensing down to picoliter volumes. This innovative, simple-to-use device is ideal for the creation of assay plates, and can cut set-up times from hours or days to just minutes. Users can choose between dispensing aqueous solutions in combination with a surfactant – for the investigation of proteins, antibodies, enzymes and nucleic acids – and DMSO, for small molecule studies, offering greater flexibility for life sciences workflows.

 

The system’s sophisticated yet simple software guides you through every operation, minimizing training times and problem-solving call-outs, and providing straightforward set-up of enzyme profiles, dose-response curves and synergy studies. Even the most complex experimental plate layouts – such as drug-drug interaction studies – can be quickly and easily generated, with optional randomization to reduce the impact of edge effects and increase data integrity. The D300e is compatible with a wide range of microplate formats from 12 to 1,536 wells, including deep-well plates and, for maximum flexibility, can even accommodate SBS-format tube racks.

radiometer

Radiometer launches new point-of-care test for procalcitonin, aiding diagnosis of sepsis

author2015-06-25authorposted by Anna,

Radiometer has launched a rapid, acute care procalcitonin (PCT) assay to aid in the diagnosis of sepsis, further extending the AQT90 FLEX test menu. Sepsis is the most prevalent and severe infection-related condition and can be difficult to identify, particularly in the initial stages. This presents a considerable diagnostic challenge to emergency department and intensive care clinicians. Undetected, it can quickly progress to severe sepsis or septic shock and, as its severity increases, mortality rates can reach 50 %. In septic patients with hypotension, a delay of just one hour in administering antibiotic therapy increases the risk of mortality by 7 %, making early identification of sepsis and initiation of appropriate antibiotic treatment vital. Radiometer’s AQT90 FLEX PCT assay enables early and convenient measurement of PCT – the biomarker of choice to aid diagnosis of sepsis – with results available to treating physicians in less than 21 minutes.

 

The easy-to-use AQT90 FLEX PCT assay is a key aid for timely diagnosis and treatment of sepsis. Procalcitonin, normally present in the blood at a very low level, is released in larger amounts in response to an infection, acting as a risk indicator for sepsis. With a negative predictive value above 95 %, it is widely acknowledged as the most sensitive biomarker to aid diagnosis of bacterial sepsis. The AQT90 FLEX PCT assay offers laboratory quality, quantitative determination of procalcitonin in whole blood or plasma at the point of patient care. Prehandling of whole blood samples is not required and turnaround times are improved, enabling earlier detection of sepsis for better patient outcomes.

tecan

Automated PBMC isolation for biobanking with Tecan’s Freedom EVO

author2015-06-24authorposted by Anna,

IBBL (Integrated BioBank of Luxembourg) has developed the world’s first fully automated technique for the isolation of viable peripheral blood mononuclear cells (PBMCs) using a Freedom EVO® workstation. Dr Fay Betsou, Chief of Biospecimen Science, explained: “PBMCs are of increasing interest for vaccine development and validation, and we have seen a steady increase in requests for PBMC-based functional assays. These cells – primarily lymphocytes and monocytes – are traditionally extracted manually using a laborious and time-consuming Ficoll-Paque method, taking a technician approximately four hours to isolate PBMCs from 10 samples.”

 

Taking advantage of the advanced liquid handling capabilities of the Freedom EVO platform, IBBL has developed a straightforward automated protocol based on the use of standardized citrate anticoagulant tubes (BD Vacutainer® CPT™). This walkaway process allows efficient isolation of PBMCs for cryopreservation while minimizing the number of granulocytes present in the final preparation. Fay continued: “This validated1 protocol is based on the mean hematocrit of the general population, and offers recovery rates and viability comparable to the manual process. This protocol can now be implemented as part of our standard portfolio of automated methods and, although high throughput is not our primary focus, the Freedom EVO system offers walkaway processing of 24 patient samples in under three hours, allowing the technician to perform other activities while it is running.”

 

1  Hamot et al. Method Validation for Automated Isolation of Viable Peripheral Blood Mononuclear Cells. Biopres Biobank, 2015, In press.

quotient

Quotient Clinical begins prostate cancer project for Druggability Technologies

author2015-06-23authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the initiation of a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate, a marketed drug prescribed in combination with prednisone to patients suffering from metastatic prostate cancer. The program will assess new formulations using DRGT’s proprietary Super-API technology, and aims to reduce dose and address food effects associated with the drug.

 

Quotient’s RapidFACT service provides formulation development, real-time GMP manufacturing and clinical testing, all in one location, creating a streamlined approach to optimizing drug formulations for clinical development. It has been proven to accelerate program timelines by at least 50 % and delivers significant cost savings.

 

Mark Egerton, CEO of Quotient Clinical, said: “We are delighted that DRGT has selected RapidFACT to support its formulation development project, targeting an important drug in the fight against prostate cancer. This program of work is an excellent illustration of how we can work with our emerging biopharma customers to rapidly validate novel drug delivery technologies and new product concepts.”

 

Gabor Heltovics, CEO of Druggability technologies, added: “We are very pleased to be working with Quotient on this very important Super-API clinical development program that promises to achieve a major dose reduction, combined with a substantial reduction or elimination of the significant food effects of the marketed drug. The successful application of our Super-API technology to abiratone acetate is yet another important milestone in the development of our oncology drug product portfolio, with the potential to improve the quality of life of patients and help unlock the full potential of drugs that prolong and save lives.”

 

glass-solutions

Glass Solutions the key to landmark sculptural lighting commissions

author2015-06-23authorposted by Sophie Woodward,

Haberdashery, a London-based design consultancy, relies on Glass Solutions to produce top quality, custom-made glassware for its landmark sculptural lighting commissions. Director Mac Cox explained: “At Haberdashery, we focus on the design, supply and installation of high end bespoke sculptural lighting for exclusive properties and developments worldwide, from penthouses in London to the Hermitage apartments in Monaco. As well as commissions from interior designers and architects drawing up plans for luxury properties, we work with up-market developers and hotels, and on individual pieces for some of the wealthiest people in the world. At this level, quality is everything.”

 

“We chose Glass Solutions because the company has the capability to reliably and consistently produce the large quantities of high quality custom-designed tubes that we need for our lighting sculptures, which comprise several thousand individual tubes of diverse lengths. Glass Solutions gives us a lead time and keeps to it, which is exactly what we need, and has the flexibility to allocate additional staff to a project to meet short deadlines when necessary. We have also occasionally asked the company to produce other unique pieces of glassware, which have been beautifully made. Over the five or six years we have been working with Glass Solutions, we have established a great working relationship built on trust. The company is in the top 10 of the hundreds of suppliers we use, and is by far one of our favored manufacturers.”

quotient

Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics

author2015-06-10authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers. The Enabled-FIH program integrated formulation development, real-time GMP manufacturing and clinical testing, using a single adaptive protocol to assess single and multiple dose safety, pharmacokinetics, and proof of pharmacological effect. The clinical timeline for the first-in-human dose through to completion of the program was only 7 months. CORT125134 was proven to be safe and well tolerated at the doses tested, and pharmacological effect was demonstrated. The drug is now progressing into the next stages of development.

 

Mark Egerton, CEO of Quotient Clinical, commented: “We were delighted to be chosen as Corcept Therapeutics’ partner for this development program. CORT125134 is an exciting new potential drug, and our Enabled-FIH service has helped to accelerate its early development timeline and deliver significant cost savings. This program again demonstrates how Enabled-FIH represents an important step forward, helping the industry to improve overall R&D productivity.”

 

“CORT125134 has great therapeutic potential,” said Dr Hazel Hunt, Corcept’s Vice President of Research. “Quotient’s innovative and flexible approach allowed us to complete initial clinical testing quickly and produce evidence of functional activity that will guide the compound’s subsequent development.”

 

 

For further information, please contact:

Robin Bodicoat

Marketing Director

Quotient Clinical

Tel: +44 (0)115 931 5102

robin.bodicoat@quotientclinical.com

 

tecan

Tecan’s Freedom EVO® ideal for automated high throughput cell separation

author2015-06-10authorposted by Anna ,

The Karlsruhe Institute of Technology has automated high throughput cell separation protocols using aqueous two-phase systems (ATPS) on a Freedom EVO® 200 liquid handling platform. PhD student Sarah Zimmermann explained: “ATPS offers many advantages compared to antibody-based methods of cell separation; cost-effectiveness, scalability and very mild, gentle conditions for purification of cell products. Initially, we performed ATPS manually, but this is tricky and can give rise to large errors and unreproducible data. Automation was the way forward.”

 

“The Freedom EVO workstation has enabled us to establish automated high throughput screening, allowing rapid, directed design of purification protocols for therapeutic cells. The process is more rapid and reproducible than manual methods, enabling 96 samples to be processed in four hours. Volumes between 10 and 990 µl are pipetted using the Liquid Handling Arm with fixed tips, with standard deviations ranging from 1.5 % for the smallest volumes to less than 0.5 % for larger volumes, even with very viscous polymer solutions. We can also accurately pipette small cell suspension volumes, reproducibly transferring 5 x 105 cells in a volume of 13 µl with a standard deviation of less than 3 %. The automated process has been applied to the separation of differentiated and undifferentiated cells from the HL-60 cell line, achieving gentle, cost-effective and scalable purification of cell products without significantly influencing the cell viability.”

dolomite

Sales of Dolomite’s Micro Droplet Systems reach record high

author2015-06-03authorposted by Sophie Woodward,

Dolomite Microfluidics, the world leader in innovative microfluidic products, has seen significant growth in the sale of its Micro Droplet Systems, particularly for cell encapsulation applications. The only commercially available complete solution for cell encapsulation, microparticle production and nanoparticle synthesis, these systems are modular, scalable and easy to use, offering reliable production of identically sized droplets, particles, emulsions, double emulsions and bubbles, typically with a coefficient of variation of 1 %.

 

“We are delighted to see such a rapid rise in interest in the benefits of using microfluidic technology for applications in biology, food, cosmetics, drug discovery and chemistry,” commented Mike Hawes, Chief Commercial Officer for Dolomite. “The ability to precisely engineer the size and contents of particles, droplets, foams and emulsions means that novel, reproducible and highly controlled formulations can be achieved, as well as allowing unique biochemical reactions to be performed. For example, by encapsulating individual cells into millions of droplets, our Micro Droplet Systems enable researchers to isolate monoclonal antibodies from blood samples or profile correctly-paired T­cell receptors. Other applications include fast and powerful directed evolution – encapsulating libraries of mutants with fluorogenic reagents for FACS analysis – and the encapsulation of cells in hydrogels for cell therapy. No other technology can achieve this type of droplet formation with such volume and consistency.”

 

For more information on Dolomite’s portfolio of microfluidic systems, pumps, chips, connectors, temperature controllers, sensors and custom-made devices, visit www.dolomite-microfluidics.com.

syrris

Syrris launches novel quantum dot synthesis system

author2015-06-02authorposted by Sophie Woodward,

Syrris, a world leader in chemistry product innovation, has launched the Atlas Nanoparticle System for the automated synthesis of quantum dots. This fully automated solution offers complete control over temperature, mixing, dosing and sampling, allowing the production of nanoparticles with a narrow size distribution.

 

The Atlas Nanoparticle System is ideal for the production of complex particles, including both core-shell and multi-layered quantum dots. It has an extremely small footprint and integrates all the required elements – dosing, heating, mixing and sampling – to enable continuous operation for up to 72 hours. Built-in magnetic stirring ensures uniform heating of the 250 ml reaction vessel up to 300 °C, with a Heated Syringe Pump and Heated Lines to maintain reagents at temperatures of up to 120 °C. The three syringes can dose up to 25 ml each in volumes ranging from 0.1 to 5 ml and, following synthesis, the system’s Sample Collection Carousel enables automatic sample collection into 10 vials.

 

Temperatures, pumping volumes, pumping rates and the timing of additions are easily controlled via the Syringe Pump or PC software. Real-time and complete reaction data can be monitored using optional absorption/fluorescence spectrophotometry, as well as temperature and turbidity probes, enabling truly optimized, reproducible synthesis of quantum dots.

 

For more information, please visit www.syrris.com.

glass-solutions

Glass Solutions rises to the challenge

author2015-05-27authorposted by Sophie Woodward,

Blackpool-based RocketScienceMods, a manufacturer of high-end electronic cigarette components, turned to glassware specialist Glass Solutions to meet its need for a bespoke high quality drip tip. Managing Director Matthew Smith explained: “Top of the range e-cigarettes have a separate mouthpiece which, traditionally, is made from either stainless steel or plastic. However, many users felt that plastic mouthpieces lacked a quality feel, while stainless steel tended to accumulate dirt. RocketScienceMods wanted to offer an alternative; a Pyrex® mouthpiece manufactured, like the rest of our products, from UK-sourced raw materials. Our search for a glass supplier that could work to tight deadlines to produce a top-end product meeting our demanding quality standards led us to Glass Solutions. The company also shares our ethics for being an entirely UK-sourced manufacturer, which is equally important.”

 

“We have a great relationship with Glass Solutions. The company worked well with us to perfect a high quality product meeting our design specifications and tolerances, adjusting its processes where necessary and providing technical advice. This expertise was particularly important in helping us accomplish the technical challenge of bonding a stainless steel collar to the Pyrex drip tip, where we not only had to meet the mechanical needs of the joint, but also health and safety requirements. Our business transactions with Glass Solutions are always straightforward, which is a big bonus, and we've no plans to change.”

 

tecan

Tecan launches new options for Spark™ 10M

author2015-05-26authorposted by Anna,

Tecan has introduced a number of new features for the Spark™ 10M multimode reader. These first updates to the innovative Spark 10M include a cuvette port for absorbance measurements and an enhanced detection module, offering straightforward performance of immunoassays using PerkinElmer’s Alpha Technology, as well as a number of advanced software features.

 

The enhanced detection module makes it easier than ever before for customers to perform AlphaScreen®, AlphaLISA® and AlphaPlex™ protocols. This option combines a high power laser light source with both low-pass and high-pass filters, using pre-optimized filter settings to ensure exceptional assay performance in 96- and 384-­well microplate formats. The introduction of a cuvette port further increases format flexibility, allowing ultra-fast absorbance measurements using Tecan’s patent-pending High­Speed Monochromators.

 

The instrument’s SparkControl™ software has also been enhanced, with a number of new and improved features to streamline routine activities and maximize productivity. The extended dynamic range option enables both low and high gain measurements within a single microplate, allowing you to obtain complete data sets without compromising on sensitivity for low signal strength measurements. This is complemented by an automated gain regulation function for fluorescence-based measurements.  Ideally suited to kinetic assays and long-term cell-based studies, this feature helps to avoid loss of data by automatically adjusting the gain settings if signal saturation is reached. The software then automatically correlates the data across different gain settings, allowing you to view the entire dataset in a single graph. In addition, the introduction of unique, one-click applications – including absorbance reading, cell counting, cell viability, nucleic acid quantification and nucleic acid labelling efficiency – makes it easy to perform optimized measurements, offering rapid, consistent results at the touch of a button.

tecan

Tecan’s Infinite® M1000 PRO reader used to develop portable testing platform for the oil industry

author2015-05-21authorposted by Anna,

Tecan’s Infinite® M1000 PRO multimode reader has helped liquid analysis specialist Aqsens to develop a portable testing platform for on-site quantitative monitoring of polymeric scale inhibitors in oil field-produced waters. Joonas Siivonen, Application Scientist at Aqsens, explained: “Polymeric scale inhibitors are used to prevent scale build-up during oil production, and the residual levels in the oil field-produced waters must be monitored to ensure treatment is effective and the oil platform can be operated safely. Using a patented detection technology combining time-resolved fluorescence (TRF) with chemical modulators, we have developed a portable system – the Aqsens QS platform – to offer a fast, accurate means of monitoring residual scale inhibitors on site.” “The Infinite M1000 PRO proved ideal for developing both the assay chemistry and a TRF reader for use in the field. It enabled us to determine the optimum wavelength and measurement settings for our chemistries, to establish manufacturing specifications for our reader, and to validate the assay protocols. It is more sensitive for our applications than most filter-based instruments, and also gives us additional flexibility. The ability to control the gain setting is a really big bonus, allowing us to adjust the instrument’s sensitivity and detect TRF signals at a much lower level than was previously possible.”

quotient

Quotient Clinical reports another successful year of record growth

author2015-05-07authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, announces another strong year of progress and growth. Quotient’s Translational Pharmaceutics platform has been adopted by more than 30 new customers – ranging from top 20 pharma companies to emerging biotech organizations – contributing to a year-on-year increase in revenue of 24%, with similar growth levels anticipated in the next 12 months. In addition, a significant proportion of studies begun in 2015 were from returning customers, with repeat business wins at record levels.

 

The company’s operational excellence and quality have been endorsed by successful routine GMP and GCP MHRA inspections and more than 50 client audits. There have also been over 20 case studies presented at leading scientific conferences, validating the time and cost savings that Quotient Clinical consistently delivers.

 

In response to the growing demand for its services, a significant investment program planned for the next 12 months will more than double Quotient’s operating capacity. Mark Egerton, CEO of Quotient Clinical, commented: “We have made significant progress over the past 12 months surpassing all expectations, with growth rates well above industry norms. Our growing customer base, coupled with the positive dynamics of the pharma R&D outsourcing market, have been the key drivers behind our decision to increase our operating capacity. We have repeatedly demonstrated that Translational Pharmaceutics can deliver significant time and cost savings for our clients, helping them to increase their overall R&D productivity. We look forward to another exciting year ahead, and to strengthening our relationships with our customers, helping to transform drug development with our science and innovation.”

tecan

HP D300 Digital Dispenser now offers aqueous liquid dispensing

author2015-05-06authorposted by Anna ,

The popular HP D300 Digital Dispenser – available from Tecan – now allows customers to titrate low volumes of biomolecules in aqueous solutions, offering greater flexibility for drug discovery workflows. Users can choose between dispensing DMSO, for small molecule studies, and aqueous solutions in combination with a surfactant, for the investigation of proteins, antibodies, enzymes and nucleic acids.

 

Newly launched T8+ and D4+ Dispenseheads*, combined with updated software, allow both new and existing customers to benefit from this breakthrough, offering straightforward set-up of dose-response curves and synergy studies. New ‘fluid class’ options allow users to optimize liquid dispensing performance to their specific buffers and surfactants, and an Enzyme Profile function enables fast and easy set-up of titrations using differing combinations of enzymes, substrates and other compounds. These innovative features, combined with the system’s proven low volume dispensing performance, make it easy to perform complex experiments – such as enzyme characterization, Km determination and exploring the effects of enzyme inhibitors – ensuring a comprehensive solution for drug discovery applications.

sonosite-fujifilm

SonoSite’s X¬-Porte® ideal for regional anaesthetic procedures

author2015-04-29authorposted by Anna,

A SonoSite X­-Porte® point-of-care ultrasound system is proving a key asset for regional anaesthesia at the Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, as consultant anaesthetist Dr James Stimpson explained: “Queen Elizabeth was one of the first trusts in the UK to set up an ambulatory service for major shoulder surgery, and has been using ultrasound for regional anaesthetic procedures since 2004, when it purchased a SonoSite MicroMaxx® system. Since then, as the use of ultrasound has increased and the technology continued to advance, further systems have been added, including two SonoSite S-Nerves™ and, more recently, an X­-Porte.”

 

“The beauty of the X-Porte is its simplicity, particularly for the younger generation of anaesthetists that have grown up with smartphone technology. Its appearance instils confidence, it boots up quickly and the touch screen interface is very intuitive to use; simple plug-and-play operation means that you can literally turn it on, pick up the probe and instantly have the correct settings to generate a functional image. The quality of the image produced is just fantastic, and the resolution is brilliant, giving much clearer differentiation of nerve tissue from other structures. Our ability to pick out small cutaneous nerves has been revolutionised, allowing us to perform more selective regional anaesthesia and enabling patients to mobilise and return home far sooner than would otherwise be possible.”

glass-solutions

Jacketed reactors for any application from Glass Solutions

author2015-04-29authorposted by Sophie Woodward,

Glass Solutions has launched a range of jacketed reactor systems combining excellent value with reliable performance for process development, reaction optimization, or production applications. Ideal for crystallizations, process work-ups, distillations and bioreactions, Glass Solutions Reactor Systems are designed for process development labs, kilo labs and pilot plants, and can be used in a diverse array of scientific disciplines, from the pharma and fine chemical industries to the flavor and fragrance, petrochemistry, and agrochemistry sectors.

 

Chemically-resistant and simple to use, these robust, high quality systems are available in a wide range of benchtop or floor standing formats, as well as customized set-ups to meet specific needs. Precision manufactured at the company’s cutting-edge UK facility, single or vacuum jacketed reactors can be supplied in a variety of sizes – from 500 ml to 70 l – accompanied by a broad choice of circulators, multi-port lids, stirrers, reflux condensers, dropping funnels and distillation systems to suit virtually any application.

 

quotient

Quotient Clinical completes innovative first-in-human program

author2015-04-22authorposted by Anna,

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a highly selective small molecule c-Met tyrosine kinase inhibitor.

 

The clinical phase, which was conducted under a single, adaptive protocol, was completed in only six months. The single ascending dose phase began with a simple solution, and the protocol included the option to assess the relative bioavailability of up to two solid oral dosage formulations. The transition from solution to a solid dosage form was successfully achieved and this product was used to complete the remaining single and multiple doses. The clinical protocol also included flexible options to assess food effect, dosing frequency and administration to older subjects. Dose proportional increases in exposure were observed and all doses were safe and well tolerated.

 

Mark Egerton, CEO of Quotient Clinical, commented: “We were very pleased to undertake this program. This is an excellent example of how our innovative Enabled­-FIH service can support and accelerate an early development program. Timelines are shortened and the consumption of drug substance is reduced by >85 % compared to a conventional program, delivering significant cost savings. We believe that Enabled-FIH represents an important step forward in helping the industry to improve overall R&D productivity.”

 

The results will be published on poster CT309 at the American Association of Cancer Research (AACR) 2015 Annual Meeting, Philadelphia, USA. 18-22 April 2015 (Millington DA, Chaplan SR, Aguilar Z et al. Rapid evaluation of a novel small molecule c-Met tyrosine kinase inhibitor in healthy subjects).

sonosite-fujifilm

FUJIFILM SonoSite landet einen Treffer für den 1.FC Köln

author2015-04-21authorposted by Anna,

Dr. Paul Klein, seit über 11 Jahren Mannschaftsarzt des Bundesliga-Fußballclubs 1.FC Köln, konnte für die Betreuung der Spieler bei einem neulich stattgefundenen Trainingscamp in den USA ein geliehenes FUJIFILM SonoSite Edge® Point-of-Care-Ultraschallsystem testen. Der zehntägige Aufenthalt in Orlando, Florida, diente der Vorbereitung auf die zweite Hälfte der Fußballsaison. Dr. Klein erwartete vom diagnostischen Ultraschallsystem, dass es ihm Zeit spart und er den Spielern gegenüber bei einer Verletzung konkrete Aussagen machen kann, so dass diese beruhigt weiterspielen können. Er erklärte: „Das Edge-System war in dieser Hinsicht ideal, weil ich sofort feststellen konnte, ob eine Verletzung vorlag oder nicht. In meiner täglichen Arbeit nutze ich Ultraschall zur Beurteilung von Gelenken und Bändern und um ultraschallgeführte Injektionen in Gelenkräume vorzunehmen, insbesondere in Hüfte und Schultergelenke.

 

„Wenn wir trainieren oder zu Hause in Köln spielen, kommen die Spieler in meine Klinik, wo ich ein wagenbasiertes Ultraschallsystem habe. In Üebersee ist das jedoch nicht so einfach, und ohne ein Point-of-Care-Ultraschallsystem müssten die Spieler zu Untersuchungen praktisch immer in ein Krankenhaus fahren. Das Edge-System war für dieses Trainingscamp ideal, denn es ermöglichte mir die rasche Erstellung guter und eindeutiger Diagnosen. Die Spieler wissen dies immer sehr zu schätzen, denn im Profi-Fußball zählt jeder Tag. Wenn ich klar sehen kann, dass nichts gebrochen, gezerrt oder beschädigt ist, muss sich der Spieler auch nicht schonen.“

 

„Die Spieler bewegen sich anders, wenn sie glauben, dass etwas nicht in Ordnung sein könnte. Mithilfe dieses Gerätes konnte ich ihnen aber „Entwarnung“ geben. Das System selbst ist leicht, robust und einfach zu transportieren, und die Bilder weisen eine hohe Qualität auf – insbesondere für die Nahfeldbildgebung von Muskeln und Kniegelenken. Man kann alles sehr klar erkennen und ich hoffe sehr, dass wir bald ein System zur Verwendung am klubeigenen Trainingsgelände kaufen können“, so Dr. Klein.

 

Für weitere Informationen über FUJIFILM SonoSite Produkte wenden Sie sich bitte an: eraf-sales@sonosite.com

syrris

Syrris Atlas Calorimeter benefits process scale-up

author2015-04-21authorposted by Sophie Woodward,

Syrris, a world leader in flow chemistry product innovation, has extended its range of Asia microreactors with the launch of ultra-low temperature 3-input microreactor chips offering fast, reproducible mixing, rapid heat transfer and minimized back pressure. Designed to complement the Asia Cryo Controller module, these chemically resistant, transparent and robust microreactor chips are ideal for solution phase flow reactions at temperatures ranging from -100 to +250 °C and pressures up to 20 bar.

 

Available in two volumes – 62.5 and 250 μl – each chip features input channels and mixing junctions located within the temperature controlled area of the flow system, enabling pre-cooling or pre-heating of input streams to the reaction temperature prior to mixing. This is invaluable for flow chemistry reactions where the mixing temperature is a critical safety parameter, typically processes employing highly reactive reagents that must be handled at low temperatures. For maximum flexibility, the microreactor chips can be used in conjunction with the Asia Cryo Controller and Asia Chip Climate Controller, as well as the Asia Heater, providing trouble-free temperature control of a wide range of flow chemistry reactions.

 

tecan

Application guide for Tecan plate washers offers an easy route to optimized results

author2015-04-21authorposted by Anna,

Tecan’s recently published Application guide for Tecan plate washers puts information at your fingertips, allowing users of its popular HydroSpeed™ and HydroFlex™ instruments to optimize their assays more easily and simply. Whether you are performing ELISAs, vacuum filtration, magnetic bead- or cell-based assays, the guide contains everything you need to know about Tecan washers.

 

The guide includes an overview of the features and highlights of each instrument – for example extra gentle cell washing with the HydroSpeed’s Cell Protection™ function – enabling users to select the most appropriate system for their particular application, as well as references to supporting literature and application notes. Instant access to all the knowledge required to precisely control critical wash parameters – such as vacuum power, aspiration position, and dispensing rates and positions – helps users to improve assay consistency by avoiding detachment of cells, beads and antibodies during wash steps. The Application guide for Tecan plate washers contains such a wealth of essential information that it is sure to prove invaluable in the laboratory.

 

For more information, or to download a copy of the guide, visit www.tecan.com/cell-protection

cepheid

Maintaining an MRSA-free zone with Cepheid’s GeneXpert® System

author2015-04-20authorposted by Sophie Woodward,

Cepheid’s Xpert® MRSA molecular diagnostic test is helping to keep the orthopaedic ward at Northern Ireland’s Craigavon Area Hospital free from MRSA, as Elaine Porter, acting lead biomedical scientist in the microbiology department, explained: “Craigavon is a busy district general hospital. In 2010, the hospital opened a purpose-built orthopaedic unit, and our department was involved in planning the patient pathway, looking at how to ensure the new unit remained MRSA free. We realised the potential of PCR technology, and so looked for a standalone molecular diagnostic system offering random access MRSA testing, choosing Cepheid’s GeneXpert System and Xpert MRSA test.”

 

“The major benefit of the Xpert MRSA test is speed of diagnosis. We can now obtain results in just 90 minutes, rather than two days by culture, which is invaluable as it ensures patients follow the correct pathway. If MRSA is confirmed, patients are nursed in a side room, given prophylaxis prior to surgery, and placed at the end of the surgical list to allow deep cleaning of the theatre afterwards. This reduces the likelihood of orthopaedic sepsis and possible repeat surgery, reducing costs and protecting all our patients, not just those that are colonised. Equally important, patients that are not colonised can be nursed in 4-bedded bays, benefitting from each other’s company, and valuable side rooms are freed up. The system has proved very effective and, five years on, the orthopaedic unit remains MRSA free.”

sonosite-fujifilm

SonoSite’s NanoMaxx® takes to the sky

author2015-04-15authorposted by Anna,

SonoSite’s NanoMaxx® ultrasound system is helping the Thames Valley and Chiltern Air Ambulance (TVCAA) to provide potentially life-saving pre-hospital care. Dr Syed Masud, a Consultant in A&E and Pre-hospital Care at the John Radcliffe Hospital in Oxford, explained: “In addition to my work at John Radcliffe, I have been a member of the medical team at TVCAA, based at RAF Benson, for almost two years. Pre-hospital care has become a sub-speciality in its own right, and the helicopter emergency medical service (HEMS) plays an important role in the delivery of both trauma and critical care.”

 

“HEMS has been using the NanoMaxx for about a year now. It is working well and proving very robust, and we are really pleased with it. The NanoMaxx is used on all major trauma and cardiac arrest calls – which account for the vast majority of TVCAA call-outs – allowing us to perform abdominal FAST scanning, chest and cardiac ultrasound. Previously, we were reliant on clinical acumen, but with ultrasound we have added a new dimension and an extra diagnostic window; instead of listening to the chest or feeling for a heartbeat, we can actually see it on screen, which is a big advantage.”

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151,

 ukresponse@sonosite.com    www.sonosite.co.uk

syrris

Syrris launches novel ultra-low temperature microreactor chips

author2015-04-08authorposted by Sophie Woodward,

Syrris, a world leader in flow chemistry product innovation, has extended its range of Asia microreactors with the launch of ultra-low temperature 3-input microreactor chips offering fast, reproducible mixing, rapid heat transfer and minimized back pressure. Designed to complement the Asia Cryo Controller module, these chemically resistant, transparent and robust microreactor chips are ideal for solution phase flow reactions at temperatures ranging from -100 to +250 °C and pressures up to 20 bar.

 

Available in two volumes – 62.5 and 250 μl – each chip features input channels and mixing junctions located within the temperature controlled area of the flow system, enabling pre-cooling or pre-heating of input streams to the reaction temperature prior to mixing. This is invaluable for flow chemistry reactions where the mixing temperature is a critical safety parameter, typically processes employing highly reactive reagents that must be handled at low temperatures. For maximum flexibility, the microreactor chips can be used in conjunction with the Asia Cryo Controller and Asia Chip Climate Controller, as well as the Asia Heater, providing trouble-free temperature control of a wide range of flow chemistry reactions.

agar-scientific

Agar Scientific goes ‘back to the future’ to secure your digital history

author2015-04-01authorposted by Sophie Woodward,

Forget the Internet. Backing up your critical science research and commercial data with floppy disks is the future of data preservation.

Google vice-president  Vint  Cerf  has  been  warning  about  the 'digital  Dark  Age.' As a ‘father of the Internet’, Cerf has said he is worried that all the images and documents we have been saving over the Internet will eventually be lost, warning that ‘bit rot’ could lead to a forgotten century.  http://bbc.in/1D3pemp

From today, Agar Scientific is now offering back-to-basics technology to make sure your data stays around for the long term. We’ll be offering an array of floppy disks, together with a taxi service to pick up of your disks for deep storage in various locations around the UK.

“We knew that the concern over data preservation was coming, and we’re now a giant step ahead of the market by offering ‘back-to-basics back-up’, which we’re calling B2B,” said Paul Smith, Marketing Manager for Agar Scientific. “Knowing this day would arrive, we’ve been working with our partner – the FrailLoop Company – for over three years to put in place the details of the service. We have a vast collection of appropriate re-conditioned machines and disks that we’ve been collecting for the last 25 years.”

From the 1st of April, Agar will be selling 8”, 5¼” and 3½” floppy disks, together with the supporting hardware, on its website at www.agarscientific.com/010415. The service offering will initially be rolled out to academic and small commercial labs. Paul added: “We are now at the forefront of plugging the digital hole, coming to the rescue of digital archiving.”

 

quotient

Quotient Clinical announces ADME success in oncology

author2015-03-31authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, has announced contract wins for three further OncoADME programs to support clinical mass balance/ADME investigations in cancer patients. Two of the programs will be undertaken on behalf of US-based biotech organizations and the third is for a top 10 global pharmaceutical company.

 

Quotient’s OncoADME service takes advantage of the company’s real-time adaptive manufacturing approach to supply 14C radiolabelled drug products to specialist oncology clinics globally. Drug products are manufactured on a ‘per patient’ basis and supplied to the clinic for dosing within two weeks of patient enrolment. This streamlined approach tailors drug product manufacturing to patient recruitment, reducing overall project costs and enabling the management and control of any issues related to instability of the 14C radiolabel.

 

Mark Egerton, CEO of Quotient Clinical, commented: “We are extremely pleased with how the OncoADME service has been accepted by our customers. Our ability to manufacture drug products in real time, and synchronize manufacturing activities with patient recruitment, is proving an effective way of reducing drug development costs and improving efficiency. Over recent years we have become one of the leading global providers of human ADME programs in healthy volunteers, and we are now able to offer oncology drug development teams the option to undertake these investigations directly in cancer patients”.

 

dolomite

Don’t miss out, enter the Dolomite and Lab on a Chip Productizing Science® Competition 2015 now!

author2015-03-31authorposted by Sophie Woodward,

Calling all entrepreneurial researchers, scientists and engineers! Dolomite and Lab on a Chip are seeking novel, microfluidics-based concepts with commercial potential for the Productizing Science Competition 2015. To make sure you don’t miss the chance to drive your microfluidics innovation forwards, simply submit your entry before the April 30th deadline.

 

The Productizing Science Competition, jointly organized by Dolomite and Lab on a Chip, aims to bridge the gap between scientific innovation and commercial success by turning early stage technologies into market-leading products. This exciting competition offers the opportunity to take advantage of Dolomite’s invaluable commercial expertise and in-depth understanding of the international microfluidics market to develop your groundbreaking idea into a profitable product. The winning entry will benefit from Dolomite’s outstanding R&D capabilities to help take the concept or prototype through to a market-ready product, backed by Lab on a Chip’s ability to reach out to the wide-ranging scientific community to maximize marketing opportunities.

 

So, if you have made a scientific breakthrough or have a prototype system that you are struggling to develop – whether financially, technically or commercially – simply submit an abstract before the 30th of April 2015 for your chance to win. Enter now, and help shape the future of microfluidics!

 

For more information, visit www.dolomite-microfluidics.com/en/design/competition 

 

cepheid

On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge

author2015-03-26authorposted by Sophie Woodward,

Cepheid and the National Health Laboratory Service (NHLS) in South Africa today recognised World TB Day 2015 by commemorating the global shipment of the 10 millionth Xpert MTB/RIF cartridge — which was received by Helen Joseph Hospital Laboratory in Johannesburg, South Africa. The Xpert MTB/RIF test runs on Cepheid’s GeneXpert® System, the world’s leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.

 

On World TB Day in 2011, the NHLS announced a national implementation programme to place GeneXpert Systems in all laboratories in the nine high-burden districts in South Africa.1 Since the programme began more than 300 GeneXpert instruments have been placed in over 200 sites. The National Health Laboratory Service is the largest diagnostic pathology service in South Africa with the responsibility of supporting the national and provincial health departments in the delivery of healthcare.

 

“The GeneXpert System adds clinical value to the NHLS as it provides a rapid turnaround time, thus increasing reliability and productivity of our organisation. The testimony to this is seen in the total of 5,353,517 specimens which have been processed from the commencement of our programme in March 2011 through February 2015,” said Sebaka Molapo, Project Manager of the National Priority

Programmes (NPP). “We are optimistic that GeneXpert technology will help us to achieve the 90–90–90 target in South Africa set by the National Department of Health (NDoH).”

 

“Tuberculosis is preventable and curable,” said John Bishop, Cepheid's Chairman and CEO. “Every year on March 24th the global community commemorates the date in 1882 when Dr. Robert Koch astounded the scientific community with his announcement that he had discovered Mycobacterium tuberculosis, the bacillus that causes tuberculosis. World TB Day is designed to build public awareness that tuberculosis remains an epidemic in much of the world. I am proud of the work that Cepheid's employees and partners have done to bring attention to the need for increased awareness of TB to the widest possible audience.”

 

Cepheid also announced the release of its RemoteXpert cloud-based monitoring software, which allows authorised agencies to view GeneXpert results in real-time for the purpose of tracking and monitoring emerging infections, including drug-resistant tuberculosis. In a pilot phase conducted from 2011-2014, RemoteXpert collected data from nearly 2.5 million TB cases in 3 countries.

 

“The detection of TB and drug resistance rates by location, in real-time, represents a major advance in the field of digital disease detection,” said Dr. David H. Persing, MD, Ph.D., Cepheid’s Chief Medical and Technology Officer. “We showed that Xpert MTB/RIF data collected from hundreds of systems could be nearly instantaneous, inherently objective, and potentially actionable.”

 

Current HBDC customers can now receive RemoteXpert connectivity free of charge if they have a service agreement.

 

Last October Cepheid, FIND, and Rutgers New Jersey Medical School announced details of a collaboration to develop Xpert® MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection.

 

Cepheid is also developing an additional test to specifically call out extensively drug-resistant (XDR) tuberculosis. XDR TB is a form of multidrug-resistant tuberculosis (MDR TB) that is resistant to the most potent TB drugs — isoniazid, rifampin, aminoglycosides, and any fluoroquinolone.

 

For more information on Cepheid’s entire menu of Xpert tests, visit www.cepheidinternational.com.

 

sonosite-fujifilm

Ultrasound ‘like an extra hand’ for sport and exercise medicine

author2015-03-25authorposted by Anna,

Advances in ultrasound technologies for musculoskeletal imaging have made point-of-care ultrasound systems a common sight in sport and exercise medicine (SEM) practices across the UK, and this rise in popularity has led the Faculty of Sport and Exercise Medicine to issue new guidelines for ultrasound use. Dr Jane Dunbar, a fellow of the Faculty and one of the few doctors recognised by the GMC as a specialist in SEM, shared her experiences of ultrasound: “I have been using ultrasound as part of my day-to-day practice for over 10 years, starting with SonoSite’s original 180PLUS hand-carried system. The change in image quality over that time has been huge, and the latest instruments – such as SonoSite’s EDGE® – offer excellent diagnostic capabilities and provide a powerful tool to help patients understand the nature of their injuries, whether they’re elite athletes, children with growth pains or older patients suffering with arthritis.”

 

“One of the biggest advantages of ultrasound for SEM is that it’s dynamic, allowing you to see what is happening in a moving joint in real time, often helping to diagnose small, insidious problems that might be missed by a static X-ray. A lot of my referrals are physiotherapy patients who are not responding as expected to treatment, and a quick scan is often enough to diagnose if there is a bigger issue, or to provide guidance on how to improve the rate of recovery. I also use it to guide joint injections, allowing me to precisely locate the needle in an area which will provide maximum benefit without causing discomfort, which is particularly useful for osteoarthritic joints. I wouldn’t be without an ultrasound system in my clinic now, it’s like an extra hand in my examinations.”

syrris

ICECHIM invests in flow chemistry with the Syrris Asia system

author2015-03-24authorposted by Sophie Woodward,

The modular Asia system from Syrris is providing researchers at the Romanian National Institute for Research and Development for Chemistry and Petrochemistry (ICECHIM) with the ability to explore a range of flow chemistry applications. Florin Oancea, Scientific Director at ICECHIM, explained: “Like many chemistry research groups, we are increasingly focusing on biochemistry and biorefinery applications, as fossil fuel-derived products will become more and more expensive in the future. Flow chemistry is the ideal solution to explore this approach, offering the flexibility to develop numerous applications and providing easy scale-up for process commercialization, particularly for the development of biological analogues of plant hormones for use in the Romanian agriculture sector.”

 

“We chose the Asia flow chemistry system because of its ability to provide options for mini-reactor, mini-column reactor and micro-reactor set-ups in a single platform: this level of flexibility is unique to the Asia products. Syrris’ close ties with its sister company Dolomite will also make it easier to integrate a microfluidics approach into our workflow, working with the support of both companies to accelerate our research. Although we are just beginning our journey with flow chemistry, we are investing in both our expertise and capabilities in this area, with the aim of fully exploring the potential of the Syrris technology.”

                                                    

dolomite

Dolomite’s microfluidics technology ideal for B cell encapsulation

author2015-03-24authorposted by Sophie Woodward,

A Dolomite droplet generation system is helping researchers at Weill Cornell Medical College in New York, USA, to encapsulate human and mouse B cells for the cloning of antibody genes. Associate Professor Moonsoo Jin from the Department of Radiology explained: “Some of our immunology research is focused on cloning antibody genes. In this work, it is important to ensure that individual genes are isolated from each other, and that is why we have adopted the droplet technology. It enables us to encapsulate a single human or mouse B cell, guaranteeing that antibody genes from one cell are not mixed with those from another cell.”

 

“Biology itself is difficult enough, and so when we needed a microfluidic system for a new project we looked for a droplet generation system that was straightforward to use and not too complex. We chose Dolomite, investing in Mitos P-Pumps and a quartz Droplet Junction Chip. We’ve had the system for about two years now, and our experience has been very positive. It is simple to use and reliable, and we've been able to generate stable, uniform-size droplets able to withstand subsequent molecular biology procedures in a very reproducible and robust manner. We plan to continue our work with B cells and, in the future, may also use the droplet generation system to look at T cells and T cell receptor diversity and specificity.”

 

For more information, visit www.dolomite-microfluidics.com.

tecan

See the light with Tecan’s Infinite® M200 PRO

author2015-03-24authorposted by Anna,

Tecan’s Infinite® M200 PRO reader has helped Californian company Sevident to establish rapid, sensitive immunofluorescence and colorimetric assays based on its proprietary NETs technology. Emily Stein, President and Chief Scientific Officer of Sevident, explained: “Our original plate reader was quite old and cumbersome to use, and so we decided to invest in a modern, up-to-date instrument more suitable for our multiplex assays, with the flexibility to perform colorimetric, luminescence- and fluorescence-based assays as our project requirements changed. After testing all the major brands, we chose the Infinite M200 PRO for its ease of use, sensitivity and precision. It allows us to change between different types of assay, accommodating our own fluorescence-based development programs and the colorimetric and luminescence-based programs of some of our partners. The flexibility of the reader’s software and the analytical prowess of Magellan™ also significantly influenced our decision to buy the system.”

 

“The Infinite M200 PRO is now one of the most widely used pieces of equipment in our R&D program. It has proved ideal for our purposes, and we are easily achieving sensitivities in the fmol/ml range. The local Tecan staff have been excellent too; the sales team is very knowledgeable, and the technical support has been really good. Everything has worked well, and I am very happy with the reader.”

 

To find out more on Tecan’s Infinite M200 PRO, visit www.tecan.com/infinite

sonosite-fujifilm

M-Turbo® de SonoSite très apprécié des footballers français

author2015-03-11authorposted by Anna,

Les footballers français bénéficient du système d’échographie au point d’intervention M-Turbo® de SonoSite, qui permet d’effectuer une évaluation rapide des blessures. Explications du Dr Franck Le Gall, médecin de l’équipe de football de Lille OSC et de l’équipe de France de football : « Lorsque vous suspectez une atteinte d’un muscle, d’un tendon ou d’un ligament, vous voulez voir ce qu’il se passe au niveau anatomique afin de compléter votre diagnostic clinique. L’échographie au lieu d’intervention est de loin la modalité d’imagerie la plus simple et la moins chère à utiliser, et beaucoup de médecins du sport l’utilisent désormais pour cette raison précise. Un autre avantage très important est que l’échographie est dynamique ; vous pouvez voir ce qu’il se passe lorsque les membres et les articulations sont en mouvement. »

 

« Si vous avez à vos côtés un appareil d’échographie et que vous savez qu’il va vous aider dans vos décisions et votre raisonnement, il faut se lancer ! C’est un examen très rapide et facile, qui n’a aucun effet indésirable ; il peut être pratiqué à plusieurs reprises sans que cela ne soit nocif pour le patient ou l’utilisateur. Un examen d’échographie ne prend que quelques minutes et nous pouvons parler des résultats tout de suite. C’est un avantage que les joueurs apprécient réellement, quand l’autre alternative pourrait être une IRM ; ils devraient alors se rendre à l’hôpital, ce qui leur prendrait plusieurs heures de leur journée. Avec l’échographie, ils peuvent voir ce qui se passe avec leur blessure, poser des questions pendant l’examen, et voir les améliorations au fur et à mesure du traitement. Globalement, cela leur fait gagner énormément de temps. »

tecan

Simplicity by design with Tecan’s HydroSpeed™ plate washer

author2015-03-10authorposted by Anna,

Melbourne-based Genera Biosystems has been testing a HydroSpeed™ plate washer with its Sirocco™ multiplexed diagnostics automation platform, allowing rapid, efficient washing of its proprietary AmpaSand™ beads. Karl Poetter, Chief Scientific Officer, explained: "Following PCR, AmpaSand plates are spun down to remove the supernatant, then washed to remove unbound reagents or PCR products prior to flow cytometry analysis. Manual bead washing is tedious and error-prone, and so we wanted to automate the post-PCR washing steps to provide the accuracy and reliability necessary for diagnostic applications. We needed an automated 96-channel plate washer that offered effective removal of unincorporated primers and reagents without disturbing the pellet, and the HydroSpeed washer from Tecan was the only system that met our specifications. It offers precise control over the wash parameters and needle positioning, allowing us to obtain very high bead retention rates and ensuring effective washing."

 

“We have successfully evaluated the HydroSpeed washer for integration with our Sirocco Automation System, and our aim now is to create a streamlined, compact and user-friendly platform that offers walkaway automation of the entire process, simply requiring the patient sample to be loaded onto the instrument. The Tecan team has always been positive and supportive of our automation efforts, and we are confident that their expertise will help us to develop this next generation of our automated system."

 

To find out more on Tecan’s HydroSpeed washer, visit www.tecan.com/hydrospeed

sonosite-fujifilm

Swansea Centre of Excellence relies on SonoSite ultrasound systems

author2015-03-10authorposted by Anna,

 

SonoSite’s point-of-care ultrasound systems play an important role in regional anaesthesia and chronic pain management at Morriston Hospital, Swansea. The Centre of Excellence uses a wide range of SonoSite systems – iLook®, MicroMaxx®, M-Turbo®, S­-Nerve™ and the recently launched X-Porte® – enjoying the benefit of increasingly advanced technology in applications where precise needle placement is essential. Consultant Anaesthetist Dr Christian Egeler explained: “Ultrasound technology is perfect for performing nerve blocks, and has revolutionised both regional anaesthesia and chronic pain management. Like many anaesthesia departments in the UK, we now use ultrasound-guided regional blocks for our routine hand surgical lists, and the financial savings are massive. We have recovered the cost of the ultrasound instrument several times over.”

 

Dr Simon Ford, also a Consultant Anaesthetist, added: “In addition to regional anaesthesia and pain management, ultrasound is used across the hospital for applications such as cardiac examinations, FAST scanning, and vascular access. This requires the ultrasound systems to be moved between different locations on a fairly frequent basis, and portability and robustness are essential. The SonoSite instruments are ideal from this perspective. The systems’ image quality is good, and they are intuitive and easy to use; you simply switch on and start scanning, which is a really big advantage.”

syrris

Syrris sets the scene for another exciting year

author2015-03-10authorposted by Anna,

Syrris, a world leader in laboratory-scale and flow chemistry systems, continues to go from strength to strength, achieving sales growth of 18 % during 2014 and best-ever sales of all its product lines – the modular Atlas and Globe batch reactors, bespoke custom reactor systems (CRS) and the revolutionary Asia range of flow chemistry products – culminating in the company’s most successful year to date.

 

Sales of Asia flow chemistry systems have increased by more than £1m year-on-year, aided by the release of several innovative modules during 2014; the Asia Tube Cooler and Asia Cryo Controller modules for sub-ambient reactions down to ­68 °C and ­100 °C respectively, and the Asia Flux, which combines continuous flow processes and electrochemistry. In addition, Syrris received a significant grant from the Advanced Manufacturing Supply Chain Initiative towards further development of novel flow chemistry systems. Users of batch chemistry products benefitted from the launch of the state-of-the-art Atlas Cryo Reactor, enabling laboratory-scale reactions to be performed at temperatures as low as -80 °C, while sister company Dolomite Microfluidics released a unique range of Micro Droplet Systems. The company also continued its popular educational program, hosting workshops in Denmark, Sweden, Switzerland, USA, UK, Canada, Germany, Belgium, France, Mexico and Japan, giving customers around the globe the opportunity to discover the advantages of flow chemistry. With such a solid foundation to build on, 2015 is set to be another very exciting year for Syrris.

sonosite-fujifilm

SonoSite’s NanoMaxx® ideal for paediatric retrievals in remote areas

author2015-02-24authorposted by Anna,

SonoSite’s NanoMaxx® ultrasound system is proving a key asset for ambulance and helicopter paediatric retrievals across Scotland, helping to ensure the safe transfer of patients from remote, rural sites. Jon McCormack, a Consultant in Paediatric Anaesthesia and Intensive Care Retrieval at the Royal Hospital for Sick Children, Edinburgh, explained: “The Paediatric Retrieval Service is responsible for the transport of critically ill and injured children across Scotland to the nearest paediatric intensive care unit, often from extremely isolated locations with no critical care facilities. While ultrasound equipment may be available, it is unlikely to be suitable for line placement in a baby or child, and so the Paediatric Retrieval Service invested in a NanoMaxx system that is taken to all call-outs.”

 

“For a retrieval service, portability, size and weight are important considerations. The system must also have a good battery life, as a retrieval can take several hours, during which time it may not be possible to charge the system. In addition, it should be easy to clean and water- wind- and drop-proof to a certain extent, as the system may be used both indoors and out, sometimes in extreme conditions. We’ve had the NanoMaxx for two or three years now, and it is ideal. It is very user friendly – just turn on and scan – allowing me to insert a line more rapidly and safely, with 100 % confidence that it is correctly placed.”

tecan

Tecan launches Cavro® Disposable Tips for OEM customers

author2015-02-24authorposted by Anna,

Tecan has created a range of Cavro Disposable Tips for use with the Company’s popular Cavro brand OEM components. Offering customers a selection of premium consumables to complement their Cavro Omni Robot and Cavro Air Displacement Pipettor (ADP) options, these high quality tips have been developed and validated to ensure optimal performance and reliable operation.

 

All Cavro Disposable Tips are manufactured to the same high quality standards as Tecan’s broad portfolio of consumables for life sciences customers, using state-of-the-art production processes and integrated quality control procedures to ensure consistent pipetting performance and provide complete peace of mind. The conductive polypropylene tips are available in a variety of tip volumes, and can be supplied in customer-branded packaging for large volume orders, providing a complete liquid handling solution to enhance your instrument design.

 

To find out more on Tecan’s Cavro Disposable Tips, visit www.tecan.com/CavroDiTi

bulgin

Elektron Technology awards EMEA Distributor of the Year prize to Farnell element14

author2015-02-17authorposted by Sophie Woodward,

Elektron Technology has named Farnell element14 as EMEA Distributor of the Year for 2014/2015. This inaugural award is in recognition of Farnell element14’s outstanding achievements over the past year, combining strong sales growth for Elektron Technology’s connectivity brands with exceptional customer support.

 

Farnell element14 has been offering Elektron’s Bulgin and Arcolectric connectivity brands for over 30 years, and currently stocks over 1,500 product lines, including the popular Buccaneer® 6000 and 7000 connectors, and the recently launched piezo switches. This long-standing relationship has helped both companies to ensure an exceptional service for their customers, while recent investments by Farnell element14 in both marketing and stock levels have helped to drive year-on-year sales growth, bringing the Bulgin and Arcolectric names to more customers than ever before.

 

Pete Johnson, EMEA Head of Sales for Elektron Technology, commented: “Farnell element14 and Elektron Technology have an outstanding business partnership. This award recognises the company’s fantastic achievements in terms of revenue growth, commitment to stock investment, new product introductions and brand promotion across the extensive range of Bulgin and Arcolectric connectors and switches, all of which have led to a significant expansion of our customer base.” 

 

Steve Herd, Global Product Director for Connectors at Farnell element14, added: “We are delighted to have been recognised as the Elektron Technology EMEA Distributor of the Year. The Bulgin and Arcolectric brands are integral to our product and customer proposition, and we continue to invest in deeper inventory and a broader portfolio of parts for design engineers and buyers to select from. We look forward to building on the successes of 2014 in the coming years, strengthening the partnership further still.”

 

 

For more information, please contact:

Elektron Technology, Woodland Road, Torquay, Devon, UK TQ2 7AY

Tel: +44 (0)1803 407700

connectivity@elektron-technology.com

www.elektron-technology.com 

sonosite-fujifilm

Besseres Point-of-Care-Ultraschalltraining in der Intensivmedizin

author2015-02-17authorposted by Anna,

Intensivmedizin ist ein interdisziplinäres Fachgebiet, was ein grundlegendes Verständnis von verschiedenen Elementen mehrerer Fachgebiete wie u.a. Anästhesie, Innerer Medizin und Chirurgie vereint. Das Anforderungsprofil eines Intensivmediziners erfordert daher das Erlernen einer Reihe von Fertigkeiten aus mehreren Disziplinen, um sie beim Kritisch kranken Patienten zeitnah bettseitig anwenden zu können. Dr. Sven Ballnus ist Chefarzt der Abteilung Intensivmedizin am Spitalzentrum Biel/Bienne, Schweiz und aktives Mitglied der Europäischen Gesellschaft für Intensivmedizin. Er erläutert den Bedarf für mehr Training bei Ultraschall in der Intensivmedizin: „Die Sicherung eines adäquaten Sauerstoffangebotes ist im Rahmen eines Schocks, gleich welcher Genese essentiell. Mit Hilfe einer bettseitig durchgeführten Ultraschalluntersuchung ist es möglich binnen weniger Sekunden die wesentlichen Determinanten des Blutflusses zu beurteilen und beispielsweise ein Problem in der Vorlast oder der Kontraktilität zeitnah zu detektieren. Dabei helfen die standardisierte Protokolle wie z.B. das FATE-Protokoll, da auch weniger erfahrene Mitarbeiter die Möglichkeit haben, sich mit diesen Techniken schnell und zuverlässig zu orientieren. Auf Boden dieser Orientierung kann dann eine rationale Strategie- und Therapieplanung erfolgen.“

Dr. Ballnus war vormals als Leitender Oberarzt für Anästhesiologie & Intensivmedizin an den Westküstenkliniken in Heide, Schleswig-Holstein, tätig und dort für die Entwicklung eines Ultraschallkurses verantwortlich, der sich auf die speziellen Bedürfnisse von problemorientierten Ultraschalltechniken im Umfeld der Akut- & Intensivmedizin bezog.

Die Unterstützung von Ultraschallgeräteherstellern – wie etwa SonoSite – ist unverzichtbar beim Ausbau von Bildungsinitiativen wie dieser, wie auch Dr. Ballnus sagt: „Mit der Bereitstellung von Leihinstrumenten für diese Kurse – und der Unterstützung der Ausbildung durch E-Learning-Ressourcen – kann sich ein Unternehmen aktiv an der Distribution solcher spezialisierten Kurse beteiligen. Ebenso wichtig ist ein enger Dialog für die Weiterentwicklung von Ultraschallgeräten im Hinblick auf die Anwendung zeitkritischer standardisierter Protokolle.“

 

Wenn Sie mehr zu den Point-of-Care-Ultraschallsysteme von FUJIFILM SonoSite sowie Weiterbildungsmöglichkeiten erfahren möchten, besuchen Sie Stand M19 in Halle 4 beim Symposium Intensivmedizin + Intensivpflege 2015 in Bremen vom 18. bis 20. Februar.

 

Für weitere Informationen über FUJIFILM SonoSite Produkte wenden Sie sich bitte an: eraf-sales@sonosite.com

 

syrris

Blacktrace Holdings acquires ChemiSens AB assets

author2015-02-16authorposted by Sophie Woodward,

Blacktrace Holdings Limited, a leading group of companies focused on Productizing Science®, is pleased to announce that with effect from 16th January 2015 it has acquired the assets of ChemiSens AB, based in Lund, Sweden. ChemiSens has a 30-year proven track record in the development, manufacture and supply of the highest performance reaction calorimeters. These sophisticated systems, which will now be supplied and supported via the Syrris brand, perfectly complement the Syrris product range.

 

Reaction calorimeters are used in a wide range of applications, including carbon capture and sequestration, biological performance, and chemical reaction kinetic and scale-up safety studies. The combined Syrris and ChemiSens product portfolio – from the straightforward, easy-to-use Atlas Calorimeter to the high performance CPA200 series – allows Syrris to meet customers’ differing needs and applications, whether an introductory or top-end calorimeter is required. And, with the company’s global presence and the knowledgeable Syrris support team, new and existing customers can be assured of continued worldwide access to professional advice.

 

Blacktrace is looking forward to working with existing ChemiSens partners, and intends to keep the current structure for the foreseeable future.

 

For more information about ChemiSens high performance reaction calorimeters, visit www.syrris.com/batch-products/chemisens-calorimeter.

bulgin

Bulgin extends Buccaneer® SMB Antenna range

author2015-02-12authorposted by Sophie Woodward,

Bulgin – an Elektron Technology connectivity brand – has launched an environmentally-sealed 90o SMB Antenna, offering greater flexibility in systems design for RF monitoring and control. Complementing the existing IP68-rated SMB Antenna, this new option is available to suit a variety of frequency bands – 2.4 GHz, 440-470 MHz and 900/1,800/1,900 MHz – and can be combined with the PX0414 SMB Buccaneer panel mounting connector to provide a completely waterproof and dustproof option for RF equipment.

 

David Luu, Product Marketing Analyst for Elektron, commented: “The Buccaneer SMB series of waterproof antennae has been developed to offer robust, hassle-free operation for industrial, scientific and medical instrumentation – as well as for smart meters, base stations and outdoor hotspot installations for wireless LAN, GSM and Bluetooth – ensuring exceptional performance and maximum system gain. This new option will simplify instrument design, helping to ensure straightforward installation and reliable operation for virtually any application.”

 

 

For more information about Bulgin products, please contact:

Elektron Technology, Woodland Road, Torquay, Devon, UK TQ2 7AY

Tel: +44 (0)1803 407700

connectivity@elektron-technology.com

www.bulgin.com

agar-scientific

Agar Scientific installs new scanning electron microscope, setting a new standard for quality control

author2015-02-11authorposted by Sophie Woodward,

Cutting-edge TESCAN VEGA3 SEM provides in-house quality control testing of Agar calibration standards and microscopy consumables

Agar Scientific, a leading supplier of microscopy equipment and consumables, has installed a brand new scanning electron microscope at its Stansted headquarters. The new SEM will allow Agar to further increase the standard of its quality control procedures, giving customers complete confidence in the products that the company supplies.

The new SEM – a TESCAN VEGA3 SBH – is already fully operational, and is being used to vet Agar’s range of gold-on-carbon and tin-on-carbon test specimens, which are vital for assessing SEM resolution. A full-time, in-house SEM operator performs thorough quality control checks to verify the particle size range present in the calibration standards manufactured by Agar, as well as checking for contaminants and physical defects.

The TESCAN VEGA3 SBH is also used to perform spot checks on the wide variety of other SEM consumables manufactured and distributed by Agar, from filaments to finder grids.

By upgrading its in-house SEM facilities to the very latest generation of technology, Agar can offer its customers the highest possible standard of service and total peace of mind.

sonosite-fujifilm

Experte für Regionalanästhesie demonstriert Scantechniken mit SonoSite-Ultraschallsystemen auf dem Symposium Intensivmedizin + Intensivpflege 2015

author2015-02-11authorposted by Anna,

Besucher des Symposiums Intensivmedizin + Intensivpflege 2015, das vom 18. bis 20. Februar in Bremen stattfindet, haben die Gelegenheit, Dr. Wolf Armbruster, ein Spezialist für anästhesiologische Ultraschallanwendungen, kennen zu lernen. Er demonstriert Scan- und Interventionstechniken am Stand von FUJIFILM SonoSite (Stand M19 in Halle 4).

 

Dr. Armbruster ist Spezialist im Bereich Regionalanästhesie, navigierte Gefäßzugänge und dem Einsatz von Ultraschall in der Notfallmedizin. Er ist zertifizierter DEGUM-Kursleiter und wird Scans mit den SonoSite Point-of-Care-Ultraschallinstrumenten durchführen, die er auch selbst in seiner täglichen Praxis und bei Ultraschallkursen in ganz Deutschland anwendet. Dr. Armbruster, Chefarzt im Evangelischen Krankenhaus in Unna, sagt: „Ich arbeite routinemäßig jeden Tag mit den SonoSite-Ultraschallsystemen und kann damit gute, extrem schnelle und detaillierte Entscheidungen auf Grundlage der Bilder treffen. Ich möchte auch meine Kollegen für Ultraschall begeistern und Diagnostik und Interventionen mit Ultraschall als unentbehrliche und leicht zugängliche Techniken vorstellen. Außerdem führe ich regelmäßig Ultraschallkurse sowie Live-Scanning-Vorführungen auf Messen durch.“ Sein systematisches Lehrbuch zum Ultraschall in der Anästhesiologie: Grundlagen, Nadelnavigation, Gefäßpunktionen, Nervenblockaden, Atemnotdiagnostik, wird im April 2015 auf dem Buchmarkt erscheinen.

 

Neben den praktischen Vorführungen von Dr. Armbruster stellt FUJIFILM SonoSite auch die innovativen Point-of-Care-Ultraschallsysteme X-Porte®, M-­Turbo, Edge®, S Series™ und NanoMaxx® vor. Ein weiterer Schwerpunkt bildet das Weiterbildungsangebot von SonoSite, wie etwa die SonoAccess™-App und der FUJIFILM SonoSite-Kanal auf YouTubeDE.

 

Wenn Sie Dr. Armbrusters Demonstrationen sehen und mehr über die Point-of-Care-Ultraschallsysteme von FUJIFILM SonoSite sowie Weiterbildungsmöglichkeiten erfahren möchten, besuchen Sie Stand M19 in Halle 4 beim Symposium Intensivmedizin + Intensivpflege 2015.

 

Für weitere Informationen über FUJIFILM SonoSite Produkte wenden Sie sich bitte an: eraf-sales@sonosite.com

dolomite

Dolomite launches Educational Microfluidic Starter Kit

author2015-02-10authorposted by Sophie Woodward,

Microfluidic's specialist Dolomite has created a low cost kit aimed at educational initiatives or those new to microfluidics. The Educational Microfluidic Starter Kit offers connect­and­go microfluidic capabilities, allowing easy set-up without the need for specialist tools or a gas supply.
The compact, highly portable system enables users to create small droplets, mix fluids or observe microchannel flow, allowing them to investigate or demonstrate a wide range of microfluidic applications. It offers customers the flexibility to choose between using either their own PDMS (polydimethylsiloxane) chips – with the PDMS Chip Interface – or Dolomite’s range of glass chips, including 2 Reagent Droplet Chips, Micromixer Chips and Y-Junction Chips. Powered and controlled via the Mitos Fluika Control Software using a USB port, the kit represents the ideal microfluidic starter system, offering exceptional value with a modular, flexible design that can be tailored to a variety of applications.
The Educational Microfluidic Starter Kit is accompanied by an application note – Introduction to Mixing and Droplet Production in Microfluidics – which gives a taste of some basic principles of microfluidics, demonstrates simple, robust and dependable set-up configurations, and shows how to achieve reliable droplet production and fluid mixing.
For more information, visit http://www.dolomite-microfluidics.co.uk/webshop/educational_microfluidic_starter_kit

tecan

Tecan launches Spark™ 10M reader at SLAS 2015

author2015-02-09authorposted by Anna,

 

Visit Tecan on booth #623 at SLAS 2015 to see the new Spark™ 10M multimode microplate reader. This all-new platform is designed to offer greater flexibility and increased productivity for cell biology and genomics customers. From microbiology research and cell-based assays to rapid DNA quantification, the Spark 10M delivers a combination of advanced capabilities and exceptional ease-of-use to simplify your daily work. 

At the heart of the Spark 10M are Tecan’s unique Fusion Optics which offer users the choice of filter- or monchromator-based measurements – or even a combination of both – at the touch of a button, meaning laboratories no longer have to make a trade-off between flexibility and sensitivity. This cutting-edge system is complemented by patent-pending High Speed Monochromators (HSM) which provide a complete absorbance scan, from 200 to 1,000 nm, in under five seconds.

 

The Spark 10M reader has been developed from the outset with cell-based assays in mind, and includes a host of software and hardware features designed to simplify cell biology protocols. It combines precise temperature regulation and plate shaking options with a fully integrated Gas Control Module (GCM™), offering advanced in-reader incubation capabilities for walkaway, long-term studies. Productivity and reproducibility are further improved by the addition of a humidity cassette and automated lid handling, helping to precisely balance gas exchange and provide exceptional evaporation protection. For even greater efficiency, the Spark 10M also features a bright-field cell counting module which uses Tecan’s disposable Cell Chip™ devices to provide rapid, label-free cell counting and analysis. Controlled by the system’s user-oriented SparkControl™ software and intuitive touchscreen interface, these advanced features make it easier than ever before to set up and run even complex assay protocols, with one-click operation and remote control for even greater efficiency and productivity.

 

To find out more about Tecan’s Spark 10M multimode reader, visit booth #623 at SLAS 2015 or go to www.tecan.com/spark

sonosite-fujifilm

SonoSite’s M-Turbo® helps to transform musculoskeletal services

author2015-02-06authorposted by Anna Corniani,

Hertfordshire Community NHS Trust’s specialist musculoskeletal (MSK) service is benefitting from a SonoSite M-¬Turbo® point-of-care ultrasound system, as Sport and Exercise Medicine (SEM) consultant Dr Stephen Chew explained: “Our primary care-based ‘one-stop’ SEM clinics were introduced to help reduce the number and improve the quality of orthopaedic referrals, as well as to enable swift initiation of treatment for a wide range of MSK conditions. Ultrasound scanning plays a key role in this, aiding diagnosis and patient education, and allowing image-guided injections to be performed in the clinic. As we operate from several locations, the M-Turbo’s portability and robustness are ideal, and its straightforward, intuitive interface gives us the capability to just switch on and start scanning, which makes all the difference when time is short.”

Dr James Noake, a fellow SEM consultant, continued: “The MSK service has been running for three years now, and is proving very popular. Inappropriate physiotherapy referrals and first appointment physiotherapy waiting times have reduced significantly, generating considerable cost savings for the Trust. At the longest established clinic, orthopaedic referral rates dropped to – and remain at – 50 % of the rate prior to the introduction of the service. Patients benefit too, receiving balanced, holistic care in an easily accessible, familiar environment close to home, with swifter access to specialist assessment and treatment. Diagnostic ultrasound and therapeutic injections are provided at the point of care, supported by priority access to physiotherapy and, if necessary, prompt referrals to appropriate secondary care.”

For more information about FUJIFILM SonoSite products, please contact:
FUJIFILM SonoSite Ltd
T +44 (0)1462 341151,
 ukresponse@sonosite.com www.sonosite.co.uk

syrris

Syrris' free flow chemistry workshops in high demand

author2015-02-05authorposted by Sophie Woodward,

Syrris, a world leader in flow chemistry product innovation, enjoyed another successful global series of flow chemistry seminars in 2014. These free events, which combine theoretical discussion with hands-on sessions, enabled chemists to develop their understanding of the many and varied benefits of flow chemistry.

Flow chemistry has emerged as an exciting technology for research and development chemists over the last decade, enabling a wide variety of chemical reactions to be quickly and easily performed, as well as allowing integration of synthesis, work-up and analysis in a single workflow. As a market leader in the sector, Syrris has been offering free flow chemistry seminars for three years, and the 2014 series – which included events in Denmark, Switzerland, USA, UK, Germany, Belgium, France, Mexico, Sweden and Japan – proved more popular than ever. Delegates from a wide range of backgrounds took advantage of the company's extensive knowledge and experience to learn how to perform reactions that are not possible using traditional techniques, seeing for themselves how flow chemistry can provide safer, faster and cleaner reactions.

Dr Laure Théveau, a postdoctoral fellow at the KTH Royal Institute of Technology, Sweden, attended the Stockholm workshop and commented: “Flow chemistry is becoming increasingly common in scientific literature, and I was keen to learn more about the technique. Both the theoretical and practical sessions were very complementary, combining clear explanations and an overview of the technique with detailed technical information and advice on troubleshooting. I would certainly recommend the workshops to anyone looking at implementing flow chemistry methods in their laboratory.”

To find out about our upcoming workshops for 2015, please visit www.syrris.com/news/chemistry-workshops or email workshop@syrris.com

dolomite

A novel approach to 3D cell culturing using the Dolomite Micro Droplet System

author2015-01-27authorposted by Sophie Woodward,

Biotechnology service provider Bioneer A/S, based in Hørsholm, Denmark, is taking advantage of the exceptional microfluidics capabilities of Dolomite’s Micro Droplet System to reliably encapsulate cells in gelatin hydrogels, enabling 3D cell culture growth in a straightforward, easy-to-handle format. The project is part of the OPTISORT Eurostars project, which sees Bioneer and Dolomite working in partnership with optical cell sorting specialist OptoRobotix to develop novel optically-based technologies for advanced cell sorting.

This latest innovative technique relies on the formation of precisely controlled hydrogel droplets using Dolomite’s microfluidic chips and flow control technology. Flemming Jørgensen, Project Manager at Bioneer, explained: “Encapsulation of protein-producing cells inside gelatin micro droplets offers an affordable, easy to manipulate 3D cell culture technology for non-adherent cells. The small size of the droplets makes it easy for nutrients to diffuse into the droplets from the surrounding medium, and for cellular products to diffuse out, while providing a distinct 3D environment for cell growth. This technology has potential applications for the sorting and isolation of, for example, cells with very high protein yields, and we have already shown the Chinese hamster ovary (CHO) cell cultures continue to grow within this gel matrix with good viability.”

“Starting with a premixed cell suspension containing 6 % gelatin, the Micro Droplet System is used to create droplets approximately 200 μm in diameter. Addition of a cross linker shortly before droplet production results in the formation of soft hydrogel particles containing just a few cells – or even individual cells if desired, depending on the starting concentration – which are then resuspended in fresh cell medium. Dolomite’s microfluidics technology makes droplet production very easy, allowing us to quickly produce large numbers of droplets for downstream analysis.

For more information, visit www.dolomite-microfluidics.com.

tecan

Tecan introduces Fluent™ Laboratory Automation Solution for compound management

author2015-01-21authorposted by Sophie,

Tecan will soon be launching a new Fluent™ Laboratory Automation Solution designed to offer greater throughput and flexibility for compound management workflows*. Building on the success of the Fluent™ cell-based assay workstation launched in summer 2014, this second application-oriented system introduces a number of new hardware and software options that simplify and improve the productivity of compound management and assay plate generation activities. The compound management workstation is ideally suited to drug discovery laboratories and centralized compound library facilities, offering a host of features intended to streamline day-to-day activities such as daughter plate generation, plate reformatting and hit picking.

Liquid handling versatility has been increased with the introduction of washable fixed tips for the instrument’s Flexible Channel Arm. Complementing the existing disposable tip options to provide cost-effective reagent and compound distribution – as well as cap piercing capabilities – the new fixed tips are also available in a low volume option, offering reliable pipetting below 0.5 µl to help minimize compound consumption and enable effective serial dilutions. Labware logistics have also been enhanced with the addition of a tube handling option for the Robotic Gripper Arm (RGA) and a Stacker for SLAS-format labware, which is ideally suited to high capacity tip storage for increased walkaway times.

These new hardware options are fully supported by the platform’s FluentControl™ software, which includes a number of new applications and pre-programmed ‘Smart Commands’ intended to streamline day-to-day activities such as plate replication, plate reformatting and hit picking. To simplify integration with upstream and downstream processes, the software will also support both worklisting and 2D barcode scanning, ensuring the Fluent Laboratory Automation Solution for compound management fits seamlessly into even the most demanding of workflows.

To find out more about Tecan’s Fluent Laboratory Automation Solution, visit www.tecan.com/fluent.

quotient

Sunesis Pharmaceuticals selects Quotient Clinical’s real-time adaptive manufacturing to support its vosaroxin clinical mass balance/ADME program

author2015-01-21authorposted by Sophie Woodward,

Quotient Clinical, the Translational Pharmaceutics® Company, and Sunesis Pharmaceuticals have announced the initiation of a clinical mass balance/ADME trial for vosaroxin – a candidate therapeutic for acute myelogenous leukemia (AML).

For this program, Quotient will employ its real-time adaptive manufacturing approach to supply 14C radiolabeled vosaroxin to a specialist oncology clinic in the Netherlands. The intravenous product will be manufactured on a per patient basis, and supplied to the clinic ready for dosing within less than two weeks of patient notification. This approach offers the most efficient use of the radiolabeled drug, and tailors drug product manufacturing to ongoing patient recruitment.

Mark Egerton, CEO of Quotient Clinical, commented: “Vosaroxin represents an exciting potential therapeutic option for AML patients, and we are delighted to be supporting Sunesis on its clinical mass balance/ADME program. Our real-time adaptive manufacturing approach offers increased flexibility and enables customization of drug product supply to the requirements of individual patients and trials.”

Gene Jamieson, Vice President of Technical Operations at Sunesis Pharmaceuticals, added: “Working with Quotient Clinical will help to accelerate the clinical mass balance/ADME program for this promising therapeutic. The Companys real-time manufacturing capabilities will ensure efficient, cost-effective and timely delivery of radiolabeled vosaroxin to the clinic, allowing faster treatment of patients as they are enrolled into the study."

dolomite

Dolomites microfluidics technology helping to advance antibody therapeutics

author2015-01-13authorposted by Sophie Woodward,

Dolomite's droplet generation system is helping AbVitro to identify potential therapeutic targets using its AbPair technology. Dr Adrian Briggs, Director of Molecular Biology R&D at AbVitro, commented: "Our aim is to develop new potential targets and therapies for a wide range of diseases, taking advantage of the specificity and sensitivity of the human immune system. To identify complete functional antibodies – pairing the correct heavy and light chains – we use a molecular barcoding technique that requires isolation of individual B or T cells. Achieving this with a flow sorter and microplate format is extremely slow and laborious, and so we looked for a reliable microfluidics solution that would enable much higher throughput."

"We investigated the various systems available, and Dolomite seemed to be the most highly engineered, optimized and mature technology. Very precise control of pressure is crucial to reproducible, reliable droplet formation, and Dolomite offers high quality pumps, flow sensors and microfluidics chips, all fully automated via the Company's software."

"Since its introduction, the system has been in use almost constantly, and we have been very happy with the performance. The systems quartz chip, in particular, is very robust and long-lasting – we have been using the same chips since we first started – and the computer-controlled Mitos P-Pumps with flow sensors offer outstanding reproducibility. Using this set-up, we can process in excess of a million cells per experiment, allowing us to obtain over 300,000 full-length, natively-paired antibodies from a single sample. This kind of throughput would be impossible with traditional methods, as the cost and time required would be prohibitive, as well as having a poor success rate. Having a robust emulsion hardware solution has saved us significant research and development time, allowing us to proceed to product development and partnerships in studies of human disease sooner.”

For more information, visit www.dolomite-microfluidics.com

sonosite-fujifilm

Point-of-care ultrasound guides relief in Nepal

author2015-00-20authorposted by Anna ,

A group of anaesthetists affiliated with the plastic surgery charity ReSurge International took a SonoSite point-of-care ultrasound system with them to help care for high risk patients caught up in the Nepal earthquakes in April 2015. The trip, funded largely by the Royal College of Anaesthetists and Association of Anaesthetists, was to Nepal’s main plastic surgery hospital at Kirtipur, which became a trauma centre in the wake of the first earthquake.

 

Joe Silsby, a consultant in anaesthesia and intensive care at Musgrove Park Hospital in Taunton, has already made several trips with the charity. He explained: “We weren’t sure what we would face when we arrived in Kirtipur, but I was fairly sure that ultrasound equipment would be helpful. We arrived a week after the first earthquake; many of the patients we saw came from remote areas where they had no immediate access to medical care following their initial injury. By the time they got to Kirtipur, their wounds were often badly infected, largely due to the humid and hot environment and poor sanitation, and they typically required soft tissue debridement or skin grafts. There were also ‘routine’ patients whose procedures had been put off since the disaster, simply because the whole system was under such stress. We were there to ease this backlog and give the Nepalese doctors a much-needed break, and were still there during the second earthquake.”

 

“We used the SonoSite system primarily to guide regional anaesthesia and pain relief in limbs – supraclavicular, distal tibial nerve and popliteal blocks. While many still needed a general anaesthetic, ultrasound-guided regional anaesthesia was ideal for high risk individuals, and became the anaesthetic of choice for the older, frailer patients – particularly those with isolated injuries – allowing procedures to take place under light sedation. The Kirtipur hospital does not have any ultrasound equipment but hopes to get a point-of-care system in the future, perhaps through charitable funding, for guiding intravenous access as well as anaesthesia. Medical equipment gets treated rather brutally in developing countries; servicing is frequently inadequate and machines need to be extremely hard-wearing and easy to maintain. Something like SonoSite’s NanoMaxx system is ideal for this kind of setting; it’s small, portable and very robust.”

sonosite-fujifilm

Meet FUJIFILM SonoSite at Intensive Care Society winter meeting

author2014-11-25authorposted by Sarah,

Join FUJIFILM SonoSite on stand #27 at the Intensive Care Societys The State of the Art Meeting to see the Companys range of bedside and point-of-care ultrasound systems. Held at the ExCeL Centre, London, from the 8th to the 10th of December, this event is the UKs largest gathering for intensive care professionals, and features international key note speakers, poster presentations and research awards and grants alongside the exhibition.

Join FUJIFILM SonoSite on stand #27 at the Intensive Care Societys The State of the Art Meeting to see the Companys range of bedside and point-of-care ultrasound systems. Held at the ExCeL Centre, London, from the 8th to the 10th of December, this event is the UKs largest gathering for intensive care professionals, and features international key note speakers, poster presentations and research awards and grants alongside the exhibition.
Visitors to the FUJIFILM SonoSite stand will be able to explore the benefits of the Companys range of point-of-care ultrasound systems for use in critical care settings, including the X¬Porte® – now with five new transducers – M¬-Turbo®, Edge® and S Series™ instruments. For those wishing to further their knowledge of ultrasound, there will also be information on FUJIFILM SonoSites educational initiatives, from training courses focusing on various techniques or specialties to the new SonoAccess™ 2.0 app which provides video tutorials, clinical image galleries and case studies to aid diagnosis and monitoring of high dependency patients.
For more information about FUJIFILM SonoSite products and services, visit stand 27 or go to www.sonosite.co.uk.

knf

KNF’s RC900 Rotary Evaporator proves popular at Oxford

author2014-11-19authorposted by Anna,

Organic chemists at the University of Oxford are benefitting from the recent acquisition of an RC900 Rotary Evaporator from KNF Lab. As one of the UKs premier academic centres for research into organic chemistry, the Chemistry Research Laboratory is engaged in a range of organic synthesis projects. Rotary evaporators are essential for this work, and the RC900 Rotary Evaporator, launched at Analytica in April this year, is a key addition to the laboratory. Charlotte Zammit, a D.Phil. student working in the laboratorys Steve Davies Group, explained: “As a chemist involved in organic synthesis, I frequently use rotary evaporators. They are one of the most commonly used pieces of equipment in the laboratory, and are always in demand.”
“We have had the RC900 Rotary Evaporator for a few months now, and I find it really easy to use. The system is designed to make attaching and detaching the round bottom flask simple, with a clip-on facility to avoid putting any strain on the glassware. It also has a number of automatic features which are really useful; functions such as the pressure that have to be set manually on other systems can be set automatically for the RC900 when used in conjunction with the SC920 vacuum system, on the RC900, which is a nice touch. I am very pleased with it.”

tecan

Simplifying SPR experiments with the HP D300 from Tecan

author2014-11-18authorposted by Anna,

The Structure and Biophysics department at AstraZeneca R&D Mölndal, Sweden, is reaping the benefits of a recently acquired HP D300 Digital Dispenser for surface plasmon resonance (SPR) studies, saving time, enhancing consistency and using significantly less compound for dose-response experiments. Principal Scientist Stefan Geschwindner explained: “The need for the HP D300 Digital Dispenser was largely driven by a demand for more effective SPR studies and increased flexibility. We already had an acoustic dispenser, but this was not ideal, as there are peaks and troughs in our work, and we needed an economical solution that could accommodate these changing demands. Tecan provided an instrument for us to try, and people immediately saw the benefits, realizing that the HP D300 could really change our way of working, helping to generate data more rapidly and shorten lead times.”
“The HP D300 is very easy to use and saves us so much time. It gives us the flexibility to use very low concentration stock solutions and perform different dilution patterns, and the instrument does all the calculations for us. Another big advantage is that we save a lot of material, which is particularly important when the amount of compound available is limited. The HP D300 can even recover any solution that has not been dispensed, which is brilliant. The savings are tremendous and, other than manual pipetting, this is probably the only effective way to prepare our dose-response curves.”
To find out more about the HP D300 Digital Dispenser, visit www.tecan.com/digitaltitration

cepheid

Cepheid to Develop Xpert Ebola for Countries Worst Hit by Epidemic

author2014-11-17authorposted by Sophie,

Cepheid (NASDAQ: CPHD) today announced that it has been awarded a grant of up to $3.3 million co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert® Ebola, a rapid test that could be run on Cepheid’s installed base of more than 3,500 GeneXpert® Systems in developing countries, including more than 1,000 in Africa. The test is expected to be offered on an emergency use only basis.
“While we are all hopeful that the Ebola epidemic dissipates quickly, we welcome the opportunity to develop an accurate, rapid and easy-to-use test with the potential to strengthen the arsenal of tools being deployed to address the current situation,“ said John Bishop, Cepheid’s Chairman and CEO. "Cepheid has historically played a leading role in developing molecular diagnostics as an aid to infection control efforts, and the current Ebola crisis represents an extreme example of the need for sensitive, rapid, and easy to use diagnostics to inform patient management and isolation requirements."
“Cepheid is well positioned to respond quickly to this urgent imperative. We are leveraging our significant investments in development of ultrasensitive HIV and TB detection technologies, and are borrowing on previous experience with an Ebola project to expedite delivery of the initial prototype and emergency use only product,” said David Persing, MD, PhD, Cepheid’s Chief Medical and Technology Officer. "We expect this technology to facilitate high throughput testing requirements of Ebola Treatment Units, as well as deployment of mobile laboratories for field surveillance."
In addition to Xpert Ebola, Cepheid and the Gates Foundation are evaluating deployment of Cepheid’s RemoteXpert cloud-based monitoring software, currently implemented for TB testing on a pilot basis in South Africa and India. In the pilot phase, RemoteXpert has collected realtime data streams from nearly 2.5 million cases being evaluated for tuberculosis and drug resistance. RemoteXpert could enable authorized agencies, for the first time, to access realtime testing activity and geopositioned Ebola test results in order to track the spread of the virus and the effectiveness of ongoing efforts to contain it.
A more comprehensive view of the test’s features will be available as the project progresses, but Cepheid currently expects the sample type for Xpert Ebola to be an oral swab or capillary whole blood specimen in order to avoid needle exposure and venipuncture.

sonosite-fujifilm

SonoSite helps clinicians make the grade

author2014-11-13authorposted by Anna,

Delegates attending the Derby Ultrasound in Critical Care (DUCC) training courses are gaining valuable hands-on experience using SonoSite’s point-of-care ultrasound systems, as Course Director Craig Morris explained: “I began using echocardiography about 10 years ago. The FATE (Focus Assessed Transthoracic Echocardiography) Protocol had just been published, and the whole notion that non-cardiologists could deliver point-of-care ultrasound was really exciting. Ultrasound is a mainstream technology now – I use SonoSite’s X-Porte™ and Edge® systems in my daily practice at the Royal Derby Hospital – and, with the introduction of accredited courses, training has become more formalised.”

“DUCC is an independent organisation offering courses in echocardiography and lung

 

For more information about FUJIFILM SonoSite products, please contact: FUJIFILM SonoSite Ltd T +44 (0)1462 341151, ukresponse@sonosite.com www.sonosite.co.uk

dolomite

Dolomite’s Resealable Chip Interface offers easy access to microfluidic chip surface

author2014-11-10authorposted by Sophie,

Dolomite – the pioneering microfluidics specialist – has launched a Pressure-driven Resealable Chip Interface System designed for applications requiring quick and easy access to the microfluidic chip surface. Compact and robust, this easy-to-use system enables tool-free assembly of glass, quartz or polymer resealable chips, allowing the user to deposit reagents, sensors, biosensors or cells onto the chip base layer for exposure to the fluid stream.

The modular, flexible system comprises a Resealable Chip Interface – allowing up to eight fluidic and eight electrical connections per chip – 4-way linear connectors, and Mitos Pressure Pumps for pulseless, stable flow from 70 nl to 5 ml a minute, at pressures of up to 10 bar. For direct, accurate control of flow rates, Mitos Flow Rate Sensors can also be included. The versatile Resealable Chip Interface System is ideal for a broad range of applications, including biosensor testing, cell culture analysis, dielectrophoresis experiments, impedance detection and applications where cleaning or replacement of some parts of the system is required between experiments. The system is also compatible with a range of microscope systems – for straightforward imaging and recording – and Dolomite’s optional Mitos P¬Pump Remote Chambers, which allow up to 30 ml of fluid to be conveniently located in a pressurised, sterile environment for easy temperature control or agitation, ensuring you can develop a set-up to meet your application needs.

For more information, visit http://www.dolomite-microfluidics.com/webshop/resealable_chip_interface_system

avacta-animal-health

Discover the unique SENSITEST® canine Lymphoma Blood Test from Avacta Animal Health at the London Vet Show 2014

author2014-11-06authorposted by Sophie,

Avacta Animal Health is delighted to be exhibiting at this year’s London Vet Show (LVS), held at Olympia, London, from the 20th to the 21st of November. Visitors to Stand H43 will be able to meet the Avacta team and learn more about the benefits of the Company’s innovative SENSITEST® canine Lymphoma Blood Test (cLBT). This unique test is the subject of an early view, open access paper – published online by Veterinary and Comparative Oncology1 – discussing the results of a blinded retrospective study using the simple, relatively non-invasive cLBT to investigate remission and recurrence of lymphoma in dogs undergoing chemotherapy. The study confirmed the test’s suitability as a cost-effective aid to monitoring lymphoma status. In addition, delegates will be able to discover the advantages of Avacta’s SENSITEST complete allergy tests, which assist in the diagnosis and management of allergies in companion animals.

Avacta is also a sponsor of the LVS Borneo Adventure competition, offering delegates the chance to win a £12,000 trip of a lifetime for two people – a 12-day working holiday to Borneo with Worldwide Veterinary Service. To enter, simply collect a stamp from each participating sponsor in your LVS passport.

To learn more about SENSITEST cLBT and SENSITEST complete allergy tests – and complete you LVS passport – visit Avacta on Stand H43.

tecan

An antioxidant assay for the real world with Tecan’s Infinite M1000® PRO

author2014-11-04authorposted by Anna,

Researchers at the French Agricultural Research Center for International Development (Centre de coopération internationale en recherche agronomique pour le développement, CIRAD) have used an Infinite M1000® PRO multimode microplate reader to develop a simple CAT (conjugated autoxidizable triene) assay allowing direct measurement of the antioxidant capacity of plant extracts and pure molecules1. Based on UV absorption, this rapid test is performed in a microemulsified system and uses an oxidizable lipid substrate – stripped tung oil – to more accurately reflect in vivo activity.
Mickaël Laguerre, who developed the CAT assay, explained: "The aim was to create a simple, relevant method that could be easily transferred to other labs or even used for routine measurements in industry. The method requires a microplate reader with very precise temperature regulation, and Tecan’s Infinite M1000 PRO was the best fit for our needs, combining format flexibility and excellent temperature control with monochromator-based optics. This set-up is ideally suited to assay development, as it allows complete freedom in wavelength selection, and also makes it more versatile for other research activities. The ability to evolve the instrument as your needs change – adding fluorescence, luminescence or polarization functions – is also a significant advantage, as your assay development choices are not limited by the reader."
To find out more on Tecan’s Infinite M1000 PRO, visit www.tecan.com/infinitem1000pro

Point-of-care ultrasound helps emergency care at King's College Hospital

author0000-00-00authorposted by Caroline,

The Emergency Department at King's College Hospital NHS Foundation Trust is a busy trauma centre dealing with over 400 cases every day. Point-of-care ultrasound has been used in the department of over 10 years, and now forms an integral part of many patient assessment pathways. Emergency Medicine Consultant Dr George Nada explained: “We currently use ultrasound for four main activities: FAST scans, insertion of peripheral lines, AAA screens and basic echocardiography, but it also has applications in many other areas, such as guiding the placement of chest drains, ascetic taps and femoral nerve blocks.” 

 

“We first started using ultrasound in late 2004, just for FAST scans and, approximately 18 months later, for pneumothoraces too. Around the same time, our ICU began using it for central line placement, and we soon followed suit for peripheral lines. We have used point-of-care ultrasound systems for almost all of this time, and the improvements – particularly in image quality – have been very impressive. Our latest system has the added advantage of a large screen which makes it very easy to see the structures of interest during a procedure. Its built-in learning modules are also excellent; new registrars coming into the department can simply work through the tutorials, and don’t need any specific training on how to use the instrument.”

 

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

eraf-sales@fujifilm.com  www.sonosite.com/uk

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

Point-of-care ultrasound helps emergency care at King's College Hospital

author0000-00-00authorposted by ,

The Emergency Department at King's College Hospital NHS Foundation Trust is a busy trauma centre dealing with over 400 cases every day. Point-of-care ultrasound has been used in the department of over 10 years, and now forms an integral part of many patient assessment pathways. Emergency Medicine Consultant Dr George Nada explained: “We currently use ultrasound for four main activities: FAST scans, insertion of peripheral lines, AAA screens and basic echocardiography, but it also has applications in many other areas, such as guiding the placement of chest drains, ascetic taps and femoral nerve blocks.” 

 

“We first started using ultrasound in late 2004, just for FAST scans and, approximately 18 months later, for pneumothoraces too. Around the same time, our ICU began using it for central line placement, and we soon followed suit for peripheral lines. We have used point-of-care ultrasound systems for almost all of this time, and the improvements – particularly in image quality – have been very impressive. Our latest system has the added advantage of a large screen which makes it very easy to see the structures of interest during a procedure. Its built-in learning modules are also excellent; new registrars coming into the department can simply work through the tutorials, and don’t need any specific training on how to use the instrument.”

 

For more information about FUJIFILM SonoSite products, please contact:

FUJIFILM SonoSite Ltd

T +44 (0)1462 341151, 

eraf-sales@fujifilm.com  www.sonosite.com/uk

 

About FUJIFILM SonoSite

SonoSite helped pioneer the concept of portable, point-of-care ultrasound, and it continues to be a world-leading manufacturer and innovator of bedside ultrasound systems as well as an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM SonoSite, Ltd., a wholly owned subsidiary of FUJIFILM SonoSite, Inc. oversees a direct sales distribution network in the UK and provides sales and marketing support.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

Sonosite logo

Point-of-care ultrasound systems prove ideal for the Children’s Acute Transport Service

author0000-00-00authorposted by Caroline,

The Children’s Acute Transport Service (CATS) depends on point-of-care ultrasound systems to get quick and accurate vascular access in critically ill children being transferred to specialist treatment centres. Advanced Nurse Practitioner Cathy Roberts explained: “In the UK, paediatric intensive care is provided at centralised units, and children needing this care must be safely transferred there by people with appropriate knowledge and skills. CATS provides a retrieval service for the North Thames area, transferring around 1,200 critically ill children a year from regional hospitals to those offering paediatric intensive care, such as Great Ormond Street, St Mary’s, the Royal Brompton, the Royal London and Addenbrooke’s.”

 

“Successful vascular access is vital for patient retrievals, and we frequently need to insert central or arterial lines as we stabilise children prior to transfer. I learned how to obtain vascular access under ultrasound guidance through a combination of supervised practice and a SonoSite training course. The training course was excellent, giving me the opportunity to practice different ways of holding the probe in the safety of a non-clinical environment, and discover various tips to help me get the most benefit from using ultrasound at the point of patient care. CATS has two SonoSite Edge® systems that we take with us wherever we go, and these are now used on around 70 to 80 % of our retrievals. Ultrasound has become so much a part of our routine that we would be lost without them.”

Sonosite logo

Point-of-care ultrasound systems prove ideal for the Children’s Acute Transport Service

author0000-00-00authorposted by Caroline,

The Children’s Acute Transport Service (CATS) depends on point-of-care ultrasound systems to get quick and accurate vascular access in critically ill children being transferred to specialist treatment centres. Advanced Nurse Practitioner Cathy Roberts explained: “In the UK, paediatric intensive care is provided at centralised units, and children needing this care must be safely transferred there by people with appropriate knowledge and skills. CATS provides a retrieval service for the North Thames area, transferring around 1,200 critically ill children a year from regional hospitals to those offering paediatric intensive care, such as Great Ormond Street, St Mary’s, the Royal Brompton, the Royal London and Addenbrooke’s.”

 

“Successful vascular access is vital for patient retrievals, and we frequently need to insert central or arterial lines as we stabilise children prior to transfer. I learned how to obtain vascular access under ultrasound guidance through a combination of supervised practice and a SonoSite training course. The training course was excellent, giving me the opportunity to practice different ways of holding the probe in the safety of a non-clinical environment, and discover various tips to help me get the most benefit from using ultrasound at the point of patient care. CATS has two SonoSite Edge® systems that we take with us wherever we go, and these are now used on around 70 to 80 % of our retrievals. Ultrasound has become so much a part of our routine that we would be lost without them.”